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1.Bone tissue
Bone is the second most transplanted tissue after blood with over 2.2 million 
bone grafting procedures being performed annually worldwide in order to repair 
bone defects in orthopedic surgery, maxillofacial surgery and trauma surgery 
[1]. The application of autologous bone is still the gold standard procedure, but 
it presents several disadvantages such as the need for an additional surgical 
procedure to harvest the bone tissue as well as donor site morbidity. Besides 
autografting, allografting is a similar tissue-based approach towards bone rege-
neration in which bone is being harvested from a cadaver avoiding the need for 
an additional surgical procedure within the patient. Still, allografting also involves 
several problems such as rejection or disease transmission. In view of these 
drawbacks, synthetic bone substitutes such as metals, polymers and ceramics 
are investigated and clinically applied as alternatives to tissue-based bone grafts.
2.Calcium phosphate cement
Ceramic materials such as calcium phosphates posses a long clinical history as 
bone substitutes due to their osteoconductivity and biocompatibility [2]. Of great 
interest are calcium phosphate cements (CPC), which were originally developed 
by Brown and Chow in the early 1980s [3]. CPC exhibits the advantages of 
calcium phosphate based materials while being injectable into a irregularly 
shaped bone defect area.  After  injection, the  material sets and becomes a 
solid. In addition, CPCs are available off-the-shelf and are not associated with 
many of the drawbacks that are related to autologous bone with respect to graft 
harvesting, donor site morbidity and increased time of surgery. Besides, their 
synthetic nature reduces the risk of disease transmission compared to auto- 
and allografting. CPCs can be classified into apatitic and brushite cements 
depending on the end-product of the setting reaction [4]. Brushite based cements 
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are resorbed faster compared to apatitic based cements, but they exhibit inferior 
mechanical properties which compromise the use of brushite cements as bone 
substitute materials in a number of applications [5-9]. Moreover, while brushite 
is not biomimetic, apatitic calcium phosphate cements have a strong chemical 
resemblance to bone tissue since about 70 wt% of bone tissue consists of apatitic 
nanocrystals.
3.Degradation of apatitic calcium phosphate 
cement
Due to the poor degradability of apatitic CPCs, various strategies have 
been explored to accelerate degradation of CPC. The addition of porogens of 
different physicochemical nature such as foaming agents, salt or sugar crystals, 
and polymers has been investigated in an attempt to generate porosity within 
CPC [10-13]. To create a pores - and thus room for bone tissue ingrowth - the 
porogens should degrade faster than the CPC material. Macroporosity allows for 
cell penetration as well as fluid flow throughout the material, thereby stimulating 
CPC degradation. Several porogens such as salt and sugar crystals [14,15], and 
polymeric microspheres from natural (e.g. gelatin) or synthetic polymers (e.g. 
poly-trimethylene carbonate (PTMC), or poly(d,l-lactic-co-glycolic acid) (PLGA)) 
[16] have been incorporated into CPC. PLGA is widely used for several clinical 
applications due to its well know safety and tailorable degradation properties 
[17-19]. When used as porogens, PLGA microspheres were shown to enhance 
degradation of CPC [20,21].
4. Objectives of this study
Although numerous in vitro and in vivo studies have been dedicated to the deve-
lopment of CPC-PLGA, the control over the effect of various material properties 
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–The influence of physicochemical properties of PLGA microspheres on  
the process of passive (i.e. acellular) degradation of CPC. Both physical 
parameters (microsphere size and morphology, (Chapters 3, 4 and 5) as well 
as chemical parameters (molecular weight and end-group functionalization) 
have been studied. 
– The influence of glucono delta-lactone on the process of (early) passive de-
gradation of CPC (Chapter 6).  
on the degradability of the CPC-PLGA composites is still not well understood. 
For instance, the molecular weight of PLGA was shown to influence the de-
gradation of CPC-PLGA composites in vivo, but controversial results have been 
reported in previous studies of our research group. Ruhé et al. [22] and Bodde 
et al. [23] included PLGA microspheres of similar molecular weight (47 and 48 
kDa, respectively) in CPC. Ruhé et al. observed complete degradation of the 
PLGA microspheres and extensive bone tissue ingrowth throughout the implant. 
Bodde et al., on the other hand, hardly observed degradation of PLGA and bone 
ingrowth into the scaffold was not observed after comparable implantation times. 
These controversial results have prompted us to systematically investigate the 
relationship between physicochemical properties of PLGA and degradation of 
CPC-PLGA composites in vitro and in vivo. In order to stimulate the formation of 
new bone tissue even further, we have also investigated biochemical approaches 
towards bone regeneration by focusing on the capacity of PLGA microspheres for 
controlled delivery of therapeutic proteins that are actively involved in the stimu-
lation of osteoblasts and osteoclasts. 
Therefore, the main objective of this thesis was to study both chemical and 
biochemical strategies to control degradation of CPC-PLGA composites and con-
comitant replacement by new bone tissue. To this end, the following sub-studies 
have been performed in order to obtain insight into the following phenomena:
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REGENERATION
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1.Introduction
Bone tissue engineering is an interdisciplinary field that applies the principles 
of biology and engineering for the development of bone substitutes to restore, 
maintain or improve the function of diseased or damaged bone tissues [1]. 
Different approaches have been used in reconstructive surgery to repair bone 
defects [2,3]. Autografting refers to the use of autologous bone. Even though 
autografting is still the gold standard, significant limitations are associated with 
autografting such as the need for an extra surgical operation for the harvesting 
procedure, donor site morbidity at the harvest site and limited supply of bone [4]. 
Besides, allografting involves harvesting and processing bone from a cadaver 
and transplantation to the patient. It entails several problems such as rejection 
or disease transmission [5]. As an alternative to tissue-based strategies to heal 
diseased or damaged bone tissue, synthetic bone substitutes can be implanted 
such as metals, ceramics and polymers [6]. Metals are the material of choice 
for load-bearing applications due to their favorable mechanical properties, 
whereas ceramics exhibit excellent biocompatibility as a result of their chemical 
composition which resembles the mineral phase of bone tissue. However, both 
metals and ceramics are generaly poorly degradable. 
In contrast, biodegradable polymers have been widely investigated and 
applied to fabricate scaffolds for tissue engineering. They can be classified as 
natural or synthetic depending on their origin. Natural polymers exhibit several 
benefits such as degradability and neglectable toxicity. However, a number of 
advantages are reported for synthetic polymers as compared to natural poly-
mers, including the highly controlled and consistent degradation properties and 
excellent reproducibility. Among synthetic polymers, aliphatic polyesters such 
as polylactic acid (PLA), polyglycolic acid (PGA), their co-polymer polylactic-co-
glycolic acid (PLGA) and polycaprolactone (PCL) have received considerable 
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interest as materials for tissue engineering, and several devices comprising PLA, 
PGA and PLGA have been approved for clinical use in humans by the American 
Food and Drug Administration (FDA) [7]. PGA is a hydrophilic, highly crystalline 
polymer with a relatively fast degradation rate. Although structurally very similar 
to PGA, PLA is exhibits different chemical, physical and mechanical properties 
because of the presence of a pendant methyl group on the alpha carbon. Gene-
rally, the co-polymer PLGA is preferred over its constituent homopolymers PLA 
and PGA for the fabrication of bone substitute constructs since PLGA offers su-
perior control over degradation properties by varying the ratio between its mono-
mers. [1]. When the crystalline PGA is co-polymerized with PLA, the degree of 
crystallinity is reduced and as a result this leads to increased rates of hydration 
and hydrolysis.
In view of its broad application range and wide variety of application forms, 
the current study has reviewed the use of PLGA as structural component or 
drug delivery vehicle in bone tissue engineering. First of all, PLGA-based 
bone substitutes have been categorized according to its application forms, i.e., 
scaffolds, coatings, fibers or spheres. Moreover, various approaches have been 
summarized to functionalize PLGA with biomolecules to enhance its efficiency for 
bone tissue regeneration.
 20 
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2.Physicochemical properties of PLGA
2.1.Synthesis
PLGA is a biocompatible and biodegradable linear co-polymer which can be 
prepared at different ratios between its constituent monomers lactic and glycolic 
acid (Figure 1).
2.2.Chemistry
The various forms of PLGA are usually identified by the ratio between the two 
monomers. The most frequently applied type of PLGA is 50:50, which relates to 
a co-polymer composed of 50% of lactic 50% of glycolic acid. 
The free carboxyl end-groups of PLGA can be used for chemical modifications 
to modulate its degradation rate or drug delivery properties. Among a wide range 
PLGA of low molecular weight 
(below 10kDa) can be obtained by 
a ring-opening co-polymerization of 
lactic and glycolic acid. PLGA of   higher 
molecular weights can be synthesized 
using the same process by using 
catalysts or by using cyclic dimers 
as a starting material [8]. Common 
catalysts used in the preparation 
of this co-polymer include tin (II) 
2-ethylhexanoate, tin (II) alkoxides or 
aluminum isopropoxide. Throughout 
the polymerization process, successive monomeric units of glycolic or lactic acid 
are linked together by ester linkages, resulting in a linear, amorphous aliphatic 
random polyester PLGA.
Figure 1: Chemical structure of 
PLGA and its monomers
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of PLGA modifications, covalent bonding between carboxyl end-group of PLGA 
with amine groups as present in e.g. the amino-bisphosphonate drug alendronate 
have been investigated as a local delivery system for treatments of metastatic 
bone diseases [9]. As a result, covalent amide bonds are formed between the 
PLGA carrier and amine-containing drugs that allow for a more sustained drug 
release kinetics. 
The presence of a pendant methyl group on the alpha carbon of PLA causes 
chirality of this molecule which makes that PLGA is available as D, L, and DL iso-
mers. Poly(D,L-lactide) is an amorphous and transparent material with a random 
distribution of the D and L units. Since Poly (D,L-lactide) is the most commonly 
employed isomer for the fabrication of PLGA, the acronym PLGA generally refers 
to the form poly D,L-lactic-co-glycolic acid where both D- and L- lactic acid forms 
are present at an equal ratio.
2.3.Degradation
PLGA experiences bulk or heterogeneous erosion in aqueous environments, 
i.e., degradation is not confined to the surface of the device. Four consecutive 
steps can be discerned during degradation of PLGA [10]:
(1) Hydration; water penetrates trough the amorphous region of the polymer 
and disrupts the secondary forces such as van der Waals forces and hydrogen 
bonding, resulting into a decreased glass transition temperature.
(2) Initial degradation; cleavage of covalent bonds, the molecular weight of the 
polymer decreases.
(3) Progressive degradation; due to the hydrolytic reaction, carboxylic end-
groups autocatalyse the degradation process and mass loss begins by massive 
cleavage of the backbone covalent bonds resulting into loss of integrity.
(4) Solubilization; the fragments of the polymer are further cleaved to molecu-
 22 
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les that are soluble in the aqueous environment. After PLGA degradation lactic 
and glycolic acid are formed as end-products. Both acids are innocuous since 
they are incorporated into the Krebs cycle and excreted in the form of carbon 
dioxide and water [11].
Many factors can affect PLGA degradation such as i) molecular weight, ii) co-
polymer composition, iii) end-group functionalization, iv) chemical derivatization, 
v) geometry of the material, and  vi)  characteristics of the surrounding medium 
[12]. 
PLGA chain length is a very important parameter to consider when selec-
ting the adequate polymer properties for specific applications since the physical 
strength and degradation speed of PLGA depend to a large extent on its molecu-
lar weight. By increasing the molecular weight of conventional PLGAs from 10-
20kDa to 100kDa degradation rates were reported to range from several weeks 
to several months [12,13].
The co-polymer composition (more specifically the ratio between lactic and 
glycolic acid) is also an important parameter to control PGLA degradation. Lactic 
acid is more hydrophobic than glycolic acid which make that lactide-rich PLGA 
co-polymers are less hydrophilic, absorb less water and, subsequently, degrade 
slower. Mixtures of D and L lactic acid monomers are most commonly used for 
PLGA fabrication since the rate of water penetration is higher in amorphous D,L 
regions leading to accelerated PLGA degradation [14].
In addition to molecular weight and co-polymer composition, PLGA can un-
dergo several end-terminal modifications (such ester end-capping of its free car-
boxylic acid end-group) which affect the final physicochemical characteristics 
considerably. A delay in degradation time of 4 to 6 weeks has been found in 
vivo for an ester end-capped PLGA in comparison with a more hydrophilic acid-
terminated PLGA of similar molecular weight and co-polymer composition.[14]. 
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Additional derivatization strategies have been developed to increase the hydro-
philicity of PLGA by the introduction of hydrophilic moieties such as hydroxyl 
groups. These hydroxyl functionalized polymers exhibit a stronger water absorp-
tion capacity than their non-functionalized counterparts, with, expectedly, increa-
sed degradation rates as a result [15,16]. Moreover, an increased compatibility 
to therapeutic proteins was reported for these hydrophilic forms of PLGA since 
the acidification that accompanies conventional PLGA degradation is less pro-
nounced for hydrophilic PLGAs. Until now, several functionalized polyesters have 
been reported containing additional hydroxyl, amino, and carboxylic acid groups 
[17] 
Finally, physical parameters such as the geometry of the PLGA device stron-
gly affect PLGA degradation behavior depending on the accessibility of water. 
In addition, the characteristics of the surrounding media affect the degradation 
process, i.e. an acidic environment will accelerate PLGA degradation due to au-
tocatalysis [18].
3.Application forms of PLGA
To meet various clinical requirements, PLGA has been used in a wide variety of 
application forms such as scaffolds, coatings, fibers or micro- and nanospheres. 
These application forms will be discussed in the following sections.
3.1.Scaffolds consisting of pure PLGA
A scaffold is support structure for cell growth composed of biocompatible 
materials. Porous PLGA-based scaffolds have been widely investigated in the 
field of bone tissue engineering [19]. PLGA scaffolds can be processed into 
3D porous structures (see Figure 2) which can be designed to fit bone defects. 
Several processing techniques for fabrication of porous PLGA scaffolds have 
 24 
DEGRADATION OF CALCIUM PHOSPHATE CEMENTS
been developed over the past three decades [20]. The most commonly used 
techniques to prepare PLGA scaffolds are solvent-casting particulate leaching 
[21-25], phase inversion particulate 
leaching [26], fiber bonding [27-29] , 
gas foaming [30-33], emulsion freeze 
drying [34,35] and rapid prototyping 
[36]. For applications in bone tissue 
engineering, PLGA scaffolds should 
promote cell adhesion and stimulate 
bone tissue ingrowth. However, 
despite being biocompatible, 
clinical application of pure PLGA 
scaffolds for bone regeneration are 
hampered by poor osteoconductivity 
and inflammatory responses which originate from the production of acidic by-
products upon PLGA degradation [39,40]. Moreover, PLGA exhibits suboptimal 
mechanical properties for use as load bearing applications. Besides pure PLGA-
based scaffolds, PLGA is often used in combination with other materials such as 
Figure 2: SEM picture of a porous PLGA 
scaffold  (Osteofoam TM) obtained by 
phase inversion /particulate leaching. 
Reprinted from 19 with permission. 
Copyright 2012, John Wiley and Sons.
polymers (section 3.1.1) or ceramics (section 3.1.2) in an attempt to render PLGA 
scaffolds biocompatible or to modify its degradation rates [41]..
3.1.1.PLGA-polymer scaffolds
PLGA scaffolds have been developed that also contain natural or synthetic po-
lymers to overcome the limited osteoconductivity of pure PLGA scaffolds. Natural 
polymers contain motifs such as RGD (Arginine-Glycine-Aspartic acid) peptide 
sequences, which can modulate cell adhesion improving the cellular behavior 
compared with other polymers that lack these cell-recognition sites. PLGA has 
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been used in combination with several natural polymers such as collagen, chito-
san or gelatin. Collagen is an attractive natural polymer for tissue regeneration 
due to its excellent biocompatibility, biodegradability and negligible immunogeni-
city [42,43]. It represents about 90% of the proteins in the bone extracellular ma-
trix and has been widely investigated within the field of bone tissue engineering. 
Since PLGA  does not promote cell adhesion and proliferation due to its hydro-
phobic nature [44], the combination of PLGA with collagen was shown to improve 
the bone tissue response while maintaining the desired shape in vivo due to the 
mechanical strength of PLGA [45]. Chitosan, a co-polymer of glucosamine and 
N-acetylglucosamine, is frequently used in bone tissue engineering [46]. Due to 
its positive charge, chitosan can be used for binding and subsequent delivery 
of (preferably negatively charged) growth factors. The addition of chitosan to 
PLGA scaffolds was reported to enhance osteoblast differentiation [47]. In addi-
tion, PLGA can be used in combination with gelatin which is produced by partial 
hydrolysis of collagen. Gelatin is widely employed in bone tissue engineering due 
to its beneficial biocompatibility, controllable degradation, and strong potential for 
functionalization [48,49]. 
The combination of synthetic polymers such as polycaprolactone (PCL) with 
PLGA has also been reported for bone tissue engineering purposes in order to 
fabricate scaffolds with an optimal balance between porosity and mechanical 
strength. To this end, PLGA can be used to create a porous scaffold while PCL is 
used as reinforcing material to enhance the mechanical strength of the scaffold. 
For instance, PLGA tubular scaffolds with a PCL nanofiber spiral structured inner 
core were developed which displayed improved mechanical properties [50]. Pure 
PCL, however, does not improve the biocompatibility when compared to pure 
PLGA and therefore its combined application is limited apart from their use when 
a delayed degradation of the implant material is desired [51].
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Bioceramic/polymer composites are being increasingly used in the bone re-
generation field because the complementary properties of PLGA and ceramics 
offer new possibilities in terms of biocompatibility and mechanical strength.  Both 
calcium phosphate ceramics and bioactive glasses have been applied in com-
bination with PLGA scaffolds. Ceramics or glasses can be used in combination 
with PLGA as a i) reinforcing material to improve the mechanical strength of the 
scaffold or as a ii) coating to improve the bone tissue response towards PLGA 
and stimulate bone apposition onto the scaffold. 
To improve the mechanical strength of PLGA, calcium phosphates in the form 
of hydroxyapatite needles or nanoparticles have been used as reinforcing mate-
rial for PLGA matrices to improve the osteoconductive properties of the resulting 
composite [52,53].  As ceramic coating, apatite has been applied onto PLGA 
scaffolds enhancing their osteoconductive properties using wet-chemical depo-
sition techniques [54]. Several studies describe the use of biomimetic processes 
to produce apatite-coated PLGA constructs for bone tissue engineering by incu-
bation of PLGA scaffolds in simulated body fluid (SBF) to obtain a mineralized 
scaffold [55-64]. The resulting coatings were shown to enhance the osteoconduc-
tive properties of PLGA. However, this procedure has drawbacks related to the 
immersion of the PLGA scaffold in SBF, since the scaffold can undergo hydrolytic 
degradation upon soaking in aqueous solutions. In addition, coating thicknesses 
can differ in the inner and outer parts of the scaffold due to limited fluid flow within 
the porous scaffold. Therefore, uniformly coated porous PLGA scaffolds have 
been produced by using a system designed to induce SBF flow throughout the 
pores of the scaffold [59]. In parallel, PLGA scaffolds with apatite-coated pores 
have been developed with alternative method to avoid immersion in SBF. This 
method involves inclusion of apatite-coated paraffin spheres into the PLGA fo-
3.1.2.PLGA-ceramic scaffolds
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llowed by dissolution of the paraffin spheres [60].
The basic components of bioactive glass are SiO2, Na2O, CaO and P2O5. 
After implantation, the outer surface of bioactive glass forms an amorphous layer 
of calcium phosphate that binds to proteins, collagen, fibrin and growth factors. 
Bioactive glass has been used in combination with PLGA as a films, microsphe-
res or fibers creating constructs that provide a good attachment and growth of 
osteoprogenitor cells [61-64]. Moreover, bioactive glass microspheres have also 
been included in PLGA matrices for delivery of antibiotics [65].
3.2.Coatings
A coating can be defined as a layer of a substance spread over a surface. In 
the field of bone tissue engineering, coatings are applied to improve the interac-
tion between cells and the surface of biomaterials. PLGA coatings have been 
applied onto ceramics, metals, natural polymers and bone allografts.
Despite the fact that bioceramics have a similar composition to natural bone, 
PLGA has been studied within the field of bone tissue regeneration as a coa-
ting material to improve the surface properties of several bioceramic materials. 
A dual porous hydroxyapatite/trical-
cium phosphate (HA/TCP) construct 
has been coated with PLGA to over-
come the drawbacks of the biphasic 
ceramics and the polymer, i.e., the low 
compressive strength of PLGA and the 
brittleness of HA/TCP ceramics (Figu-
re 3). PLGA-coated HA/TCP scaffolds 
exhibited a higher compressive streng-
th and compressive modulus than bare 
Figure 3: SEM image of a ceramic scaffold 
covered by a PLGA coating. Adapted 
from 66 with permission Copyright 2012, 
Elsevier.
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HA/TCP scaffolds [66] 
Patterned PLGA coatings have been developed to modify the surface morpho-
logy of titanium composites to improve cell-material interactions, thereby increa-
sing osteoblast proliferation and adhesion [67, 68].
The addition of a PLGA coating to a chitosan scaffold resulted in a more 
controlled degradation process. Still,  a decreased osteoblast proliferation was 
observed in vitro when compared to apatite-coated chitosan. Nevertheless, 
PLGA-coated chitosan scaffolds were shown to enhance bone formation in 
comparison to plain chitosan scaffolds after implantation in a rat calvarial defect 
[69,70]. 
PLGA coatings have been applied even into cortical bone allografts in an 
attempt to maintain bone structural architecture immediately after implantation. 
Despite the biocompatibility of bone allografts, improved subsequent host bone 
response was reported [71].
3.3.Fibers 
Though less popular than PLGA scaffolds, electrospun PLGA fibers are increa-
singly studied for bone tissue engineering purposes. Polymer fibers are used for 
several applications in bone tissue engineering. Commonly, they are either used 
for scaffold fabrication by the fiber bonding technique or as the dispersed phase 
when combined with other materials.
Electrospinning is a widely used method to prepare polymer fibers. It uses an 
electrical charge to draw very fine fibers (typically at micro- or nanoscale) from 
a polymer solution. Electrospinning shares characteristics of both electrospra-
ying and conventional solution dry spinning of fibers. During this process high 
temperatures are not needed to fabricate solid threads from precursor solutions. 
This procedure is particularly suitable for the production of fibers using large and 
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complex molecules such as enzymes. Depending on the composition of the initial 
PLGA solution, micro- or nanofibers can be obtained by electrospinning. Fibers 
exhibit a very high surface-to-volume ratio and a relatively smooth structure at the 
molecular level. Similar to other types of PLGA structures, fibers exhibit a contro-
llable degradability, biocompatibility and favorable mechanical strength. 
PLGA fibers have been employed for the fabrication of composites with bioce-
ramics in order to reinforce calcium phosphate cements [72]. Promising results 
were shown for electrospun PLGA fibers when used in combination with calcium 
phosphate nanoparticles for enhanced bone tissue formation [73-75] and hydrox-
yapatite nanoparticles to improve the mechanical properties [76, 77] (Figure 4). 
Similar to PLGA scaffolds, PLGA electrospun fibers can also be used in bone 
tissue engineering in blends with natural polymers such as elastin, gelatin and 
collagen [78-80], as well as in combination with synthetic materials such as poly 
(3-hydroxybutyrate-co- 3-hydroxyvalerate) [81] or diamond nanoparticles [82] to 
form composite fibers of improved functionality.
Figure 4: Scanning electron microscopy images of electrospun scaffolds: Pure 
PLGA (a,b) and PLGA containing 60% of amorphous TCP (c,d). Reprinted from 
75 with permission. Copyright 2012, John Wiley and Sons.
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PLGA spheres can be classified into nanospheres or microspheres depending 
on their diameter. Several methods such as water/oil/water emulsion, oil/water 
emulsion, coacervation or spray drying are used to fabricate PLGA microspheres. 
During fabrication, the sphere size can be optimized by varying parameters such 
as solvent type, surfactant, viscosity emulsification speeds, emulsification time, 
polymer concentration and/or by sieving. Novel approaches have been develo-
ped over the past decades to achieve PLGA spheres with a more narrow size dis-
tribution and consequently controlled porosity (when used as porogen) or geome-
try of scaffolds fabricated by microsphere fusion. Berkland et al. fabricated PLGA 
spheres with controlled particle size by spraying the polymer solution through a 
nozzle with acoustic excitation to produce droplets and an annular, non-solvent 
carrier stream to allow further control of the particle size [84]. Microspheres with 
controlled diameters from 5 to 500 µm were produced by this method. PLGA 
spheres smaller than 10 µm were produced by laser ablation (Figure 5) in which 
an ultra-short pulse of a laser beam strikes periodically into a liquid jet to create 
highly monodisperse microspheres [85]. Porous membranes are also employed 
for controlled fabrication of monodisperse PLGA spheres ranging in diameter 
from 1-100 µm. Using this method, the polymer solution is permeated through 
the uniform pores of a membrane into an aqueous solution containing an emul-
sifier allowing excellent control over particle diameter and polydispersity [86,87].
3.4.PLGA spheres
Figure 5: Representative SEM image 
of PLGA microspheres fabricated by 
the laser ablation technique. Adapted 
from 85 with permission. Copyright 
2012, Elsevier.
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PLGA microspheres are used as main component of sphere-based scaffolds, 
as porogens for scaffolds or as drug delivery vehicle. Both PLGA fibers and PLGA 
spheres can be sintered by melting the PLGA at temperatures between 170 and 
230 °C depending on their initial chemical composition to create scaffolds for 
bone regeneration [88,89] . These sphere-based scaffolds can be coated or rein-
forced with calcium phosphate to enhance the osteoconductive properties of the 
construct [90-92]. Moreover, PLGA spheres have been combined with apatitic 
nanoparticles [93,94] to reduce fibrous encapsulation of PLGA, promoting new 
bone ingrowth while enhancing direct bone contact [95-103].
Porosity can be created in tissue engineered scaffolds by the incorporation of 
PLGA spheres, since a porous scaffold is gradually formed upon degradation of 
PLGA spheres. Degradation of injectable calcium phosphate cements has been 
accelerated considerably by the incorporation of PLGA microspheres into the 
injectable paste. After PLGA degradation, a porous CPC scaffold was formed 
which undergoes accelerated degradation due to acid production by PLGA po-
rogens, thereby allowing for enhanced bone tissue formation within the scaffold 
[104-106] (Figure 6).
Figure 6: Representative histological sections of calcium phosphate cement 
containing (A) acid-terminated or (B) end-capped PLGA microspheres after 12 weeks 
of implantation in a rabbit femoral condyle defect. Accelerated material degradation 
and bone tissue ingrowth can be observed when acid-terminated PLGA microspheres 
are used. Adapted from 105 with permission. Copyright 2012, Elsevier.
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Finally, oppositely charged PLGA nanospheres can be employed for the fabri-
cation of cohesive colloidal gels which can be applied as injectable drug-loaded 
filler to promote healing in bone defects [107]. To this end, PLGA nanoparticles 
were derivatized to increase their electrical charge and colloidal gels were formed 
by mixing different ratios of positively and negatively charged PLGA particles.
Besides the use of PLGA as structural component, PLGA has a strong potential 
for use as  drug delivery carrier. Different drug delivery vehicles such as porous 
scaffolds, coatings, fibers, and micro- and nanospheres have been fabricated 
using PLGA [108]. Several loading methods have been used to functionalize 
PLGA-based constructs and improve the biological response. Biomolecules can 
be included in PLGA-based bone substitutes by either adsorption or encapsulation.
4.1.Loading of drugs
4.1.1.Adsorption
Adsorption is by far the most simple and frequently studied drug loading 
method which involves dipping the PLGA constructs into a solution containing 
the biomolecule of interest. [109,110]. Nevertheless, several drawbacks are 
associated with this loading method such as limited control over delivery of 
biomolecules due to reversible, weak interactions between PLGA and the 
biomolecule of interest. Due to these weak interactions, drugs are often desorbed 
from the surface in an uncontrolled manner.
4.Drug delivery from PLGA
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4.1.2.Encapsulation 
Encapsulation is a commonly employed approach for drug loading into PLGA 
microspheres. In contrast to adsorption procedures, drugs are mixed with PLGA 
during and not after the particle preparation upon encapsulation [111].
Emulsion/solvent evaporation is a widely used technique to encapsulate bio-
molecules into PLGA microspheres. By this approach hollow microspheres can 
be prepared by a double emulsion technique. The PLGA is therefore solved in 
dichloromethane and emulsified with an aqueous solution in which the drug is 
dissolved. This first emulsification step is followed by a second emulsification 
step with an aqueous solution containing polyvinyl alcohol. PLGA spheres are 
formed upon pouring the result of both emulsification steps into large volume of 
the polyvinyl alcohol solution in a stirred beaker.
Solvent displacement is another production method for spheres in which the 
PLGA is dissolved in a water-miscible solvent such as acetone or ethanol. The 
drug incorporated by this method needs to be insoluble in water. PLGA-drug 
spheres are formed after pouring this water-miscible solution into an aqueous 
phase.
Additions to modify the drug encapsulation efficiency of microspheres can be 
performed by including e.g. hydroxyapatite or silica into microspheres [112, 113]. 
However, despite the fact that drug encapsulation into PLGA spheres is a widely 
used technique, it has to be taken into account that the use of organic solvents, 
harsh production processes, and acid production upon PLGA degradation can 
denature and deactivate encapsulated biomolecules [114-116].
4.2.Applications of functionalized PLGA
PLGA microspheres have been used as delivery vehicle for a wide variety of 
therapeutic agents while embedded in different materials such as collagen [117], 
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polyurethanes [118], hyaluronic acid hydrogels [119], gelatin hydrogel [120], po-
lypropylene fumarate [121], carboxymethylcellulose [122,123], or within a PLGA 
scaffold of different chemical characteristics and corresponding release charac-
teristics of the drug of interest [124]. In addition, PLGA has been proposed as a 
component of multilayered poly(L-lysine)/hyaluronic acid reservoirs which can be 
applied as coatings that can achieve a programmed delivery of specific proteins 
or peptides while maintaining their biological activity [125].
4.3.Delivery of growth factors from PLGA
Several growth factors such as bone morphogenetic proteins (BMP-2, BMP-
4, BMP-7), transforming growth factors beta (TGF-β1, TGF-β3), basic fibroblast 
growth factor (FGF), insulin like growth factor (IGF), platelet-derived growth fac-
tor (PDGF) or osteoblast stimulating factor-1 (OSF-1) have an essential role in 
the process of bone healing. The addition of growth factors to PLGA constructs is 
aimed at stimulating osteogenesis and angiogenesis. The latter is necessary for 
the nutrition and viability of the newly formed tissue. BMPs have been released 
from PLGA scaffolds [126-128] and spheres [129-140] to stimulate differentiation 
of mesenchymal stem cells and osteoblasts. Other members of the well-known 
regulators of bone formation such as TGF-β1 and TGF-β3 have been released 
from PLGA scaffolds enhancing osteoblast differentiation, matrix formation and 
mineralization [141-143]. In parallel, controlled release of IGF from PLGA spheres 
induced osteoblast proliferation [144-146]. OSF-1, also known as pleiotrophin, is 
an extracellular matrix associated protein which targets the deposition of new 
bone and it has been released from PLGA constructs [147]. Vascular endothelial 
growth factor (VEGF) stimulates the growth of new blood vessels. In view of this, 
VEGF release from PLGA scaffolds [148] and spheres [149] has been studied 
showing enhanced angiogenesis. Ideally, both osteogenesis and vascularization 
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should be stimulated for optimal new tissue formation. Combinations of osteo- 
and angiogenic growth factors have been released from PLGA scaffolds in order 
to enhance bone tissue formation [150]. 
For the delivery of these osteo- and angiogenic factors from PLGA spheres, 
growth factors have been either adsorbed [132-136,139,143] or encapsulated [1
29,130,138,140,142,144,146,149].
4.4.Delivery of miscellaneous biomolecules
PLGA microspheres have also been studied as delivery vehicles for antibiotics 
to reduce infections within the bone  implant site or in the surroundings areas. 
Controlled release from PLGA microspheres was reported for several antibiotics 
such as gentamicin [151,152], vancomycin [153, 154] colistin [155] tombramycin 
[156] and teicoplanin [157]. Moreover, PLGA microspheres have also been stu-
died for delivery of gentamicin when embedded in calcium phosphate cements 
[158].
A different approach for the delivery of bioactive molecules within PLGA cons-
tructs is the addition of plasmid DNA encoding for osteogenic growth factors. 
Using this approach, DNA encoding for BMP-4 and BMP-2 has been delivered 
from PLGA scaffolds and fibers, respectively [159-162].
5.Conclusions
The potential of PLGA for bone tissue engineering has been explored for se-
veral decades due to its biological safety and tunable degradation properties. 
The current study has reviewed the use of PLGA for bone regeneration by cate-
gorizing PLGA according to its application form, i.e., scaffolds, coatings, fibers or 
microspheres. Moreover, the potential of PLGA for drug delivery of adsorbed or 
encapsulated biomolecules was reviewed as well. 
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1. Introduction
With an estimated, annual number of ~2.5 million procedures, bone grafting 
has become a substantial surgical intervention in medical and dental healthcare 
[1], Although autografts represent the primary choice for a grafting material, is-
sues related to autograft availability and quality urge for alternatives.
From a practical point of view, the use of synthetic bone substitutes for bone 
regenerative treatments has several advantages over autografts, including off-
the-shelf availability and minimal patient discomfort, as no additional surgery is 
necessary to harvest autologous bone. Additionally, the application of the bone 
substitute material should be simple and effective, meaning that material prepa-
rations within the operating theatre do not involve cumbersome steps and that 
the handling properties of the bone substitute material allow to perfectly fill the 
bone defect. In this respect, injectable bone substitute materials are appealing 
for reasons of their syringe-based application via minimally invasive surgery and 
their capacity to optimally fill irregularly-shaped defects [2;3].
In view of the composition of such synthetic bone substitutes, calcium phospha-
te (CaP) based ceramics are well-known for their superior biological performance 
in bone regenerative approaches [4]. In an injectable form, CaP cements (CPCs) 
were introduced by Brown and Chow in the early 1980’s [5]. Such CPCs are 
currently available with either brushite [6] or apatite [7] as the main end-product. 
Although brushite CPCs are readily degradable, their low mechanical properties 
limit their wide application. On the other hand, apatite CPCs have higher mecha-
nical properties, but their slow degradation limits timely full replacement by newly 
formed bone tissue.
Research efforts in the past decade have focused on enhancing the degrada-
tion of apatite CPC by introducing porosity within the ceramic matrix. Initial efforts 
utilized foaming agents (e.g. CO2) that induce the formation of gas bubbles within 
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the CPC during setting [8]. For reasons of lack of control on pore size and pore 
distribution, the inclusion of rapidly degrading microspheres was explored. From 
multiple polymeric materials, poly(lactic-co-glycolic acid) (PLGA) demonstrated 
to have most suitable properties regarding both control on degradation [9] as well 
as tissue response [10]. More specifically, the amount of PLGA microspheres 
[11], PLGA molecular weight and end-group functionalization demonstrated to 
have significant effects on the degradation of PLGA microspheres, leading to 
fast degradation and substantial bone formation for CPC formulations containing 
PLGA microspheres with a low molecular weight (~< 20kDa) and acid-terminated 
polymer chains [12;13].
To date, the effects of pore dimensions obtained after hydrolytic degradation 
of PLGA microspheres within CPC have not been addressed. Several discrepan-
cies exist with respect to adequate pore size of ceramic materials to allow bone 
ingrowth and substantial bone formation. A number of reports concluded that 
pore dimensions of at least 50 µm are required to allow cell ingrowth and blood 
vessel ingrowth to aid in scaffold degradation [14,15]. In contrast, other studies 
concluded that human osteoblasts can penetrate into interconnective porosity 
if the pores are over 20 micrometer in size [16] or even that pore size does not 
significantly affect tissue ingowth and resorption of calcium phosphate scaffolds 
[17].
In view of these controversial results, the aim of the current study was to elu-
cidate the true effect of the pore dimensions within CPC on bone formation after 
injection of CPC/PLGA in a guinea pig tibial intramedullary model. To this end, 
injectable CPC/PLGA formulations were prepared using PLGA microspheres with 
either a small (~25 µm) or large (~100 µm) diameter, which were incorporated at 
a 20/80 ratio (wt.%) within apatite CPC. Both CPC/PLGA formulations were in-
jected into a marrow-ablated tibial intramedullary cavity and after an implantation 
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period of 12 weeks, histology and histomorphometry were used to address bone 
formation.
2. Materials and Methods
2.1. Materials
The chemical composition of the cement consisted of commercially available 
calcium phosphate powders: 85% (wt/wt) alpha-tricalcium phosphate (α-TCP; 
CAM Implants BV, Leiden, The Netherlands), 10% (wt/wt) dicalcium phospha-
te anhydrous (DCPA; J.T. Baker Chemical Co., Phillipsburg, USA) and 5% (wt/
wt) precipitated hydroxyapatite (pHA; Merck, Darmstadt, Germany). An aqueous 
solution of 2% Na2HPO4 (Merck, Darmstadt, Germany) was used as the li-
quid component. Poly(lactic-co-glycolic acid) (PLGA; Purasorb® PDLG 5002A 
(MW=17kDa, acid-terminated, L:G=50:50) was provided by Purac Biomaterials 
(Gorinchem, the Netherlands). For the preparation of the PLGA microspheres, 
polyvinyl alcohol (PVA; 88% hydrolyzed, Mw=22.000, Acros, Geel, Belgium), iso-
propanol (IPN; analytic grade, MERCK, Darmstad, Germany) and dichlorometha-
ne (DCM; analytic grade, MERCK) were used.
2.2. Preparation of PLGA microspheres
PLGA microspheres were prepared using a water/oil/water (w/o/w) double 
emulsion solvent evaporation technique. A total of 1.0 g of PLGA was dissol-
ved in 4 ml of DCM in a 20 ml glass tube, 0.5 ml of milliQ water was added and 
the emulsion was emulsified (small diameter microspheres: 8000 rpm for 90 se-
conds; large diameter microspheres: 3200 rpm for 90 seconds) with an emulsifier 
(IKA® T25 digital ultra-Turrax®, IKA® Werke GMBH & Co. KG, Germany). Sub-
sequently, 6 ml of a 0.3% PVA solution was added and emulsified again at 8000 
rpm for another 90 s. The content of the 50 ml tube was transferred to a stirred 
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1000 ml beaker containing 394 ml of 0.3% PVA. Following addition of 400 ml of 
a 2% IPN solution, the suspension was stirred for 1 hour. After the microspheres 
were allowed to settle for 15 minutes, the suspension was centrifuged and the 
supernatant solution was decanted. This washing procedure was repeated twice 
and the microspheres were collected, lyophilized for 24 hour and stored at -20°C.
2.3. Characterization of PLGA microspheres
The morphology and size distribution of the PLGA microspheres was determi-
ned by light microscopy. Microspheres were suspended in H2O and images were 
acquired using an optical microscope equipped with a digital camera (Leica/Leitz 
DM RBE Microscope system, Leica Microsystems AG, Wetzlar, Germany). The-
reafter, digital image software (Leica Qwin®, Leica Microsystems AG, Wetzlar, 
Germany) was used to determine microsphere size distribution using a sample 
size of >300 microspheres. In addition, microsphere morphology was assessed 
using scanning electron microscopy (SEM, JEOL 6310) at an accelerating volta-
ge of 10 kV, which was performed at the microscope imaging centre (MIC) of the 
Nijmegen Centre for Molecular Life Sciences (NCMLS).
2.4. Preparation of CPC/PLGA formulations
CPC/PLGA formulations were generated by adding 0.2 g PLGA microsphe-
res to 0.8 g CPC powder inside a 2-ml plastic syringe. The two different CPC/
PLGA formulations as such created contained either small microspheres (CPC/
PLGA-S) or large microspheres (CPC/PLGA-L). All syringes were sealed with a 
closed tip and sterilized using gamma radiation (25-50 kGy; Isotron BV, Ede, the 
Netherlands).
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2.5. Characterization of CPC/PLGA composites
The physico-chemical characterization of the CPC/PLGA formulations was 
conducted as described previously [9;13]. Briefly, the porosity of these formula-
tions was assessed by preparing pre-set, cylinder-shape scaffolds (n=3) using 
Teflon molds, after which the diameter, height, and weight of these scaffolds were 
measured before and after heating the scaffolds at 650°C for 2 hours. The total 
porosity and the macro-porosity were derived by the equations described pre-
viously [18].
2.6. Animal model and implantation procedure
Twenty guinea pigs (age: 7 months; gender: female; Harlan, Horst, the Ne-
therlands) were used as experimental animals, which each received uni-lateral 
surgery of only the right tibia. The study was approved by the Animal Ethics Com-
mittee of Nijmegen, the Netherlands (DEC 2009-127) and national guidelines for 
the care and use of laboratory animals were respected. General anesthesia was 
maintained by 0.5-2% Isoflurane, administered through inhalation and the depth 
of anesthesia was monitored by a lack of response to toe pinch and by monito-
ring the depth of respiration. To reduce peri-operative infection risk and minimize 
post-operative discomfort, antibiotic prophylaxis (Baytril®, 2.5%; Enrofloxacin, 10 
mg/kg) was administered prior to surgery and daily from day 1-3 post-surgery.
For injection of the CPC/PLGA formulations, the animal was immobilized on its 
back and the right hindlimb was shaved, washed and disinfected with povidone-
iodine. Two small longitudinal incisions were made along the distal and proximal 
tibial diaphysis. After exposure of the tibia, a full-thickness cortical defect (2.0 mm 
in diameter) was made in both distal and proximal sites using low rational drill 
speeds (max. 450 rpm) and constant saline irrigation. The content of the marrow 
space was evacuated by curettage using a dental file and repeated irrigation 
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with saline; a sterile cotton gauze was applied to stop bleeding. Then, the CPC/
PLGA formulation was prepared within the operating theatre by adding 0.38 ml 
of sterile 2% Na2HPO4 solution to a syringe containing either CPC/PLGA-S or 
CPC/PLGA-L and mixed vigorously for 30 seconds (Silamat® mixing appara-
tus, Vivadent, Schaan, Liechtenstein). After removing the tip of the syringe, the 
CPC/PLGA formulation was immediately injected into the bone marrow ablated 
tibia medullar cavity. The distal hole served as entrance and the proximal one as 
evacuation site for CPC/PLGA (Figure 1a). After injection, the CPC/PLGA for-
mulation was allowed to set for 10 minutes, after which the excess material was 
removed with a spatula. Subsequently, the soft tissues were closed in two layers 
using resorbable sutures (monocryl 4-0). After surgery, animals were housed in 
groups and given water and chow ad libitum. Animals were physically examined 
on a daily basis during the first 10 days post-surgery with focus on body weight, 
Figure 1:(A) Injection of CPC/PLGA into the bone marrow ablated tibia medullar 
cavity where the distal hole served as entrance and the proximal one as evacuation 
site.	 (B)	Three	different	 regions	of	 the	 tibia	defined	 for	 histological	 analysis;	P	
and D indicates proximally and distally drilled hole, respectively. (C) Regions of 
interest (ROI): ROI-1 demarcates the intramedullary cavity and ROI-2 refers to 
the CPC-PLGA area within ROI-1.
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2.7. Histological and histomorphometrical evaluation
Immediately after euthanasia, the tibias were retrieved and fixed in 4% formal-
dehyde for 1 week and dehydrated in a graded series of alcohol. After dehydra-
tion, tibias were cut into two parts: a proximal and a distal part. These parts were 
alternately allocated to two groups: the first group was composed of proximal hal-
ves of even tibias and distal halves of odd tibias, the second group was compo-
sed of distal halves of even and proximal halves of odd tibias. The first group was 
left non-decalcified, and embedded in poly methyl methacrylate (PMMA). After 
polymerization, these blocks were used to prepare thin (10 µm) sections (n=3 for 
each half tibia) using a Leica SP1600 saw microtome. These sections were made 
perpendicular to the long axis of the tibia and stained with methylene blue/basic 
fuchsin. The second group of specimens was decalcified with a specific-purpose 
apparatus (TDE30, Sakura) and dehydrated in a graded series of ethanol. Finally, 
the specimens were embedded in paraffin and histological sections were prepa-
red using a standard microtome (RM 2165, Leica) in three different regions of the 
tibia (Figure 1b): close to the distal entry site, in the central part of the diaphysis, 
and close to the proximal exit site. For each region, a total of six sections were 
stained with hematoxylin and eosin (HE) and another six sections were stained 
with Elastica van Gieson (EVG).
Histological evaluation was done using an optical microscope (Axio Imager 
Microscope Z1, Carl Zeiss Micro imaging GmbH, Göttingen, Germany) and con-
sisted of a concise description of the observed specimens.
Histomorphometrical evaluation was performed using EVG-stained paraffin 
sections in order to have the highest resolution for detecting bone formation in-
infection and adverse reactions. At 12 weeks post-implantation, animals were 
euthanized by an injection of concentrated sodium pentobarbital.
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side the medullar cavity. For quantification, 3 sections of each region per tibia 
(Figure 1b) were used. Two regions of interest (ROI) were set: ROI-1 was set to 
demarcate the intramedullary cavity, ROI-2 was determined based on morpho-
logical and color discrimination between tissue and ceramic matrix within ROI-1 
(Figure 1c). The bone area within both these ROIs was measured using Leica 
Qwin software (Leica Microsystems Imaging Solution, Cambridge, UK).
2.8. Statistical analysis
Statistical analysis were performed using GraphPad Instat 3.05 software (Gra-
phPad Software Inc., San Diego, CA, USA). The statistical comparison between 
the two CPC/PLGA formulations was performed using an unpaired Student’s t-
test. Alternatively, a one-way ANOVA was used to analyze bone formation at di-
fferent regions. Differences were considered significant using at P-values <0.05.
3. Results
3.1. Characterization of PLGA microspheres and CPC/PLGA 
composites.
SEM micrographs of the prepared PLGA microspheres and obtained CPC/
PLGA composites are depicted in Figure 1.
Both small and large PLGA microspheres showed a spherical morphology. The 
size distribution measurements revealed an average microsphere diameter of 
27±7 μm for small and 100±35 μm for large PLGA microspheres (p<0.05).
When incorporated within CPC, the morphology of pre-set CPC/PLGA scaffolds 
showed a tight packing of the PLGA microspheres. Furthermore, the PLGA mi-
crospheres were distributed homogeneously throughout the CPC-matrix. An 
apparent increase in interconnection  of PLGA microspheres was observed for 
CPC/PLGA-S compared to CPC/PLGA-L (Figure 2b,d). 
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The total porosity of CPC/PLGA-S and CPC/PLGA-L was similar with values 
of. 67.2±1.5% and 66.9±0.6%, respectively, (p>0.05), to which the PLGA micros-
pheres contribute in the form of macroporosity of ~45% (Table 1).
3.2. Clinical observations.
The surgical procedure was uneventful for all animals. In the course of the 
implantation period, 3 animals (2 CPC/PLGA-L and 1 CPC/PLGA-S)  were sa-
crificed due to a tibial fracture. The other 17 animals remained in good health 
and did not show any wound complications (i.e. signs of inflammation, such as 
swelling and redness). After the 12-week implantation period, a total of 17 tibias 
with injected CPC/PLGA formulations (i.e. 9 CPC/PLGA-S and 8 CPC/PLGA-S) 
Name PLGA/CPC-S PLGA/CPC-L
Average size 
microspheres (μm) 27 ± 7 100 ± 35
Wt % microspheres 20 20
Porosity (%) 67.2 ± 1.5 66.9 ± 0.6
Macroporosity (%) 44.5 ± 2.5 44.1 ± 1.0
Table 1: Characteristics of PLGA microspheres and CPC/PLGA formulations
Figure 2: SEM micrographs of (A) 
large, (B) small PLGA microsphe-
res, (C) CPC/PLGA-L  and (D) CPC/
PLGA-S.
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Experimental 
group 
Composition Implants placed Implants 
retrieved
CPC/PLGA-L
CPC with 20 wt.% 
large PLGA 
microspheres
10 8*
CPC/PLGA-S
CPC with 20 wt.% 
small PLGA
microspheres
10 9*
Table 2: Experimental groups, number of implants placed and retrieved
were retrieved. An overview of the number of implants placed and retrieved is 
given in Table 2.
3.3. Histology and histomorphometry
3.3.1.Descriptive histology
PMMA-sections (Figure 3) demonstrated presence of CPC/PLGA within the 
intramedullary cavity (dark areas) at the distal side with full contact with the corti-
cal bone. In contrast, the proximal side showed less contact between CPC/PLGA 
and cortical bone, leaving voids. These voids were partially filled with newly-for-
med bone (Figure 3C). Since PMMA sections did not allow accurate discrimina-
tion between CPC and tissue, paraffin-sections of decalcified specimens were 
used. EVG-stained sections clearly showed abundant bone formation within the 
intramedullary cavity (Figure 4). More specifically, H&E-stained sections (Figure 
5) allowed identification of the CPC-matrix and showed two distinct morphologies 
with trabecular-like bone structures in the areas outside CPC-matrix (either not 
present or degraded) and round bone structures inside the CPC-matrix (Figure 
5). For CPC/PLGA-L, these round bone structures showed embedded osteo-
cytes within the bone matrix and had dimensions ~100 µm in diameter, in which 
frequently cavities with marrow-like tissue was observed. 
* Deviation from # implants placed due to fracture of the tibia during implantation period.
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For CPC/PLGA-S, much smaller dimensions for these round bone structures 
were observed (~20 µm), which frequently had fused into trabecular-like bone 
structures. Marrow-like tissue was observed between these larger trabecular-like 
bone structures inside the CPC-matrix. The newly-formed bone showed always 
(also, in the round boen structures) the presence of osteocytes.
Figure 3: Representative histological images 
of PMMA sections of the (A) proximal, (B) 
central and (C) distal regions of the tibia 
containing CPC/PLGA-L composites. The 
voids between the CPC/PLGA and cortical 
bone in the distal region are indicated with 
asterisks (*). 
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Figure 4: Representative EVG-stained sections of (A) CPC/PLGA-L and (B) CPC/
PLGA-S.	Black	 arrows	 indicate	 interconnected	 pores	 filled	with	 bone	 and	white	
arrows	point	at	pores	filled	with	bone	that	maintain	the	original	size	and	morphology	
of PLGA microspheres.
Figure 5: Representative HE histologi-
cal sections of the proximal region with 
(A) CPC/PLGA-L and (B) CPC/PLGA-S. 
Lower	panels	are	magnifications	of	 the	
indicated boxes in the image above. 
Yellow and black asterisks indicate the 
presence of marrow-like tissue and tra-
becular-like bone structures containing 
osteocytes, respectively. Black arrows 
point at remnants of CPC.
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3.3.2. Histomophometrical evaluation.
Bone formation was evaluated within 2 different ROIs, which covered either 
the entire intramedullary cavity or the area of the CPC-matrix (Figure 1c). The 
results on bone formation are depicted in Figure 6.
Figure	 6:	 Quantification	 of	
bone formation. (A) Total bone 
formation in ROI-1 
(= average of all different levels 
at which sections were made 
(distal, central, proximal) and 
total bone formation in ROI-2 
(= average of all the different 
levels at which sections were 
made (distal, central, proxi-
mal). (B) Bone formation in 
ROI-1 at the different levels. 
(C) Bone formation in ROI-2 at 
the different levels.
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Total bone formation within ROI-1 (= average of measurements at different 
regions, i.e. distal, central and proximal; Figure 6A) for CPC/PLGA-S and CPC/
PLGA-L was 26.9±19.2% and 24.4±18.7, respectively (p>0.05). Total bone for-
mation measurements within ROI-2 (= average of measurements at different re-
gions, i.e. distal, central and proximal; Figure 6A) revealed that CPC/PLGA-S 
showed significantly higher amounts of bone (23.8±15.6%) compared to CPC/
PLGA-L (9.9±7.9; p=0.0093). (Figure 6A).
For different regions of the tibial intramedullary cavity (i.e. distal, central and 
proximal), both CPC/PLGA formulations demonstrated similar amounts of bone 
within ROI-1 (p>0.05; Figure 6B), whereas region- and CPC/PLGA formulation-
related differences were observed within ROI-2 (Figure 6C). Region-related 
specification showed for both CPC/PLGA-formulations significantly lower bone 
formation in the central region compared to both the distal and proximal regions 
(p<0.05). Alternatively, formulation-related specification showed significantly hig-
her bone formation for CPC/PLGA-S compared to CPC/PLGA-L in both the proxi-
mal and distal regions (p<0.05), but not in the central region (p>0.05).
4. Discussion
The aim of the present study was to evaluate the effect of PLGA microsphere 
dimension on bone formation after injection of CPC/PLGA in a guinea pig tibial 
intramedullary model. The reported results reveal evidently that bone tissue can 
grow into porosity within CPC as created by the degradation of PLGA microsphe-
res with dimensions as small as ~25 µm. Importantly, total bone formation within 
the CPC/PLGA bone substitute demonstrated >2-fold bone formation for CPC 
containing small PLGA microspheres compared to CPC containing large PLGA 
microspheres. Additionally, the pattern of bone and marrow formation showed 
distinct differences depending on the dimensions of the PLGA-microspheres wi-
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thin the CPC-PLGA formulations.
Compared to other small animal models used for the pre-clinical evaluation 
of bone substitute performance (e.g. murine calvaria and femoral epiphysis) 
[19,20], the presently used model comprises several differences. Firstly, an intra-
medullary cavity is not a bony site in the sense that the native tissue in that area 
consists of bone. As such, it cannot be considered as a bone defect, but rather as 
a bone augmentation model, in which native bone tissue is activated from the en-
dosteal site following bone marrow ablation [21,22]. Secondly, the tissue surroun-
ding the site of injection is different from that in normal bone defect and bone 
augmentation models. Whereas in these latter models, the site is surrounded by 
either bone tissue or soft tissue, the intramedullary cavity is composed of bone 
marrow and fat tissue, while being circumferentially surrounded by cortical bone. 
Despite this difference with regular bone defect and bone augmentation models, 
the guinea pig tibial intramedullary model was chosen because it allows that the 
cement can indeed be tested as an injectable material and also provides large-
sized histological specimens, which can be subjected to multiple approaches for 
analysis (i.e. both embedding in PMMA and paraffin of alternate tibial halves).
Regarding the quantification of CPC/PLGA degradation, the intramedullary 
model has several limitations. For a reliable assessment, it is mandatory to achie-
ve complete filling and setting of the injectable CPC/PLGA bone substitute. Wi-
thin a secluded cavity connected to liquid areas (i.e. bone marrow) proximally and 
distally, it remains speculative if that can be achieved. It needs to be emphasized 
that for regular bone defect models, the defect is maximally dried to avoid inter-
ference of bodily fluids with filling and setting [23;24].
Examination of the PMMA sections revealed that both CPC/PLGA formulations 
were still present within the intramedullary cavity at the end of the 12 weeks im-
plantation time. Due to the high density of the CPC/PLGA composite material, the 
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relative thickness of PMMA sections and artifacts caused by staining, analysis of 
bone formation using PMMA embedding is inaccurate [25]. In contrast, HE and 
EVG staining of de-calcified paraffin sections indicated the presence of abundant 
bone formation within the CPC-matrix. As such, these results demonstrate the 
importance of combined analysis (calcified/de-calcified) for a complete understa-
ting of both processes (material degradation and bone formation.
The quantitative assessment of bone formation showed no differences in total 
bone formation within the tibial intramedullary cavity related to PLGA microsphere 
dimension. However, within the CPC-matrix, bone formation of CPC/PLGA with 
small PLGA microspheres was >2-fold higher compared to CPC/PLGA with large 
PLGA microspheres. Further specification of this difference showed that especia-
lly the proximal and distal regions of the tibial intramedullary cavity contributed to 
this result. This effect is likely to be caused by bone marrow as left at the proximal 
and distal ends of the intramedullary cavity after the ablation procedure. This 
remained bone marrow could have acted as an initiator for new bone formation.
Review of previously performed studies indicate that no conclusive statement 
can be made about the scaffold requirements (porosity, composition, etc.) to 
allow bone ingrowth. For example, in vivo studies with ectopic implantation of 
pre-set CPC/PLGA scaffolds have shown that soft tissue ingrowth throughout 
the scaffold is feasible with PLGA microsphere sizes >50 µm incorporated at 20 
wt.% [15]. Alternatively, the assessment of bone ingrowth into biomaterials with 
different compositions (i.e. sintered hydroxyapatite with ‘cellular’ or ‘strut-like’ de-
sign) and porosity characteristics (i.e. porosity 32-56%, pore radius 71-167 µm) 
showed that pore size was strongly correlated to bone ingrowth with a strong en-
hancement of bone ingrowth when pore diameters exceed 100 µm [26]. Also one 
of our recent studies indicated that a CPC/PLGA formulation with 30 wt.% PLGA 
microspheres of 40 µm would be optimal regarding mechanical properties, poro-
 74 
DEGRADATION OF CALCIUM PHOSPHATE CEMENTS
sity, and interconnectivity [11]. This inconsistency in observations is confirmed by 
the present study, which shows that bone ingrowth throughout the material was 
obtained for an injectable CPC/PLGA formulation with 20 wt.% PLGA microsphe-
res of ~25 µm. This formulation showed even significantly more bone formation 
compared to the CPC/PLGA formulation with 20 wt.% PLGA microspheres of 
~100 µm, while formulations had a similar total porosity (~67%) to which the 
PLGA equally contributed (i.e. macroporosity of ~44%). In contrast with previous 
studies, which reported that small pore sizes (40-80 µm) lead to less bone for-
mation than larger pore sizes (200-400 µm) [27,28], it seems straightforward to 
conclude that a higher pore interconnectivity of the CPC/PLGA-S material cau-
sed the currently observed favorable effect on bone ingrowth. However, it has to 
be emphasized that in addition to the created macroporosity due to PLGA degra-
dation, CPC/PLGA possesses an intrinsic nanoporosity. Therefore, the majority 
of CPC/PLGA pores are additionally interconnected via this nanoporosity, which 
allows for enhanced fluid flow and nutrient circulation within the material. At the 
same time, the fluid flow circulation can accelerate the transformation as well as 
degradation of the CPC resulting in more space for tissue ingrowth.
Within the tibial intramedullary cavity. the response to several ceramic bone 
substitutes has previously been described to follow a pattern from endosteal bone 
healing via marrow cavity remodeling to marrow restoration [29]. The results of 
the present study not only show an effect of remaining bone marrow on bone 
formation, but also demonstrate that marrow regeneration occurred within the 
CPC-matrix. Interestingly, the location of regenerated bone marrow was depen-
dent on the size of the PLGA microparticles: whereas large PLGA microspheres 
evoked bone formation in round patterns and marrow in the center, small PLGA 
microparticles appeared to give rise to trabecular-like bone formation with bone 
marrow present between such trabeculae. As described in the literature, anato-
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mical restrictions necessitate specific dimensions (i.e. porosity) to allow bone ma-
rrow and blood vessel formation [30,31]. However, this study provides sufficient 
evidence that new bone formation occurs throughout a CPC-matrix with pores of 
25 µm in diameter. Therefore, it can be hypothesized that CPC nanoporosity, in 
combination with the porosity generated after PLGA degradation, provides suffi-
cient space for nutrient diffusion to allow bone cells to survive with the presence 
of bone marrow, but without the formation of new blood vessels until further de-
gradation of the CPC-matrix. This observation closely resembles the situation 
that occurs in nature within the cortical bone structures, where the Haversian 
system contains blood vessels only in the Volkmann’s canal. Nutrients diffused 
out from the vessel within these canals to the osteocytes in the Haversian system 
via nano-sized canaliculi.
5. Conclusion
The results of the present study demonstrate that the dimension of PLGA 
microspheres within injectable CPC/PLGA have a substantial effect on bone 
formation. Whereas both small (~25 μm) and large (~100 μm) microspheres 
allowed bone ingrowth throughout the CPC-matrix, a >2-fold higher amount of 
newly formed bone was observed for CPC/PLGA with small PLGA microspheres 
within the CPC-matrix. Additionally, the pattern of bone and marrow formation 
showed distinct differences related to PLGA microsphere size. In general, this 
study demonstrates that PLGA microsphere dimensions of ~25 μm, leading to 
pores of ~25 μm within CPC, are sufficient for bone ingrowth and allow substantial 
bone formation. Further, the results demonstrate that PLGA microsphere 
dimensions provide a tool to control bone formation for injectable CPC/PLGA 
bone substitutes.
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1. Introduction
Calcium Phosphate Cements (CPCs) are widely used as bone substitute. They 
exhibit several advantages compared to other materials such as biocompatibility, 
excellent osteoconductivity and injectability [1, 2]. However, apatitic CPC is 
hardly degradable, which makes that this material acts as a barrier for complete 
regeneration of a bone defect. 
CPC can be degraded by active or passive resorption. Active resorption is 
a cellular process mediated by osteoclasts, while passive resorption is based 
on the chemical solubility of the CPC material. The introduction of an adequate 
(macro)porosity and pore interconnectivity into the CPC will favor fluid flow as 
well as cell penetration and will accelerate as a consequence its degradation. 
A plethora of strategies has already been explored to introduce macroporosity 
into CPCs, but the majority of these strategies can only be applied to pre-made 
calcium phosphate ceramics. For example, porosity generation by means of 
particle leaching is incompatible with CPCs since the liquid component of CPCs 
dissolves these inorganic porogens prior to setting of the cement in the bone 
defect site [3-8]. Foaming agents such as carbon dioxide, hydrogen peroxide 
or albumin have been studied also as macroporosity inducers [9-11]. Although 
an interconnected pore network can be generated by this approach, pore size 
distribution cannot be controlled. In addition, the foaming agents can interfere 
with the in vivo setting properties of the CPC [12].
A more promising approach is offered by the inclusion of polymeric microspheres 
from natural (e.g. gelatin) or synthetic polymers (such as poly-trimethylene-
carbonate (PTMC), chitosan, pectin or poly(D,L-lactic-co-glycolic) acid (PLGA)) 
into CPC in order to introduce macroporosity [1, 13-15]. PLGA is a widely used and 
approved polymer. A major advantage of PLGA is that it degrades hydrolytically 
leading to the production of its monomers lactic and glycolic acid, which are then 
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incorporated into the Krebs cycle and naturally excreted as carbon dioxide and 
water. The acidic nature of the resulting monomers lactic and glycolic acid is 
an additional advantage of PLGA in combination with poorly degradable CPCs. 
These by-products acidify the surrounding area of the PLGA microspheres, which 
might lead to accelerated dissolution of CPC, since calcium phosphate ceramics 
generally dissolve under acidic conditions [16]. However, it should be realized that 
an acidified environment caused by acidic degradation by-products can induce 
inflammatory responses in vivo [17]. For this reason, PLGA is often combined 
in combination with other materials that can counteract excessive acidification, 
thereby reducing adverse tissue responses in vivo [18-20].
Though PLGA microspheres have been previously used in combination with 
CPC, there is a need to fine-tune the properties of PLGA microspheres to achieve 
a controlled polymer degradation and concomitant bone formation. For example, 
it is known that several parameters, such as chemical characteristics of the used 
PLGA or the morphology of the microspheres can affect their degradation and 
subsequent generation of CPC porosity. Regarding chemical characteristics, the 
major parameters to influence polymer degradation rate are; (1) lactic/glycolic 
acid (L/G-A) ratio, (2) molecular weight, and (3) end-group functionalization. 
In this study, PLGA with a fixed 50:50 L/G-A ratio was selected because of its 
recognized fast degradation behavior [21,22]. Considering molecular weight, 
high molecular weight polymers are known to degrade in a slower ratio than low 
molecular weight polymers [23,24]. Further, functionalization of PLGA end-groups 
is an important property in polymer chemistry and more specifically in PLGA 
degradation [25,26]. However, in the majority of the studies dealing with PLGA, 
this material property is left aside [27,28]. PLGA is commercially available with 
two different end-group functionalizations: end-capped or acid-terminated (Figure 
1). Acid-terminated, often referred as uncapped or hydrophilic PLGA, exhibits a 
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free carboxylic group at the polymer 
terminus. End-capping of the PLGA 
occurs after reaction of the polymer 
with an alcohol group and as a 
result, the last acid group of the 
polymer is replaced by an ester 
group. This ester group at the end 
of the polymer results in a more hydrophobic polymer, which theoretically should 
delay PLGA degradation.
Besides PLGA chemical characteristics, the morphological structure of the pre-
pared microspheres can be used to include more PLGA in a similar pore volume. 
Both dense and hollow PLGA microspheres are reported in literature, but the 
effect of this morphological feature has never been studied in a direct comparati-
ve study. It can be hypothesized that the larger PLGA content upon incorporation 
of dense PLGA microspheres will enhance the degradation of CPC matrices and 
consequently increase the amount of porosity formation.
The aim of the current study was to investigate the effect of chemical and 
morphological properties of PLGA microspheres on the in vitro degradation rate 
of these microspheres as well as the CPC-PLGA composites that contain these 
microspheres. Therefore, the effects of PLGA molecular weight (5, 17 and 44 
kDa), PLGA end-group functionalization (acid-terminated vs. end-capped) and 
microsphere morphology (dense vs. hollow) on the degradation of PLGA micros-
pheres and CPC matrices were studied. Although it is known that particle size of 
microspheres can affect the degradation rate of polymeric microspheres [29,30], 
Figure 1: PLGA end-group 
functionalizations.
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the particle size was fixed at 40 µm in the current study to eliminate material 
parameters other than PLGA molecular weight, end-group functionalization and 
particle morphology. The particle diameter of 40 µm was selected based on re-
sults obtained in previous in vivo experiments [31].”
For this part of the study, only PLGA-17A was selected, which was based 
on the obtained molecular weight and end-group functionalization data. CPC 
and PLGA degradation were evaluated by scanning electron microscopy (SEM), 
micro-computed tomography (micro-CT) and reverse phase high performance 
liquid chromatography (RP-HPLC).
2.Materials and Methods
2.1.Materials 
Poly (lactic-co-glycolic acid) (PLGA) Purasorb® materials were provided by 
Purac, Gorinchem, The Netherlands. Five types of polymers were used to prepare 
the microspheres: Purasorb® PDLG 50021A (Mw= 5 kDa, acid-terminated, L:G 
= 50:50); Purasorb® PDLG 5002A (Mw = 17 kDa, acid-terminated, L:G = 50:50); 
Purasorb® PDLG 5002 (Mw= 17 kDa, end-capped, L:G = 50:50); Purasorb® 
PDLG 5004A (Mw= 44 kDa, acid-terminated, L:G = 50:50); Purasorb® PDLG 
5004 (Mw= 44 kDa, end-capped, L:G = 50:50). For the preparation of the PLGA 
microspheres poly vinyl alcohol (PVA) (88% hydrolyzed, MW 22000, Acros, Geel, 
Belgium), isopropanol (IPN) (analytical grade, MERCK, Darmstadt, Germany) 
and dichloromethane (analytical grade, MERCK) were used. CPC (85% alpha-
tricalcium phosphate (α-TCP), 10% dicalcium phosphate anhydrous (DCPA) and 
5% precipitated hydroxylapatite (pHA)) and 2% Na2HPO4 (MERCK) were the 
components of the CPC phase. For the RP-HPLC analysis acetonitrile (super 
gradient; Lab Scan Sciences) and NaH2PO4 (MERCK) were used.
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2.2.Preparation of PLGA microspheres
Five different types of PLGA hollow microspheres were prepared using the 
following PLGA types: 5 kDa acid-terminated (PLGA-5A), PLGA-17A (PLGA-
17A), 44 kDa acid-terminated (PLGA-44A), 17 kDa end-capped (PLGA-17E) 
and 44 kDa end-capped (PLGA-44E). 5 kDa end-capped PLGA was not used to 
prepare PLGA microspheres, since this material was not commercially available.
To study the effect of microsphere morphology, dense microspheres were 
produced from both acid-terminated and end-capped PLGA while the molecular 
weight was fixed at 17 kDa.
Hollow microspheres were prepared by a double emulsion technique. 1.0 g of 
PLGA was solved in 4 mL of dichloromethane in a 20 mL glass tube. 500 µL of 
demineralized water (ddH2O) was added, while emulsifying at 8000 rpm for 90 
seconds. Subsequently 6 mL of a 0.3% PVA solution was added and emulsified 
again at 8000 rpm for 90 seconds. (ULTRA-TURRAX® high-performance disper-
ser (IKA®)). The content of the glass tube was transferred into a stirred 1000 mL 
beaker containing 394 mL of 0.3% PVA solution. Directly 400 mL of a 2% IPN so-
lution was added. The solution was stirred for 1 hour. The spheres were allowed 
to settle for 15 minutes and the clear solution was decanted. The suspension left 
was centrifuged and the clear solution on top was aspirated. Finally, the spheres 
were frozen, freeze-dried for 24 hours and stored at -20ºC.
Dense PLGA microspheres were prepared by a single emulsion technique. 
Briefly, 0.2 g of PLGA was solved in 2 mL of DCM in a 20 mL glass tube. 2 mL 
of this solution was transferred into a stirred beaker containing 100 mL of 0.3% 
PVA solution. Subsequently 50 mL of 2% IPN solution was added. The solutions 
were stirred for 1 hour. The spheres were allowed to settle for one hour and 
the supernatant was decanted. The sediment left was centrifuged and the clear 
solution on top was aspirated. The spheres were frozen, freeze-dried for 24 hours 
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and stored at -20ºC. 
The size distribution of both groups of PLGA microspheres was determined 
via image analysis. Spheres were suspended in H2O and pictures were taken 
with an optical microscope (Leica/Leitz DM RBE Microscope system, Leica Mi-
crosystems AG, Wetzlar, Germany). Subsequently, size distribution was determi-
ned from 300 microspheres of each PLGA microsphere group by digital image 
software (Leica Qwin®, Leica Microsystems AG, Wetzlar, Germany). 
The surface and inner morphology of the microspheres was determined by 
scanning electron microscopy (SEM) (JEOL 6310 at 10 kV).
2.3.Preparation of CPC-PLGA composites
PLGA microspheres were added to CPC powder. 0.2 g of hollow PLGA micros-
pheres were added to 0.8 g of CPC powder inside a plastic syringe. 
For 40 µm microspheres, the theoretical PLGA content of dense microspheres 
is 3 times higher than for the same volume of hollow microsphere with a wall thic-
kness of 5 µm as determined using SEM (see Figure 2E, 2F). As a consequence, 
0.36 g of dense PLGA microspheres were added to 0.8 g of CPC powder inside a 
plastic syringe to obtain a similar 
theoretical porosity including the 
same volume of both microsphe-
res types. Besides the theoretical 
Figure 2: SEM micrographs of PLGA 
microspheres hollow (A), dense (B) 
hollow embedded in CPC (C) dense 
embedded in CPC (D) cross-section 
of hollow (E) and cross-section of 
dense (F).
 88 
DEGRADATION OF CALCIUM PHOSPHATE CEMENTS
calculation, micro-CT analysis confirmed that the initial macroporosity (before 
polymer degradation) due to PLGA was equal for both composites containing 
dense and hollow microspheres since vol.
Subsequently, 350 µL of the 2% Na2HPO4 solution was added to each syrin-
ge and mixed vigorously for 30 seconds (Silamat® mixing apparatus, Vivadent, 
Schaan, Liechtenstein). Mixtures were injected inside a teflon mold with standar-
dized shape (discs 7.8 mm x 1.8 mm), after which the samples were left to set at 
room temperature for 24 hours. 
Three different types of CPC-PLGA composites, containing acid-terminated 
hollow microspheres of 5, 17 and 44 kDa, were prepared to study molecular 
weight effect. Based on molecular weight results, four composite types were 
fabricated to study the end-group functionalization effect (17 and 44 kDa both 
acid-terminated and end-capped). 5 kDa end-capped PLGA microspheres were 
not studied since they were not commercially available. Finally, four CPC-PLGA 
composites were made to investigate the effect of microsphere structure on CPC 
degradation, i.e. dense and hollow microspheres of PLGA-17A and of PLGA-17E.
2.4.In vitro degradation studies
For the degradation studies, each CPC-PLGA disc was incubated in 1.5 mL of 
phosphate buffer saline (PBS) at 37 ºC in a shaking water bath for 2, 4, 6, 9 and 
12 weeks. All assays were always performed in triplicate.
The morphology of the composite cements during the different degradation 
stages was determined by SEM.
The amount of glycolic and lactic acid in the incubation media of the different 
CPC-PLGA composites was analyzed by Reverse Phase High Performance 
Liquid Chromatography (RP-HPLC) as a measure of PLGA degradation. The 
system consisted of a Hitachi L2130 HPLC pump, Hitachi L-2400UV detector 
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and Hitachi L-2200 auto sampler, and an Atlantis dC18 column (Waters) 250 
mm x 4.6 mm, 5 µm. Two mobile phases were used; 1% acetonitrile in 20 mM 
NaH2PO4 pH= 2.2 (mobile phase A) and 100% acetonitrile (mobile phase B). 
The flow was 1 mL per minute, the injection volume 20 µL and the UV detection 
wavelength 210 nm.
pH measurements of the incubation media were performed directly after remo-
val of the samples from the water bath (PHM210, Standard pH meter, MeterLa-
bTM Radiometer, Copenhagen).
Micro-computed tomography was used to examine the morphological structure 
of the composites during PLGA degradation at the different degradation times (0, 
2, 4, 6, 9 and 12 weeks). Composites containing dense and hollow microspheres 
were scanned at energy of 100 kV and intensity of 98 µA at a resolution of 2.26 
µm pixel without filter (Skyscan -1072 X-ray microtomograph, TomoNT version 
3N.5, Skyscan®, Belgium). Cone beam reconstruction was performed and the 
data were analyzed by CT analyzer (version 1.4, Skyscan®). The region of 
interest (ROI), in which porosity was measured, was specified as a 1 mm x 1 mm 
x 1 mm cube.
Micro-CT analysis provided information about the initial macroporosity due to 
the PLGA microspheres as present in the CPC. However, CPC contains also an 
intrinsic micro/nanoporosity below the detection limit of micro-CT imaging. There-
fore, the initial total porosity (macro- and micro/nanoporosity) of pre-made sam-
ples containing hollow and dense microspheres was also determined according 
a method as described in a previously published study [32]. In brief, the PLGA-
CPC composites were weighted before and after placement in a furnace at 650ºC 
for 2 hours. Subsequently, total porosity was calculated by using the equation: 
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where  εtot = total porosity (%), mburnt = average mass sample (after burning out 
polymer), V = volume sample (cm3), and ρHAP = density hydroxy apatite (g/cm3).
In order to validate this method to calculate porosity, the total porosity of cal-
cium phosphate cements without any polymeric microspheres was determined 
before and after heat treatment. No differences in weight were observed before 
and after heat treatment, indicating that the heat treatment did not affect the po-
rosity of the CPC.
2.5.Statistical analysis
Data were presented as mean ± standard deviation. Significant differences 
were determined using analysis of variance (ANOVA). Results were conside-
red significant if p<0.05. Calculations were performed using GraphPad Instat® 
(GraphPad Software Inc., San Diego, CA, USA).
3.Results
3.1.Characterization of PLGA microspheres and   
PLGA-CPC composites
Hollow and dense microspheres were fabricated with a spherical and smooth 
appearance (Figure 2A, 2B). The average particle size of all microspheres types 
is listed in Table 1. Both microspheres types were found to be embedded in the 
CPC in a homogeneous distribution (Figure 2C, 2D). Transversal sections of the 
microspheres confirmed their hollow and dense structure (2E, 2F).
The volume fraction of the polymeric microspheres as determined by micro-
CT was equal to 56 ± 0.5 % and 55 ± 0.3 % for composites containing hollow or 
dense PLGA, respectively, confirming that equal polymer volume fractions were 
obtained for all experimental groups despite the different initial weight fractions of 
PLGA. In addition, total initial porosity of the composites with hollow and dense 
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microspheres was 73 ± 1.3 % and 75 ± 1.0 % respectively.
3.2.Effect of chemical characteristics of PLGA on     
microsphere degradation
SEM images were taken from all the samples at the different incubation times 
to monitor the morphological appearance of the degradation process (Figures 3, 
4 and 5).
To study the effect of molecular weight in microsphere degradation, acid-ter-
minated PLGA of three different molecular weights (5, 17 and 44 kDa) was used 
as starting material. Initial microsphere degradation was observed after 2 weeks 
of incubation for the three molecu-
lar weights tested (Figure 3A, 3C, 
3E). Degradation continued after 4 
weeks (data not shown) and after 6 
weeks the majority of microspheres 
Figure 3: SEM micrographs of 
composites. 5 kDa (A), 17 kDa (C) 
and 44 kDa (E) acid-terminated after 2 
weeks of incubation. 5 kDa (B), 17 kDa 
(D) and 44 kDa (F) acid-terminated 
after 6 weeks of incubation.
Type Morphology Particle size (µm)
PLGA-5A Hollow 36 ±07
PLGA-17A Hollow 38 ± 10
PLGA-44A Hollow 37 ± 12
PLGA-17E Hollow 36 ± 11
PLGA-44E Hollow 40 ± 09
PLGA-17A Dense 40 ± 06
PLGA-17E Dense 43 ± 06
Table 1: Particle size distribution of the PLGA microspheres.
 92 
DEGRADATION OF CALCIUM PHOSPHATE CEMENTS
had disappeared (Figure 3B, 3D, 3F). At 9 weeks the pores became less sphe-
rical (Figure 4A) and after 12 weeks the calcium phosphate matrix lost partially 
its structural integrity (Figure 4C). These late incubation time phenomena were 
observed for all three different molecular weight samples.
Regarding the end-group functionalization, two different PLGA microsphere 
batches were prepared; 17 and 44 kDa both end-capped. A similar degradation 
pattern was seen for both PLGA types. No signs of degradation were visible 
after 2, 4 and 6 weeks of incubation (Figure 5). Initial degradation was detected 
only after 9 weeks (Figure 4B). After 12 weeks of incubation, the majority of the 
microspheres were degraded and the CPC pores became less spherical (Figure 
4D). 
Evidently, SEM analysis revealed a stronger effect of end-group functionali-
zation than molecular weight on PLGA microsphere degradation. No differences 
Figure 4: SEM micrographs of composites 
containing 17 kDa PLGA. After 9 weeks 
incubation: acid-terminated (A), end-
capped (B). After 12 weeks incubation: 
acid-terminated (C), end-capped (D).
Figure 5: SEM micrographs of composites 
containing end-capped PLGA. 17 kDa(A) 
and 44 kDa (C) after 2 weeks of incubation. 
17 kDa (B) and 44 kDa (D) after 6 weeks of 
incubation.
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were observed between the different molecular weights at the different degrada-
tion times, while a very strong delay in degradation was seen for the end-capped 
PLGA microspheres.
In order to confirm and quantify the SEM data, the glycolic and lactic acid 
as released into the incubation media was measured by RP-HPLC. Both acidic 
monomers were released at a comparable rate and therefore only the glycolic 
acid release data are shown (Figure 6). The data revealed a gradual increase in 
concentration of acidic monomers in the incubation media. 
Comparison of the data showed that end-group functionalization had a strong 
significant effect on the degradation of the PLGA microspheres after their inclusion 
in CPC. At all incubation times, statistical testing indicated a higher glycolic acid 
release for acid-terminated PLGA microspheres compared with end-capped 
PLGA microspheres (P = 0.001).
Further comparison of the data revealed that also molecular weight had a 
significant effect on the glycolic acid release of the PLGA-5A, PLGA-17A and 
Figure 6: Glycolic acid detection by RP-HPLC.
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PLGA-44A microspheres at 2, 3, 4 and 6 weeks of incubation (P = 0.001). The 
release pattern of glycolic acid was at all these times 5kDa > 17 kDa > 44 kDa. 
After 9 weeks of incubation, only a significant difference existed between the 5 
or 44 kDa samples (P = 0.05). No significant differences at all were seen after 
12 weeks of incubation,  which is in agreement with the SEM imaging, where 
complete degradation of the all PLGA microspheres was seen for all samples.
For the end-capped PLGA microspheres, molecular weight had only a signi-
ficant effect on glycolic acid release at 6 and 9 weeks of incubation with 17kDa 
> 44 kDa. This late detection of differences is in agreement with the observed 
delayed degradation of end-capped samples by SEM.
3.3.Effect of PLGA microsphere morphology on CPC 
degradation
SEM examination demonstrated that after 2 weeks of incubation, both types 
of composites containing hollow and dense PLGA-17A microspheres exhibited 
initial degradation of the polymer. The different morphology of dense and 
hollow microspheres was clearly observed at this stage of degradation. Upon 
degradation of the hollow microspheres, remnants of the shell were observed in 
the CPC (Figure 7C). In contrast, the initial internal compact structure of dense 
microspheres became porous, indicating an intermediate stage in the degradation 
Figure 7: SEM micrographs of com-
posites containing dense (A) and 
hollow (C) PLGA microspheres after 
2 weeks of incubation. SEM micro-
graphs of composites containing 
dense (B) and hollow (D) PLGA mi-
crospheres after 6 weeks of incuba-
tion.
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process (Figure 7A). After 6 weeks of incubation, both types of microspheres 
had degraded to a large extent (Figure 7B, 7D). Similar intermediate degradation 
stage occurs between hollow and dense microspheres when PLGA-17E is used 
as starting material. Differences where only observed in degradation times, 
revealing a delay in degradation when PLGA-17E is used to fabricate both hollow 
and dense microspheres when compared (data not shown).
RP-HPLC analysis was performed on the incubation media of both composi-
tes containing hollow and dense microspheres. The results indicated significant 
differences (P = 0.001) at 4, 6 and 9 weeks when PLGA-17A was used as star-
ting material and at 6 and 9 weeks when PLGA-17E was used. This reveals an 
accelerated PLGA degradation of dense microspheres when compared to hollow 
microspheres fabricated from the same starting PLGA material (Figure 8).
pH measurements were performed in the incubation media at the different 
incubation times to obtain information about the amount of acid production due to 
PLGA hydrolysis (Figure 9). 
The pH of the incubation media of composites containing dense microspheres 
was significantly lower (more acidic) upon degradation than the pH of the incuba-
Figure 8: Glycolic acid detection by RP-HPLC to monitor morphology effect.
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tion media of composites with hollow microspheres. This effect occurs both when 
PLGA-17A is the material of choice to fabricate both types of PLGA microspheres 
as well as when PLGA-17E is the starting material.
Micro-CT images were obtained from cements containing both hollow and 
dense microspheres fabricated from PLGA-17A microspheres and 3D models 
Figure 9: pH change of the incubation media during degradation studies of 
PLGA hollow or dense microspheres embedded in CPC.
Figure 10: 3D models of 
composites containing 
hollow (A) and dense (B) 
PLGA microspheres prior 
to incubation. 3D models 
of composites containing 
hollow (C) and dense (D) 
PLGA microspheres after 4 
weeks incubation.
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were made (Figure 10). CPC macroporosity at different incubation times was 
quantified by micro-CT and expressed as a percentage (Figure 11). Before PLGA 
degradation, equal initial macroporosity was observed for both composite types 
containing dense (55%) or hollow microspheres (56%). At 2 weeks of incubation, 
a significant increase (P = 0.01) in macroporosity was found for cements contai-
ning dense PLGA microspheres (59%), whereas this porosity enhancement was 
not observed for CPC containing hollow PLGA microspheres. This difference in 
macroporosity between dense and hollow microspheres increased further at 4 
weeks (65% vs 56%). After 6 weeks, the macroporosity of composites containing 
dense microspheres was still significantly higher (P = 0.001) than when hollow 
microspheres were embedded, but the total percentage of porosity had decrea-
sed for both types of composites compared to previous incubation times. At 9 
and 12 weeks of incubation, total macroporosity of CPC containing dense PLGA 
microspheres could not be reliably measured due to disintegration of the CPC-
Figure 11: Porosity analysis of the micro-CT data during degradation of dense and 
hollow PLGA microspheres in CPC.
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PLGA composite specimens. Similar effect of porosity enhancement was found 
when both dense and hollow PLGA microspheres where prepared from PLGA-
17E. Again, only a delayed in creation of porosity was found when comparing with 
PLGA-17A microspheres. Here, macroporosity was significantly enhanced by the 
degradation of dense microspheres after 6 weeks, 9 and 12 weeks of incubation 
(data not shown).
4.Discussion
The objective of the current study was to investigate the influence of several 
polymer related parameters on the in vitro degradation characteristics of injectable 
CPC-PLGA composite cement. The results clearly demonstrated that chemical 
characteristics and morphological structure of PLGA microspheres embedded in 
CPCs have a strong influence on the creation of macroporosity within the CPC 
matrix.
Though several parameters can affect PLGA degradation such as monomer 
composition or nature of the initiator used for polymerization, molecular weight 
is frequently the parameter of choice to control PLGA degradation [33,34]. It 
is generally known that degradation rates of polymers generally increase with 
decreasing molecular weight. [35, 36]. The results of the present study are in line 
with these observations, but the effect of molecular weight on in vitro degradation 
was overshadowed by the effect of end-group functionalization. The results of 
the in vitro degradation assays revealed that the end-capping of the polymer with 
an ester group has a much stronger effect on PLGA microsphere degradation 
than molecular weight. SEM micrographs and RP-HPLC data depicted that end-
capped microspheres were more resistant towards hydrolytic degradation than 
acid-terminated microspheres of the same molecular weight. The fact that after 
6 weeks of incubation, a large percentage of the end-capped microspheres still 
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exhibited an intact morphology, while the majority of the acid-terminated had 
degraded, indicates that this parameter strongly affects microsphere degradation. 
Evidently, PLGA end-group functionalization is a very useful tool to control the 
creation of porosity in CPC. By varying the polymer end-group, a large degree 
of control of PLGA degradation is possible. The effect of this parameter has 
already been reported before to influence the degradation of polymers such us 
Poly (D, L,- lactide), where low molecular weight material showed a delayed 
degradation when end-capped [37]. Nevertheless, end-group functionalization is 
commonly not taken into account in studies dealing with PLGA microspheres 
and this information is often not provided at all [38-40]. Considering the observed 
evident effect of end-group functionalization, contradictory results as obtained in 
previous studies of our group can now be explained. For example, Ruhé et al. 
[41] and Bodde et al. [42] included both hollow PLGA microspheres of similar 
molecular weight (47.6 KDa and 48.0 kDa respectively) into CPC. Ruhé et al. 
observed complete degradation of the PLGA microspheres associated with bone 
tissue ingrowth throughout the implant. However, limited PLGA degradation and 
no bone tissue was observed in the study of Bodde et al. By tracking the data 
sheets corresponding to the polymers that were used in both in vivo studies, it 
was found that the PLGA as used by Bodde et al. was end-capped whereas the 
one used by Ruhé et al. was acid terminated, which explains the remarkably 
different degradation rates observed in both studies. In another in vivo study, 
considerable differences in bone formation after 12 weeks of implantation were 
explained on basis of differences in molecular weight (4.6 vs. 54.2 kDa) [43]. 
In this study, 4.6 kDa hollow PLGA microspheres degraded completely after 
12 weeks implantation, while the majority of the 54.2 kDa PLGA microspheres 
remained intact. As mentioned before, it was found that the results of this study 
were mainly caused by differences in end-group functionalization.
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Next to PLGA degradation, the CPC itself should degrade at a desired rate to 
allow complete replacement by newly formed bone. In the current study design, 
it was hypothesized that a larger PLGA content within the CPC can lead to an 
accelerated CPC degradation due to an enhanced acidity as generated after the 
PLGA hydrolysis. Therefore, dense as well as hollow PLGA microspheres were 
included in CPC. To test the effect of microsphere morphology on the mechanical 
properties of the CPC-PLGA constructs, additional compression tests were per-
formed prior to the degradation studies using a tensile bench for cement cylinders 
(4.5 x 9 mm) containing dense or hollow microspheres. From these experiments, 
it can be concluded that microsphere morphology does not affect the mechanical 
strength of the composites as compression strengths of 22 ± 5 MPa and 24 ± 
3 MPa were measured for hollow and dense microspheres, respectively. SEM 
analysis revealed an intermediate degradation stage for the dense PLGA mi-
crospheres. When degradation takes place, the initial dense morphology of the 
microspheres is transformed into a porous sphere prior to complete degradation. 
The micro-CT results revealed an increased macroporosity after PLGA degrada-
tion in the cements containing dense microspheres as compared to the cements 
with hollow microspheres. This indicates that CPC dissolution rate is accelera-
ted by the enhanced acidity as generated after dense microsphere degradation. 
However, this increase in porosity continued only up to 4 weeks of incubation 
and decreased again at prolonged incubation times. This observation can be 
explained by the poor mechanical properties of porous CPC. The acidic environ-
ment, as generated during/after PLGA degradation, stimulated CPC degradation, 
but did also induce CPC disintegration and loss of its characteristic porous 3D 
structure.
The pH measurements confirmed that embedding of dense PLGA microsphe-
res in CPC resulted in an increased acidity of the incubation media compared to 
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CPC composites containing hollow PLGA microspheres. This pH decrease is the 
effect of the release of a larger amount of glycolic and lactic acid by the dense 
microspheres, which overcomes the buffer capacity of the PBS. The decrease of 
pH can have a supplementary influence accelerating PLGA microsphere degra-
dation [44]. This accelerated degradation is the result of an autocatalytic effect 
due to the low pH of the surrounding environment generated by the previously 
cleaved lactic and glycolic acid monomers. The presence of a larger concentra-
tion of monomers in the incubation media at early time points for the dense mi-
crosphere loaded CPC confirmed the occurrence of such an autocatalytic effect.
Resulting from the above-mentioned acidification of the environment, the crea-
tion of porosity was enhanced by CPC dissolution in the direct vicinity of the 
dense microspheres.
Although both lactic and glycolic acids are harmless physiological metabolites, 
the enhanced acidity created after degradation of PLGA implants can induce an 
inflammatory reaction or tissue necrosis in the host bone. For this reason, several 
approaches such as inclusion of titania nanoparticles or impregnation of PLGA 
materials with demineralized bone particles, have already been investigated in 
order to lessen an unfavorable tissue reaction after implantation [45,46]. Here, 
the CPC is hypothesized to act as buffer that can reduce inflammation around 
PLGA-containing implants by consuming excessive protons upon cement degra-
dation. Upon degradation of embedded PLGA microspheres, lactic and glycolic 
acid monomers are released into the surrounding cement. These acid monomers 
(pKa of 3.08 and 3.83 for lactic and glycolic acid, respectively) release protons 
that lower the pH of the body fluids which hydrate the inorganic CPC phase. The-
se protons interact with phosphate ions as present in the apatitic lattice (forming 
divalent HPO42- and monovalent H2PO4- anions), thereby reducing the total 
negative charge of the phosphate anions and increasing the solubility of apatitic 
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CPC. As a consequence, acid by-products are neutralized by consumption of 
protons upon CPC dissolution.
Generally, however, it has to be emphasized that direct extrapolation of these 
in vitro findings to the in vivo situation cannot be made. Therefore, further investi-
gations are currently being carried out to study the influence of PLGA characteris-
tics on cement degradation under more in vivo conditions that are more dynamic 
than in vitro studies.
5.Conclusion
Based on the present in vitro results, the combination of dense PLGA 
microspheres with CPC emerges as a successful combination to achieve 
enhanced apatitic CPC degradation. The obtained data indicate that structure 
and end-group functionalization exhibit a much stronger effect on the degradation 
of PLGA microspheres in CPC than molecular weight under the applied in vitro 
conditions. By modifying the morphological structure (dense vs. hollow) and end-
group functionalization, the acid production of the PLGA microspheres can be 
fine-tuned. This tailorable acid production leads to a controllable formation of 
macroporosity and subsequent CPC degradation in vitro. Future investigations 
have to be focused in transferring and evaluating these findings to the in vivo 
situation.
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CHAPTER 5
BONE RESPONSE TO 
FAST-DEGRADING, INJECTABLE 
CALCIUM PHOSPHATE CEMENTS 
CONTAINING PLGA 
MICROPARTICLES
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1.Introduction
Calcium phosphate (CaP) materials are widely used in the regeneration of 
bone defects because of their chemical similarity to native bone tissue. As a 
consequence, bone tissue is formed in direct contact with calcium phosphate 
ceramic without the generation of an intermediate soft tissue layer. Calcium 
phosphate materials are available in different configurations, such as dense 
blocks, granulates or cements. Currently, there is an increased interest in calcium 
phosphate cements (CPC), since they are injectable and therefore easy to deliver 
into a bone defect by the surgeon [1,2].
In addition to bone biocompatibility, CaP-based bone substitutes should ideally 
degrade at the same rate as the formation of new bone. CPC can be degraded 
by two parallel pathways: active or passive resorption. While active resorption is 
a cell-mediated process, passive resorption is an acellular process dependent on 
the chemical solubility of the CPC material. 
In order to enhance the degradation rate of CPC and subsequent replacement 
by bone tissue, macroporosity can be introduced into CPCs [3-6]. Macroporosity 
allows for cell penetration as well as fluid flow throughout the material, thereby 
stimulating both active and passive degradation pathways. Among the various 
strategies to introduce macroporosity into CPCs, the inclusion of poly (D,L-lactic-
co-glycolic) acid (PLGA) microspheres as porogen is particularly promising due 
to the well-known biocompatibility and tailorable properties of PLGA [7-9]. Hollow 
microspheres made of poly (D,L-lactic-co-glycolic) acid (PLGA) have been 
used previously as porogen since these microspheres were shown to be able 
to induce macroporosity upon degradation of PLGA microspheres by hydrolysis 
of its ester linkages in the presence of water. In addition to acting as porogen, 
PLGA microspheres can also be utilized to accelerate the degradation of CPC 
matrices surrounding these microspheres, since acidic monomers (lactic and 
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glycolic acid) are produced upon PLGA degradation that are known to dissolve 
calcium phosphate ceramics. In order to study the mutual dependence between 
degradation of PLGA microspheres and CPC matrices, we have recently 
optimized the capacity of PLGA microspheres to induce porosity in CPCs in vitro 
by investigating the influence of important PLGA characteristics on the amount 
of acid production and corresponding in situ pore formation in CPC matrices 
[10]. It was found that the inclusion of dense PLGA microspheres results in a 
CPC with an enhanced porosity compared to the use of hollow microspheres 
as porogen. By using dense microspheres, the larger amount (by weight) of 
PLGA resulted into increased acidification of the environment (also caused 
by an autocatalytic effect) and accelerated CPC degradation. Moreover, the 
chemical properties of PLGA (such as the molecular weight, lactic/glycolic acid 
ratio or end-group functionalization) strongly affected the degradation rate of the 
prepared microspheres and surrounding CPC matrices [11;12]. PLGA and CPC 
degradation rates were mainly dependent on the end-group functionalization, 
while the molecular weight affected the polymer degradation rate to a lesser 
extent. Specifically, microsphere degradation was delayed for more than 6 weeks 
for end capped PLGA in comparison to acid terminated PLGA microspheres 
embedded in CPC. In contrast, degradation of microspheres made of PLGA of 
molecular weight 17 vs. 44 kDa differed only by 1 week. To date, however, it 
remains unknown to what extent the acidification caused by the degradation of 
PLGA microspheres affects the overall bone response of a CPC/PLGA composite 
in vivo. Since CPC consumes protons upon CPC dissolution, it was hypothesized 
that the buffering capacity of the CPC [13] in combination with the continuous flow 
of body fluids in bone tissue can overcome potentially negative effects caused by 
excessive acidity. 
Also, it is known that results obtained by in vitro studies cannot be directly 
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extrapolated to (pre-) clinical conditions due to the large difference in experimen-
tal conditions. The proof-of-concept for the development of apatitic CPCs that 
degrade within clinically relevant time periods can only be provided by in vivo 
implantation studies in osseous implantation sites.
Therefore, the aim of the current investigation was to study the effects of PLGA 
microsphere morphology (dense vs. hollow) and end-group functionalization (acid 
terminated vs. end capped) in order to confirm the outcome of our earlier in vitro 
studies. To this end, four types of PLGA microspheres (hollow acid terminated, 
hollow end capped, dense acid terminated and dense end capped) embedded 
in CPC were implanted in circular defects as created in the femoral condyle of 
rabbits. CPC degradation and new bone formation were evaluated histologically 
and histomorphometrically after 6 and 12 weeks of implantation.
2.Materials and Methods
2.1.Materials
Poly (lactic-co-glycolic acid) (PLGA) Purasorb® materials were provided by 
Purac, Gorinchem, The Netherlands. Two types of polymers were used to prepare 
the microspheres: Purasorb® PDLG 5002A (Mw = 17 kDa, acid terminated, 
Lactic:Glycolic acid ratio (L:G) = 50:50) and Purasorb® PDLG 5002 (Mw= 17 
kDa, end capped, L:G = 50:50). For the preparation of the PLGA microspheres, 
poly vinyl alcohol (PVA) (88% hydrolyzed, MW 22000, Acros. Geel, Belgium), 
isopropanol (IPN) (analytical grade, MERCK. Darmstadt, Germany) and 
dichloromethane (DCM) (analytical grade, MERCK) were used. 
The CPC powder consisted of a mixture of 85% alpha-tricalcium phospha-
te (a-TCP), 10% dicalcium phosphate anhydrous (DCPA) and 5% precipitated 
hydroxyapatite (pHA). 2% Na2HPO4 was used as liquid phase for the preparation 
of the cement.
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2.2.Preparation of PLGA microspheres.
Hollow microspheres were prepared by a double emulsion technique. 1.0 g 
of PLGA was solved in 4 mL of DCM in a 20 mL glass tube. 500 µL of demine-
ralized water (ddH2O) was added while emulsifying at 8000 rpm for 90 seconds. 
Subsequently, 6 mL of a 0.3% PVA solution were added and emulsified again at 
8000 rpm for 90 seconds. The content of the glass tube was transferred into a 
stirred 1000 mL beaker containing 394 mL of 0.3% PVA solution. Directly, 400 mL 
of a 2% IPN solution was added. The solution was stirred for 1 hour. The sphe-
res were allowed to settle for 15 minutes and the clear solution was decanted. 
The suspension left was centrifuged and the clear solution on top was aspirated. 
Finally, the spheres were frozen, freeze-dried for 24 hours and stored at -20ºC. 
Dense PLGA microspheres were prepared by a single emulsion technique. 
Briefly, 0.2 g of PLGA was solved in 2 mL of DCM in a 20 mL glass tube. Two mL 
of this solution was transferred into a stirred beaker containing 100 mL of 0.3% 
PVA solution. Subsequently, 50 mL of 2% IPN solution was added. The solution 
was stirred for 1 hour. The spheres were allowed to settle for one hour and the 
clear solution was decanted. The suspension left was centrifuged and the clear 
solution on top was aspirated. Finally, the spheres were frozen, freeze-dried for 
24 hours and stored at -20ºC.
2.3.Characterization of PLGA microspheres
The morphology and size distribution of the PLGA microspheres was deter-
mined by light microscopy. Spheres were suspended in H2O and pictures were 
taken with an optical microscope (Leica/Leitz DM RBE Microscope system, Leica 
Microsystems AG, Wetzlar, Germany). The size distribution of the microspheres 
was determined by digital image software (Leica Qwin®, Leica Microsystems AG, 
Wetzlar, Germany) using a sample size of 300 microspheres. In addition, mor-
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phology was further observed by Scanning Electron Microscopy (SEM, JEOL 
6310) at an accelerating voltage of 10 kV.
2.4.Preparation of CPC-PLGA composites
In order to prepare CPC-PLGA composites in which composites containing 
dense PLGA microspheres present 1.8 higher content of PLGA than composi-
tes with hollow PLGA microspheres, 0.2 g of hollow PLGA microspheres was 
added to 0.8 g of CPC powder inside a plastic syringe to obtain a higher initial 
macroporosity than previosly achieved where no bone ingrowh was visible within 
the CPC-PLGA composite [14].  While 0.36 g of dense PLGA microspheres was 
added to 0.8 g of CPC powder inside a plastic 2 mL-syringe according to results 
obtained in a previous study [10]. Micro-CT analyses was performed to confirm a 
similar porosity in both composite materials. And the initial PLGA volume fraction 
(prior to degradation) in the CPC was 56 ± 0.4 % and 53 ± 0.5 % for composites 
containing hollow or dense PLGA, respectively.
Finally, four different CPC compositions were created containing four types of 
PLGA microspheres: (1) hollow end capped, (2) dense end capped, (3) hollow 
acid terminated, and (4) dense acid terminated. All syringes were sealed with a 
closed tip and sterilized using gamma radiation.
Before implantation, 0.4 mL of sterile 2% Na2HPO4 solution was added to each 
sample and mixed vigorously for 30 sec (Silamat® mixing apparatus, Vivadent, 
Schaan, Liechtenstein). After removing the tip, mixtures were immediately injec-
ted into the femoral condyle defects.
2.5.Characterization of CPC-PLGA composites
Micro-computed tomography (µCT) was used to examine the morphological 
structure of the composites before PLGA degradation. Composites containing 
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dense and hollow microspheres were scanned at energy of 100 kV and intensity 
of 98 µA at a resolution of 2.26 µm pixel without filter (Skyscan -1072 X-ray mi-
crotomograph, TomoNT version 3N.5, Skyscan®, Belgium). Cone beam recons-
truction was performed and the data were analyzed by CT analyzer (version 1.4, 
Skyscan®). The region of interest (ROI), in which porosity was measured, was 
specified as a 1 mm x 1 mm x 1 mm cube.
2.6.Surgical procedure
24 healthy skeletally mature female 8 weeks old New Zealand White rabbits 
with a weight between 3.2 and 3.6 kg were used as experimental animals. The 
protocol was approved by the Animal Ethical Committee of the Radboud Univer-
sity Nijmegen Medical Centre (Approval no: RU-DEC 2010-004) and national 
guidelines for the care and use of laboratory animals were applied.
Surgery was performed under general inhalation anesthesia. The anesthesia 
was induced by an intravenous injection of Hypnorm (0.315 mg/mL fentanyl citra-
te and 10 mg/ml fluanisone) and atropine, and maintained by a mixture of nitrous 
oxide, isoflurane and oxygen through a constant volume ventilator. To reduce the 
peri-operative infection risk, the rabbits received antibiotic prophylaxis (Baytril®, 
2.5% (Enrofloxacin), 10 mg/kg). The animals were immobilized on their back and 
the hind limbs were shaved, washed and disinfected with povidone-iodine. After 
exposure of the distal femoral condyle a 1.0 mm pilot hole was drilled. The hole 
was gradually widened with drills of increasing size until a final defect size of 4 
mm in width and 6 mm in depth was reached. Low rotational drill speeds (max. 
450 rpm) and constant physiologic saline irrigation were used. After preparation, 
the defects were thoroughly irrigated and packed with sterile cotton gaze to stop 
bleeding. Surgery was performed in both legs of the rabbits and one defect was 
created in each condyle.
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The four different PLGA-CPC formulations were injected into the created 
condylar defects in a randomized manner (N=6). After injection, the superfluous 
cement was removed with a scalpel blade and soft tissues were closed layer-by-
layer using resorbable Vicryl sutures after approximately 10 minutes of setting. 
After 6 and 12 weeks of implantation, rabbits were euthanized using an over-
dose of Nembutal® and the femoral condyles were harvested for evaluation.
2.7.Histological procedures
After harvesting of the femoral condyles and removal of surrounding soft tissues, 
each condyle was divided into medial and lateral halves along its longitudinal 
axis. Subsequently, the medial half was fixed in 4% formaldehyde for 2 days, 
dehydrated in a graded series of ethanol and embedded in methylmethacrylate 
(MMA). After polymerization, at least three 10 µm sagittal cross sections of the 
condyle part containing the composite implants were prepared using a sawing 
microtome technique. Sections were stained with methylene blue/basic fuchsin 
and examined with a light microscope (Leica Microsystems AG, Wetzlar, 
Germany).
2.8.Histomorphometrical analysis
In addition to a subjective histological description, quantitative histomorpho-
metrical analysis was performed. Therefore, a 4 mm diameter circular area was 
superimposed on the bone defect area (Figure 1). Digitalized images (magnitude 
5x) were recorded and bone as well as cement content were determined by co-
lor recognition using image analysis techniques (Leica Qwin Pro-image analysis 
system, Wetzlar, Germany). During analysis, the evaluator was always blinded 
for the CPC composition.
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Figure 1: 4 mm circular zone used 
for the histomorphometrical measu-
rements.
2.9.Statistical analysis
All statistical analyses were performed with SPSS® software (IBM Corporation, 
Somers, NY, USA) using linear regression analysis to study the influence of 
PLGA end-group functionalization and PLGA microsphere morphology was 
evaluated as a combination and both parameters separately. A Student T-test 
was applied for comparison of the groups at different implantation periods. 
Significant differences between the groups were determined using analysis of 
variance (ANOVA). Results were considered significant if p<0.05.
3.Results
3.1.Characterization of PLGA microspheres and PLGA/CPC 
composites
PLGA microspheres displayed a round and smooth appearance with an average 
particle size of 50 ± 20 µm for hollow PLGA microspheres and 53 ± 6 µm for 
dense PLGA microspheres. All composite materials presented a good dispersion 
and homogeneous distribution of the polymeric microspheres. According to 
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previously obtained results, an average PLGA microsphere particle size of 50 
µm led to interconnected CPC porosity when a 20% loading percentage was 
used within CPC materials [8]. Representative SEM micrographs of both types of 
microspheres and both composite materials are depicted in Figure 2.
Figure 2:SEM micrographs of dense (A) and hollow (B) PLGA microspheres, 
as well as the CPC composites containing dense (C) and hollow (D) PLGA 
microspheres.
3.2.Clinical observations
All 24 rabbits exhibited good health and did not show any wound complication. 
At the end of the two implantation periods, a total of 48 implants were harvested 
(24 implants after 6 week implantation and 24 implants after 12 week implanta-
tion). At retrieval, no visual signs of inflammatory or adverse tissue reaction were 
observed.
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3.3.Descriptive light microscopy
3.3.1.CPC/ hollow end capped microspheres
Representative histological images at 6 and 12 weeks of implantation are 
depicted in Figure 3A and 4A, respectively. After both implantation times, the CPC 
showed an intact morphology without any evident sign of cement degradation. 
The edges of the created defect were clearly visible. No bone ingrowth into the 
CPC was observed due to the lack of degradation of the CPC-PLGA material. 
At the defect border, the bone was in tight contact with the CPC without the 
presence of an intermediate fibrous tissue layer. Bone remodeling areas were 
found sporadically in the bone-implant contact area. This was also confirmed at 
higher magnification (Figure 5A).
Figure 5: Histological sections at 6 weeks implantation of composites containing 
hollow end capped PLGA microspheres (A) and dense acid PLGA microspheres 
(B). No CPC degradation can be observed when hollow end capped microspheres 
act as porogen whereas bone ingrowth is visible when dense acid microspheres 
are used. Scale bare = 500 µm.
3.3.2.CPC/ dense end capped microspheres
At 6 weeks of implantation, the morphological appearance of CPC with den-
se end capped microspheres was similar to CPC containing hollow end capped 
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PLGA microspheres. No signs of PLGA microspheres or CPC degradation were 
detected (Figure 3B). The cement material presented an intact morphology and 
no new bone formation was observed at the defect borders. Only, sporadically 
bone remodeling lacunas were found in the peripheral area of the composite ma-
terial indicating the initiation of a bone remodeling process. 
Figure 3: Representative histological sections of the CPC-PLGA composites 
after 6 weeks of implantation. A: Hollow end capped PLGA microspheres. 
B: Dense end capped PLGA microspheres. C: Hollow acid PLGA 
microspheres. D: Dense acid PLGA microspheres. Composites containing 
end capped microspheres display an intact morphology. Composites with 
acid terminated microspheres reveal initial degradation of the surface when 
hollow microspheres are embedded, and enhanced degradation when 
dense microspheres are used as porogen. Scale bar = 1 mm.
In contrast, CPC degradation was clearly observed after 12 weeks of implan-
tation and newly formed bone was found in the areas where the cement had 
disappeared (Figure 4B). Cement degradation and new bone formation occurred 
mainly in the outer area of the CPC, but newly formed bone was also found in the 
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central part of the cement. This indicated that PLGA microspheres had degraded 
resulting in an open porosity, which allowed the ingrowth of bone throughout the 
material.
Figure 4: Representative histological sections of the CPC-PLGA composites 
after 12 weeks of implantation. A: Hollow end capped PLGA microspheres. B: 
Dense end capped PLGA microspheres. C: Hollow acid PLGA microspheres. 
D: Dense acid PLGA microspheres. Composites containing hollow end ca-
pped microspheres displayed initial degradation of the peripheral area of the 
implant. Composites with dense end capped microspheres exhibit enhanced 
degradation rates compared to composites containing hollow microspheres of 
the same chemical nature. Composites containing hollow acid terminated mi-
crospheres overcome peripheral degradation. Almost complete degradation 
of the CPC material can be observed when dense acid 
terminated microspheres are used. Scale bar = 1 mm.
3.3.3.CPC/ hollow acid terminated microspheres
Light microscopical examination of the CPC containing hollow acid terminated 
PLGA microspheres revealed clear signs of cement degradation in the peripheral 
area of the implant already after 6 weeks of implantation. Newly formed bone had 
grown into the space as created in the outer area of the implants. The bone was 
always in close contact with the cement surface. Degradation of the cement was 
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not associated with an increase in cellular activity. No sign of bone formation was 
observed in the inner areas of the cement (Figure 3C).
Degradation continued up to 12 weeks of implantation, when open porosity was 
observed mainly in the outer area of the material and the degraded microspheres 
had been replaced by bone. In addition, in the majority of the materials, some 
bone was observed in the inner areas of the cement, which indicated the pre-
sence of an interconnected porosity, allowing bone ingrowth through the material 
whereas other composites of the same group presented still a dense core in the 
interior area of the material (Figure 4C).
3.3.4.CPC/ dense acid terminated PLGA microspheres
The CPC containing dense acid terminated PLGA microspheres showed 
a completely different behavior compared to the other three materials. CPC 
scaffolds had lost their structural integrity already at 6 weeks of implantation, and 
bone growth was observed throughout the degraded CPC material (Figure 3D). 
In areas where CPC material was still present, a complete interconnected bone 
network could be observed indicating interconnection of the pore network (Figure 
5B). The deposited bone was constantly in close contact with the remaining ce-
ment. The newly formed bone had a woven appearance including the presence 
of remodeling lacunae.
At 12 weeks, the degradation had continued and the cement had disappeared 
to a large extent (Figure 4D). In areas with some remnants of CPC, images at 
higher magnification showed that newly formed bone tissue was visible in the 
pores (Figure 6). This newly formed bone was present in different stages of de-
velopment, stressing that the combination of CPC with dense acid terminated 
PLGA microspheres was highly supportive to new bone formation. Occasionally, 
a compact bone structure was observed (Figure 6A) growing as concentrically 
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distributed circular areas. Also, trabecular-like bone was visible as characterized 
by the presence of an open porous structure with active bone marrow formation 
(Figures 6B and 6C).
Figure 6: Mature bone development in histological sections with remnants 
of cement after 12 weeks implantation of composites containing dense acid 
terminated PLGA microspheres. Compact bone (A), different stages of 
trabecular bone with bone marrow in an early (B) or late (C) development stage. 
While early bone formation leads to the creation of a compact bone area, at 
a later bone development stage creation of a trabecular structure with bone 
marrow occurs. At the early development, small bone marrow areas are visible 
while	at	later	development	stages	larger	areas	of	bone	marrow	filled	with	blood	
cells can be observed.
3.4.Histomorphometry
3.4.1.Bone formation
Quantitative evaluation of the amount of bone formation after 6 and 12 
weeks of implantation revealed that bone formation increased with increasing 
implantation time (p<0.05). Significantly more bone formation was observed 
in the samples containing acid terminated PLGA microspheres than samples 
containing end capped PLGA microspheres (Figure 7). Samples containing dense 
acid terminated microspheres presented a larger amount of newly formed bone 
compared to composites containing hollow acid terminated PLGA microspheres. 
The statistical data revealed that at 6 weeks of implantation especially the end-
group functionalization (acid versus end capped) had a significant effect on new 
bone formation. At 12 weeks implantation time, statistical analysis revealed 
significant differences in amount of bone formation between CPC composites 
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varying in end-group functionalization, microsphere morphology and the 
combination of both. Composites containing dense-acid PLGA microspheres 
presented the largest amount of new bone formation at both implantation times.
3.4.2.Cement degradation
Quantitative evaluation of the amount of CPC degradation after 6 and 12 weeks 
of implantation revealed that cement degradation increased with increasing 
implantation time (p<0.05). Furthermore, composites containing dense acid 
terminated PLGA microspheres showed significantly more cement degradation 
after 6 weeks of implantation than the other three cement types (Figure 8). 
Regression analysis indicated that after 6 weeks of implantation, end-group 
functionalization had the most  dominant effect on CPC degradation as well as 
the combination acid end group with a dense microsphere morphology.
After 12 weeks, both types of composites (acid terminated and end capped) 
Figure 7: Quantitative evaluation of bone formation: Bone formation in the defect 
area (ROI) in the four composite types after 6 and 12 weeks of implantation.
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with dense microspheres showed a significantly increased degradation rate in 
comparison to composites containing hollow microspheres. Also, end-group 
functionalization as well as the combination end-group functionalization/PLGA 
morphology had a strong effect on CPC degradation.
Figure 8: Quantitative evaluation of cement degradation: Non-degraded cement 
in ROI of the four composite types after 6 and 12 weeks of implantation.
4.Discussion
Injectable, apatitic CPCs combine favorable clinical handling properties with 
an excellent biological response in bone tissue, but their low biodegradation ra-
tes are a yet unresolved problem. The current study provides strong evidence 
that truly biodegradable CPCs can be developed by exploiting the capacity of 
PLGA microspheres to accelerate CPC degradation and concomitant formation 
of new bone tissue. By varying  the end-group functionalization (acid versus end 
capped) as well as morphology (hollow versus dense) of PLGA microspheres, the 
rate of new bone formation after 12 weeks ranged from 5 to 55%. These results 
indicate that injectable CPCs can be developed with custom-made biodegrada-
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tion rates that match the formation of new bone.
The degradation mechanism of resorbable implants such as PLGA has been 
described as a five consecutive steps process; hydration, chemical cleavage of 
the polymer backbone, loss of integrity, absorption and elimination [15,16]. In the 
particular case of PLGA, the chemical cleavage that takes place is the hydrolytic 
degradation of its ester linkages in the presence of water. After losing integrity, 
complete resorption of the PLGA implant occurs in the last step, when the degra-
dation products enter the Krebs cycle and are secreted as carbon dioxide and 
water. The end-group functionalization plays an important role in the degradation 
rate, especially during the first and second degradation step. End-capped PLGA 
experiences reduced polymer interactions with the water molecules if they take 
place in the COOH end of PLGA delaying polymer degradation.
During PLGA degradion lactic and glycolic acidic monomers are released due 
to the hydrolytical cleavage of the covalent esters bonds forming the polymer 
backbone. It was reported earlier that calcium phosphate dissolution rate is 
accelerated in a demineralizing solution that mimics the acidic environment as 
produced by osteoclasts [17]. The current study hypothesized that an acidified 
environment caused by PLGA degradation can evoke a similar reaction. However, 
acidification of a bone defect site can induce an adverse reaction of the host bone 
tissue due to the occurrence of an inflammatory response [18,19]. Inflammation 
leads to the creation of a fibrous tissue formation in the vicinity of the bone 
substitute, preventing bone formation around and within the material. 
In this study, four different CPC compositions have been assessed for their 
potential to degrade and support formation of new bone tissue at 6 and 12 weeks 
after their injection into the femoral condyle of rabbits defects. Histological and 
morphological analysis indicated that the majority of composites containing acid 
terminated PLGA microspheres showed initial degradation after 6 weeks implan-
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tation time, resulting into the creation of a porous CPC material. In contrast, CPC 
containing end capped PLGA microspheres presented an intact morphology after 
6 weeks of implantation, although degradation was observed at 12 weeks. The 
efficiency of the end-group functionalization to control PLGA degradation has 
been previously reported in vitro [10] and it is now also confirmed under in vivo 
conditions. Evidently, end-group functionalization plays a very important role in 
PLGA degradation and thus creation of CPC porosity. 
In the current study PLGA was applied in the form of microspheres with two 
different morphologies (hollow versus dense) in combination with CPC. This 
different morphology allows the encapsulation of a higher amount of PLGA (by 
weight) when dense PLGA microspheres are used in comparison to hollow 
microspheres. Due to the well known buffering capacity of CaP material, our 
hypothesis was that CPC may overcome the enhanced acidity upon of the PLGA 
dense microsphere degradation. Histological and histomorphometrical analysis 
confirmed that the amount of newly formed bone was significantly higher for 
CPC incorporating dense PLGA microspheres compared to the use of hollow 
microspheres without the occurrence of any inflammatory reaction. This effect 
was apparent already after 6 weeks of implantation when acid terminated PLGA 
was used as starting material and after 12 weeks for the use of end capped PLGA. 
The increase in the amount of bone within the defect area could be related to the 
dissolution rate of the CPC, as the cement area was significantly reduced for the 
CPC containing dense microspheres in comparison to CPC incorporating hollow 
microspheres. This confirms the capacity of dense microspheres to enhance 
CPC porosity after the hydrolytical PLGA cleavage and the ability of the buffering 
capacity of the CPC and/or the surrounding tissues to overcome the associated 
increase in acidity.
The observed accelerated degradation of CPC containing dense microsphe-
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res was also associated with an autocatalytic effect in PLGA hydrolysis that is 
known to affect degradation of PLGA bulk implants. When PLGA degradation 
occurs, lactic and glycolic acid monomers are released decreasing the pH in the 
surrounding area of the polymer. Dense microspheres, because of the higher 
PLGA content, generate more acidic monomers during degradation than hollow 
PLGA microspheres. A larger content of acidic monomers will thus catalyze PLGA 
degradation. This is in agreement with previous studies where it was described 
that lower pH values stimulate the PLGA degradation rate [20,21].
Summarizing, it can be concluded that the incorporation of dense, non-capped 
PLGA microspheres into CPC resulted into the most pronounced local acidifica-
tion compared to the other types of microspheres without causing any excessive 
inflammation. As a result, the CPC matrix containing these dense non-capped 
PLGA microspheres dissolved considerably faster, resulting into significantly 
more macroporosity and corresponding replacement by newly formed bone tis-
sue. 
Besides the passive resorption of CPC due to PLGA microsphere degradation, 
osteoclastic activity can have an effect on the remodeling of calcium phosphate 
material [22,23]. It is known that osteoclastic activity can be stimulated under 
acidic conditions [24,25]. As a consequence the acidified milieu as created by the 
degradation of the dense microspheres may not only have a positive effect by 
accelerating CPC degradation by chemical dissolution, but also by stimulating its 
resorption by osteoclast activity. 
5.Conclusion
Injectable calcium phosphate cements (CPCs) have been developed with 
enhanced degradability by fine-tuning chemical and morphological characteristics 
of PLGA microspheres without compromising the excellent bone response of the 
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ACCELERATED CALCIUM 
PHOSPHATE CEMENT 
DEGRADATION DUE TO 
INCORPORATION OF GLUCONO 
DELTA-LACTONE AS POROGEN
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1.Introduction
Bone tissue consists of calcium phosphate mineral crystals for about 70 wt% 
(specifically hydroxyapatite). Correspondingly, synthetic hydroxyapatite ceramics 
have been shown to stimulate osteoblast adhesion and differentiation in seve-
ral in vitro studies [1-4]. Hydroxyapatite scaffolds of complex three-dimensional 
geometries can be fabricated by a wide variety of techniques [5], but they are not 
easily applicable in locations with difficult accessibility such as maxillofacial bone 
defects. In 1986, injectable calcium phosphate cement (CPC) was developed by 
L.C. Chow and W.E. Brown [6]. Calcium phosphate powder generates a molda-
ble paste when mixed with an aqueous solution that can be shaped after injection 
to fit to the irregularities of bone defects.
Still, apatitic CPC is poorly resorbable and cannot be substituted by new bone 
tissue in time. To enhance the speed of CPC replacement by newly formed bone, 
various polymeric porogens have been included in CPC. Provided that these 
porogens degrade at a faster rate than the ceramic CPC, a porous scaffold can 
be obtained which is accessible for fluid flow and ingrowth of new bone tissue, 
thereby enhancing its degradation rate. An ideal porogen is biocompatible, fast-
degradable, cost-effective, available off-the-shelf and easy to handle by surgeons 
in the operation room.
Porogens can be classified depending on their degradation pathways. Porogens 
such as poly-trimethylene-carbonate [7] or gelatin [8] undergo enzymatic digestion 
that leads to slow surface erosion and degradation. Gelatin is well known for 
its excellent biocompatibility and therefore it is being used in various medical 
areas. Upon use as porogen in CPC in vivo, however, very slow degradation 
rates were observed [9]. On the other hand, porogens such as poly(lactic-co-
glycolic) acid (PLGA) degrade by hydrolysis [10]. PLGA has been used frequently 
as pore generator because, among several other advantages, it degrades into 
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lactic and glycolic acid which are eliminated from the body by the Krebs cycle as 
carbon dioxide and water once the pores have been created in the CPC material. 
These acidic lactic and glycolic acid monomers  were recently shown to enhance 
calcium phosphate cement dissolution both in vivo and in vitro [11; 12].
Despite the fact that CPC formulations containing PLGA microspheres revea-
led enhanced degradation and abundant new bone formation throughout the 
scaffold, degradation rates of PLGA containing CPCs are still in the order of se-
veral months depending on the chemical nature of the PLGA porogens [13,14]. 
In contrast to the relatively slow degradation rates of PLGA, inclusion of 
glucono-delta-lactone (GDL) as porogen into CPC would allow for fast creation 
of macroporosity within apatitic CPC owing to its fast dissolution in aqueous 
media. GDL is a neutral compound that hydrolyzes gradually in aqueous systems 
to gluconic acid, thereby leading to a local acidification which facilitates the 
dissolution of surrounding CPC matrix and formation of macroporosity [15]. No 
major adverse biological effects were expected since GDL is a naturally occurring 
food-additive which is metabolized to glucose. GDL is classified as GRAS 
(Generally Recognized As Safe) for use as curing and pickling agent, pH control 
agent or as sequestrant. Finally, GDL is commercially available as fine powder 
in contrast to gelatin or PLGA, which adds to the attractiveness of GDL since it 
can be mixed directly with the powder phase of CPCs without the need for further 
processing into microspheres.
Therefore, the aim of the current study was to investigate the effect of incorpo-
ration of GDL as porogen into CPC both in vitro and in vivo. First, in vitro studies 
have been performed using MicroComputed Tomography, Reverse Phase High 
Performance Liquid Chromatography, X-Ray Diffraction and Scanning Electron 
microscopy to optimize the cement formulations containing GDL. Second, two 
CPC-GDL formulations containing either low (10%) or high (30 wt%) amounts 
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of GDL (abbreviated as CPC-10%GDL and CPC-30%GDL) were selected for 
further in vivo evaluation in an established orthotopic implantation model in order 
to test the bone response and degradation behaviour of CPCs containing GDL. 
These GDL-containing formulations were compared to CPCs containing poro-
gens made of either gelatin or PLGA. CPC degradation and new bone formation 
were evaluated histologically and histomorphometrically after 2 and 12 weeks of 
implantation.
2.Materials and Methods
2.1.Materials
CPC powder consisted of a mixture of 85% alpha-tricalcium phosphate (a-TCP; 
CAM Bioceramics BV, Leiden, the Netherlands), 10% dicalcium phosphate 
anhydrous (DCPA; Sigma Aldrich, St. Louis, MO, USA) and 5% precipitated 
hydroxyapatite (pHA; Merck, Darmstadt, Germany). Na2HPO4 was purchased 
from Merck (Darmstadt, Germany).
PLGA Purasorb® materials were obtained from Purac Biomaterials (Gorin-
chem, the Netherlands). Purasorb® PDLG 5002A (Mw = 17 kDa, acid terminated, 
L:G = 50:50) was used to prepare microspheres. Polyvinyl alcohol (PVA; 88% 
hydrolyzed, MW = 22 kDa) was obtained from Acros (Geel, Belgium) and iso-
propanol (IPN; analytical grade), dichloromethane (DCM; analytical grade) and 
D-(+)-Glucono-delta-lactone were obtained from Merck (Darmstadt, Germany). 
Anionic gelatin (from bovine skin, Type B Bloom 225, IEP~5) as well as aceto-
ne and glycine was purchased from Sigma-Aldrich (St. Louis, MO, USA). Olive oil 
and glutaraldehyde (GA, 25 wt% solution in water) were commercially available 
from Acros Organics (Geel, Belgium).
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2.2.Preparation and characterization of PLGA and 
gelatin microspheres
Dense PLGA microspheres were prepared by a single emulsion technique. 
Briefly, 0.2 g of PLGA was dissolved in 2 mL of DCM in a 20 mL glass tube. Then, 
this solution was transferred into a stirred beaker containing 100 mL of 0.3% PVA 
solution. Subsequently, 50 mL of 2% IPN solution was added. The solution was 
stirred for one hour. The microspheres were allowed to settle for one hour and 
the clear solution was decanted. The remaining suspension was centrifuged and 
the clear solution on top was aspirated. Finally, the microspheres were frozen, 
freeze-dried for 24 hours and stored at -20ºC.
The morphology and size distribution of the PLGA microspheres was determi-
ned by light microscopy. Microspheres were suspended in H2O and pictures were 
taken with an optical microscope equipped with a digital camera (Leica/Leitz DM 
RBE Microscope system, Leica Microsystems AG, Wetzlar, Germany). The size 
distribution of the microspheres was determined by digital image software (Leica 
Qwin®, Leica Microsystems AG, Wetzlar, Germany) using a sample size of at 
least 300 microspheres. In addition, morphology of the microspheres was ob-
served by Scanning Electron Microscopy (SEM, JEOL 6310) at an accelerating 
voltage of 10 kV.
Gelatin microspheres were prepared using a surfactant-free water-in-oil emul-
sion method. A 10 w/v% gelatin solution was obtained by dissolving gelatin in 
deionized water at 45°C. Thereafter, 10 mL of this gelatin solution was added 
dropwise into a 500ml round bottom flask containing 300 mL olive oil while stirring 
at 500 rpm (upper stirrer) at 45°C. Spontaneous gelation of the gelatin droplets 
was then obtained by moving the emulsion into an ice bath under continuous 
stirring. After 30 minutes, 150 mL of chilled acetone (4°C) was then added to the 
emulsion followed by another 15 minutes of stirring. Gelatin microspheres without 
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crosslinking were collected by filtration (Whatman 90 mm filterpaper) and washed 
with chilled acetone to remove residual olive oil. Subsequently, gelatin micros-
pheres were re-suspended in water/acetone (1/3 in volume ratio) solution, and 
further crosslinked using GA with a molar ratio of GA relative to the amount of free 
amine groups present in gelatin of 0.5. After crosslinking for 16 hours, glycine so-
lution (100 mM) was added into the microsphere suspension to block unreacted 
aldehyde groups from GA. The suspension was then subjected to three cycles of 
centrifugation (5000 rpm for 5 minutes) and re-suspension in deionized water by 
vortexing. After freeze-drying, microspheres were stored at 4 °C until further use.
2.3.Preparation of cement formulations containing 
PLGA, gelatin or GDL porogens
First, the amount of porogen was optimized to yield comparable volumetric 
percentages of porogen for PLGA, gelatin and GDL. Several CPC-porogen com-
binations were scanned using uCT (Skyscan -1072 X-ray microtomograph, To-
moNT version 3N.5, Skyscan®, Belgium; X-ray source was set to100 kV, current 
to 98 µA and the resolution was 7 µm pixel). Cone beam reconstruction was 
performed and the data were analyzed by CT analyzer software (version 1.4, 
Skyscan®).The resulting weight percentages of the porogens in order to achieve 
comparable CPC porosity were equal to 5 wt% for gelatin (CPC-gelatin), 31 wt% 
for PLGA (CPC-PLGA) and 30 wt% GDL (CPC-30%GDL) yielding volumetric 
percentages of porogen in the CPC pre-set discs of 53 ± 3 % for CPC-gelatin, 
50 ± 4 % for CPC-PLGA and 48 ± 2 % for CPC-30%GDL. In addition, a fourth 
CPC-GDL formulation was fabricated by reducing the amount of GDL to 10 wt% 
corresponding to a volumetric porogen percentage of 19 ± 2 % (CPC-10%GDL) 
in order to test if low amounts of GDL can produce sufficient acidity to degrade 
CPCs without be compromising the biocompatibility of CPC-GDL formulations. 
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Subsequently, the amount of liquid phase was optimized to obtain cement for-
mulations that exhibited comparable injectability and setting properties. It was 
observed that considerably lower amounts of liquid phase (2 w/v% aqueous solu-
tion of Na2HPO4) were needed for GDL-containing formulations to yield handling 
properties similar to composites containing PLGA or gelatin. Therefore, 350 µL 
of aqueous Na2HPO4 solution were added to composites containing gelatin or 
PLGA, whereas 290 µL or 210 µL of aqueous Na2HPO4 solution were added to 
the powder precursor phase for CPCs containing 10% or 30% of GDL, respecti-
vely. 
After combining all liquid and powder precursor compounds as well as po-
rogens, the mixtures were mixed vigorously for 30 seconds in 2 mL syringes 
(Silamat® mixing apparatus, Vivadent, Schaan, Liechtenstein) and the cement 
was injected into Teflon molds (6 mm x 3 mm). Initial and final setting times of 
the different CPC pastes were assessed using Gilmore needles (ASTM C266). 
Briefly, a bronze block was used as mould containing holes of 6 mm diameter and 
12 mm height. The mould was placed in a water bath at 37ºC. Samples of each 
formulation were mixed and injected into the mould and initial and final setting 
time was determined (see Table 1), confirming that initial setting times were equal 
for CPC-PLGA, CPC-gelatin, CPC-10%-GDL, whereas longer initial setting times 
were observed for formulations containing the highest amount of GDL (CPC-
30%GDL). 
Initial setting time 
(minutes)
Final setting time 
(minutes)
CPC-PLGA 3.0 ± 0.1 15.2 ± 0.3
CPC-gelatin 3.2 ± 0.4 16.1 ± 0.5
CPC-10%GDL 3.2 ± 0.2 16.3 ± 0.5
CPC-30%GDL 4.6 ± 0.1 20.2 ± 0.2
Table	1:	Initial	and	final	setting	time	of	CPC	materials
 140 
DEGRADATION OF CALCIUM PHOSPHATE CEMENTS
To investigate the rate of GDL hydrolysis, pre-set CPC-30%GDL composites 
were incubated at 37 ºC in 1.5 mL of phosphate buffered saline (PBS) for 30 
minutes, 1 day, 3 days and 5 days. The amount of gluconic acid in the incubation 
media of the different CPC-GDL composites was analyzed by Reverse Phase 
High Performance Liquid Chromatography (RP-HPLC) as a measurement of 
GDL degradation. The system consisted of a Hitachi L2130 HPLC pump, Hitachi 
L-2400UV detector and Hitachi L-2200 auto sampler, and an Atlantis dC18 
column (Waters) 250 mm x 4.6 mm, 5 µm. Two mobile phases were used; 1% 
acetonitrile in 20 mM NaH2PO4 pH= 2.2 (mobile phase A) and 100% acetonitrile 
(mobile phase B). The flow was 0.5 mL per minute, the injection volume 40 µL 
and the UV detection wavelength 210 nm.
The crystal structure of the CPC containing 30% GDL was evaluated after 
crushing pre-set samples (24 hours at room temperature followed by 24 hours 
of freeze drying) before and after soaking in PBS for 3 days with a mortar until 
the discs were reduced to a fine powder and subsequently analyzed using X-Ray 
Diffraction (XRD) (PW3710 Philips, The Netherlands) using a Cu Ka radiation 
source at a wavelength of 1.5405 Ǻ, an accelerating voltage of 40 kV and a cu-
rrent of 30 mA. Diffractograms were collected for 2θ values between 3° and 45°.
Morphology of the CPC materials was observed by Scanning Electron 
Microscopy (SEM, JEOL 6310) at an accelerating voltage of 10 kV after being 
lyophilized for 24 hours.
2.4.Preparation and characterization of injectable CPC 
composites for in vivo implantation
In order to prepare CPC-PLGA composites, 0.36 g of dense PLGA microspheres 
was added to 0.8 g of CPC powder yielding a mass percentage of 31 wt% PLGA.
Two different CPC-GDL composites were prepared containing either 10 wt% 
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GDL or 30 wt% GDL. Briefly, 0.1 g of GDL was mixed with 0.9 g of CPC (abbrevia-
ted as CPC-10%GDL) or 0.3 g of GDL were mixed with 0.7 g of CPC (abbreviated 
as CPC-30%GDL). All formulations containing PLGA or GDL were sterilized in 
the 2 mL syringes (sealed with a closed tip) using gamma radiation (25-50 kGy; 
Isotron BV, Ede, the Netherlands). Gelatin microspheres, on the contrary, were 
sterilized prior to mixing with the CPC precursor powder by exposure to ethylene 
oxide (Isotron BV, Ede, the Netherlands) to avoid excessive additional crosslin-
king of gelatin microspheres due to gamma irradiation. Ethylene oxide steriliza-
tion was carried out as a mixed cycle consisting of 10 hours pre-conditioning, 3 
hours dwell time, 10 hours of sterilization and 48 hours of post-conditioning. 0.05 
g of sterile gelatin microspheres were mixed with 200 µL of filter-sterilized dH2O 
and subsequently mixed after 10 minutes of microsphere swelling with 0.95 g of 
CPC powder (sterilized previously using gamma irradiation under the conditions 
as described above) in a 2 mL plastic syringe, yielding a gelatin mass percentage 
of 5 wt%.
CPC was formed by adding 350 µL of aqueous Na2HPO4 solution to composi-
tes containing gelatin or PLGA, whereas 290 µL or 210 µL of aqueous Na2HPO4 
solution were added to the powder phase for CPCs containing 10% or 30% of 
GDL, respectively. Subsequently, the mixtures were mixed vigorously for 30 se-
conds and the cement was injected into the bone defects.
2.5.Surgical procedure
24 skeletally mature female 8 weeks old New Zealand White rabbits with a 
weight between 3.2 and 3.6 kg were used as experimental animals. The protocol 
was approved by the Animal Ethical Committee of the Radboud University Nijme-
gen Medical Centre (Approval no: RU-DEC 2010-174) and national guidelines for 
the care and use of laboratory animals were applied.
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Surgery was performed under general inhalation anesthesia. The anesthesia 
was induced by an intravenous injection of Hypnorm (0.315 mg/mL fentanyl citra-
te and 10 mg/ml fluanisone) and atropine, and maintained by a mixture of nitrous 
oxide, isoflurane and oxygen through a constant volume ventilator. To reduce the 
peri-operative infection risk, the rabbits received antibiotic prophylaxis (Baytril®, 
2.5% (Enrofloxacin), 10 mg/kg). The animals were immobilized on their back and 
the hind limbs were shaved, washed and disinfected with povidone-iodine. After 
exposure of the distal femoral condyle a 1.0 mm pilot hole was drilled. The hole 
was gradually widened with drills of increasing size until a final defect size of 4 
mm in width and 6 mm in depth was reached. Low rotational drill speeds (max. 
450 rpm) and constant physiologic saline irrigation were used. After preparation, 
the defects were thoroughly irrigated and packed with sterile cotton gaze to stop 
bleeding. Surgery was performed in both legs of the rabbits and one defect was 
created in each condyle.
The four different CPC formulations were injected into the created condylar de-
fects in a randomized manner (N=6). After injection, the superfluous cement was 
removed with a scalpel blade and soft tissues were closed layer-by-layer using 
resorbable Vicryl sutures after approximately 10 minutes of setting. 
After 2 and 12 weeks of implantation, rabbits were euthanized using an over-
dose of Nembutal® and the femoral condyles were harvested for evaluation.
2.6.Histological procedures 
After harvesting of the femoral condyles and removal of surrounding soft tissues, 
each condyle was divided into medial and lateral halves along its longitudinal 
axis. Subsequently, the medial half was fixed in 4% formaldehyde for 2 days, 
dehydrated in a graded series of ethanol and embedded in methylmethacrylate 
(MMA). After polymerization, at least three 10 µm sagittal cross sections of 
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the condylar part containing the composite implants were prepared using a 
sawing microtome technique. Sections were stained with methylene blue/basic 
fuchsin and examined with a light microscope (Leica Microsystems AG, Wetzlar, 
Germany).
2.7.Histological and histomorphometrical analysis
In addition to a subjective histological description, quantitative histomorpho-
metrical analysis was performed. Therefore, a 4 mm diameter circular area was 
superimposed onto the bone defect area as region of interest (ROI) for further 
quantifications of new bone formation (Figure 1). Digital images (magnitude 5x) 
were recorded and bone as well as cement content were determined by color 
recognition using image analysis techniques (Leica Qwin Pro-image analysis 
system, Wetzlar, Germany).
Next to conventional bone measurements by color recognition, measurements 
of new bone formation were also expressed relative to a region of interest (ROI) 
consisting of 100% trabecular bone (TB) to avoid underestimation of new bone 
formation due to the presence of bone marrow and fat tissue in the trabecular 
Figure 1: 4 mm circular region of in-
terest (ROI) used for the 
histomorphometrical measurements.
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2.8.Statistical analysis
All statistical analyses were performed with SPSS® software (IBM Corporation, 
Somers, NY, USA). Significant differences between the groups were determined 
using analysis of variance (ANOVA). A Tukey-Kramer (Multiple Comparisons) 
Test was applied for comparison of the groups at different implantation periods. 
Results were considered significant if p<0.05.
3.Results
3.1.Physicochemical characterization of porogens and 
composites
The average microsphere size was 42 ± 5 µm for PLGA microspheres and 37 
± 10 µm for swollen gelatin microspheres. In contrast, the size of commercially 
available GDL microparticles was 595 ± 40 µm (Figure 2). SEM micrographs of 
the pre-set CPC composites revealed the presence of micron-sized porogens 
within a nanoporous CPC matrix for compo-
sites containing PLGA or gelatin, whereas 
single porogens were not recognizable in for-
mulations containing 10% GDL., A remarkably 
compact morphology was observed for CPC-
30%GDL formulations in which the amount of 
nanoporosity was considerably reduced as 
well as the initial GDL particle size (Figure 3). Figure 2: SEM picture of GDL microparticles.
bone as present in femoral condyles. A region of interest consisting of 100 % 
trabecular bone corresponded to a value 70 vol% of trabecular bone tissue in the 
rabbit femoral condyles, the remaining 30 vol% consisting of  bone marrow or fat 
tissue. 
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Figure 3: SEM pictures of CPC-PLGA (A), CPC-gelatin (B),CPC-
10%GDL (C), and CPC-30%GDL (D) composites after setting during 24 
hours at room temperature followed by 24 hours of lyophilization.
3.2.CPC-GDL in vitro tests
The rapid dissolution rate of GDL upon incorporation into CPC can be obser-
ved in the RP-HPLC results (Figure 4). After 1 day of incubation in PBS the ma-
jority of the GDL was released and detected by HPLC (96 % ± 2).
Figure 4: Detection of gluconic acid release from pre-set CPC-30%GDL 
composites by means of RP-HPLC
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Regarding the XRD results (Figure 5), it was observed that the diffraction 
peaks related to the CPC phase in the CPC-30%GDL composites (characterized 
by sharp reflections at 22.9, 30.7 and 34.2 º2θ for the cement precursor α-TCP 
according to the Joint Committee on Powder Diffraction Standards file 9-348) 
were unaltered by inclusion of 30% GDL. Additional reflection peaks were obser-
ved that were attributed to crystalline GDL. These observations indicate that the 
incorporation of up to 30 wt% of GDL did not hamper the setting of the CPC by 
precipitation of apatitic nanocrystals. After incubation of the CPC-30%GDL sam-
ples in PBS for three days, the intensity of the GDL peaks decreased in intensity 
considerably.
Figure 5: X-ray diffraction (XRD) analyses of the calcium phosphate cement discs 
after setting during 24 hours at room temperature followed by 24 hours of  lyophili-
zation. The XRD powder patterns of 100% GDL (A), 100% CPC (B), CPC- 30% GDL 
(C), CPC-GDL after 3 days incubation in PBS (D), CPC after 3 days incubation in 
PBS	(E).	(*=	GDL	peaks,	+=	α-TCP	peaks	according	to	JCPDS	file	9-348).
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3.3.Pre-clinical observations
All 24 rabbits exhibited good health and did not show any wound complications. 
At the end of the two implantation periods, a total of 48 implants were retrieved (12 
rabbits x 24 implants after 2 weeks of implantation and 12 rabbits x 24 implants 
after 12 weeks of implantation). At retrieval, no visual signs of inflammatory or 
adverse tissue reactions were observed.
3.4.Descriptive light microscopy
A uniform tissue reaction was observed for specimens of the same experi-
mental group and implantation time. Representative light microscope sections 
corresponding to 2 and 12 weeks implantation time are presented in Figure 6 and 
Figure 7, respectively.
Examination of the sections after 2 weeks implantation revealed variable 
amounts of cement degradation and new bone formation in the region of interest 
(ROI).The newly formed bone displayed a cancellous structure similar to the pre-
existing bone in the vicinity of the defect location. CPC-PLGA  and CPC-gelatin 
Figure 6: Histological sections at 2 
weeks implantation of CPC-PLGA 
(A), CPC-gelatin (B), CPC-10%GDL 
(C), and CPC-30%GDL (D) compo-
sites.
 148 
DEGRADATION OF CALCIUM PHOSPHATE CEMENTS
composites presented an intact circular shape which confirmed that these CPC-
based formulations did neither degrade nor were substituted by new bone tissue. 
In contrast, CPC degradation was clearly observed in the peripheral areas of the 
circular defects that were filled with CPC-10%GDL. These degraded areas were 
substituted with newly formed bone tissue. For CPC-30%GDL, on the contrary, 
only minor degradation was observed in the peripheral areas of the defects.
After 12 weeks of implantation, the majority of the CPC-PLGA composites 
were completely degraded and only small remnants of CPC were observed in 
between the newly formed interconnected bone network. CPC-gelatin compo-
sites revealed minor degradation of the implant peripheral area and limited new 
bone formation occurred throughout these degraded implant margins. Regarding 
CPC-10%GDL composites, major degradation of the material was detected and 
excessive new bone formation was observed throughout the entire ROI. Similar 
to the CPC-PLGA, a cancellous bone network was formed in the defect location 
after degradation of CPC-10%GDL implants. In CPC-30%GDL composites, ce-
ment degradation and concomitant new bone formation was only observed in the 
Figure 7: Histological sections at 
12 weeks implantation of CPC-
PLGA (A), CPC-gelatin (B), CPC-
10%GDL (C), and CPC-30%GDL 
(D) composites. * = undissolved 
GDL crystals.
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outer regions of the circular implant, whereas big undissolved GDL particles with 
and approximated size of 500 µm were observed within the CPC matrix (Figure 
7D).
For both CPC-10%GDL and CPC-30%GDL, no signs of inflammatory respon-
se were observed.
3.5.Histomorphometry
3.5.1.Bone formation
Quantitative evaluation of new bone formation within the ROI revealed that 
the amount of newly formed bone varied considerably among the experimental 
groups (Figure 8). 
Figure 8: Quantitative evaluation of bone formation: Bone formation in the defect 
area (ROI) in the four composite types after 2 and 12 weeks of implantation. 
(a)	significantly	different	compared	to	CPC-10%GDL
(b)	significantly	different	compared	to	CPC-30%GDL
(c)	significantly	different	compared	to	CPC-PLGA
(d)	significantly	different	compared	to	CPC-gelatin
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After 2 weeks implantation CPC-10%GDL showed significantly higher amounts 
of new bone formation (32.8 %) compared to all other experimental groups 
(p<0.001). CPC-30%GDL presented significantly more newly formed bone 
(12.5%) than composites with PLGA (2.0 %) or gelatin (1.9 %) microspheres 
(p<0.05).
After 12 weeks implantation CPC-PLGA (64.0 %) and CPC-10%GDL (66.0 
%) revealed significantly (p<0.001) enhanced bone formation in comparison to 
CPC-30%GDL (25.8 %) and CPC-gelatin (4.4 %). CPC-30%GDL composites dis-
played significant more bone formation than CPC-gelatin (p<0.01).
3.5.2.Bone formation relative to trabecular bone
After 2 weeks implantation, values for new bone formation relative to a region 
of interest solely composed of trabecular bone equalled  46.8 %, 17.9%, 2.9 %, 
2.8 % for defects that were filled with CPC-10%GDL, CPC-30%GDL, CPC-PLGA 
and CPC-gelatin, respectively.
Figure	9:	Bone	formation	relative	to	a	ROI	filled	with	trabecular	bone	after	12	weeks	
implantation.	Significantly	(*)	less	fone	formation	occurred	within	CPC-30%GDL	and	
CPC-gelatin	samples	when	compared	to	a	ROI	filled	with	trabecular	bone.
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After 12 weeks implantation both CPC-PLGA (91.4 %) and CPC-10%GDL 
(94.3 %) specimens revealed similar new bone formation values as when the 
region of interest is filled for 100% with bone, confirming that trabecular bone 
was regenerated almost completely using these implants. On the contrary, signifi-
cantly less bone formation occurred for CPC-30%GDL (36.8 %) and CPC-gelatin 
composites (6.2 %) (p< 0.01) (Figure 9).
4.Discussion
The aim of the current study was to evaluate the application of glucono-delta-
lactone (GDL) as porogen in calcium phosphate cements (CPCs) both in vitro and 
in vivo to render these injectable bone fillers resorbable within weeks rather than 
months. It was hypothesized that the incorporation of GDL would result into a fast 
generation of porosity within apatitic CPCs, thus enhancing CPC degradation rates 
and subsequent replacement by newly formed bone compared to formulations 
containing conventional porogens such as PLGA. The results indeed confirmed 
that incorporation of GDL resulted into enhanced CPC degradation at early time 
points (2 weeks) and almost complete resorption of the CPC and substitution by 
newly formed bone tissue at later time points (12 weeks).
GDL is a commonly used additive in the food industry and it is applied in a 
variety of products such as a.o. milk [16], cheese [17] or cookies [18]. Recently, 
the use of GDL in biomedical applications has also been investigated for appli-
cations as acidifier in alginate hydrogels for tissue engineering applications [19] 
or as a part of cell-biomaterials constructs for regenerative medicine [20].  Within 
the current study, it was observed that GDL positively influences the injectabili-
ty of CPCs since GDL-containing CPCs were injectable at considerably lower 
liquid-to-powder ratios without compromising the final setting times. Inclusion of 
GDL resulted into local acidification, thereby increasing the dissolution rate of 
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α-TCP precursors. As such, GDL acts as accelerator of cement setting similar 
to the addition of acidic phosphates such as Na2HPO4 in the liquid phase of 
the CPC. In other studies the addition of acidic components such as citric acid 
was also shown to improve CPC injectability and setting properties [21,22]. Local 
acidification of the microenvironment of the setting cement will have resulted into 
increased (positive) charges of the precursor powders and precipitating apatitic 
nanoparticles, thereby increasing the interparticle repulsion forces which are res-
ponsible for the observed improved injectability.
Upon inclusion of 30% of GDL microparticles, the morphology of the resulting 
composites was less granular and more compact than the nanoporous morpholo-
gies of other experimental groups. This compaction was also suggested to relate 
to the acidification caused by the incorporation of GDL. GDL might have acted as 
dispersant by increasing the positive surface charge of precipitating apatitic na-
noparticles. Compaction of ceramic slurries and cements depends on achieving 
the dispersion of fine ceramic particles in an aqueous medium by electrostatic/
steric stabilization. As a result, the formation of a heterogeneous structure contai-
ning large powder agglomerates can be avoided while a uniform particle packing 
will result into a better microstructure.  Acidic additives such as hyaluronic acid 
were shown before to  improve the mechanical strength and cohesion of CPCs 
[23-25].
The PLGA microspheres used in the current study were fabricated from 17 
kDa acid terminated polymers. Microspheres of these chemical and morpholo-
gical characteristics were the material of choice due to their recently observed 
beneficial properties with respect to CPC degradation and new bone formation 
[12]. As before, the results from the current study confirmed the efficacy of dense 
PLGA microspheres as a porogen for CPCs. Nevertheless, degradation of the 
CPC-PLGA composites did not occur after 2 weeks of implantation (2 % of new 
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bone formation) whereas a large part of the CPC-10%GDL materials was degra-
ded and replaced by newly formed bone (32.8 % of new bone formation). These 
differences in the rate of new bone formation for CPCs containing GDL vs. PLGA 
can be attributed to differences in the time necessary to generate CPC porosity 
owing from the different physicochemical characteristics of PLGA and GDL. The 
relatively slow degradation of PLGA porogens is related to the lag time between 
initial exposure of the hydrophobic PLGA to water and the actual hydrolytical de-
gradation of the water-insoluble polymer into lactic and glycolic acid monomers. 
GDL, on the other hand, is a highly hydrophilic monomer with a solubility of 47% 
in water [26]. Upon contact with an aqueous solution, GDL dissolves rapidly fo-
llowed by hydrolytical cleavage of the cyclic ester into gluconic acid. The current 
results revealed that GDL undergoes almost complete hydrolytical degradation 
within 24 hours in PBS upon incorporation into CPC. In contrast, hydrolytical 
cleavage occurs at much later time points for 17 kDa PLGA microspheres within 
CPC [11] since it was observed that comparable degrees of hydrolysis (90%) 
were observed after 9 weeks only for PLGA. Moreover, GDL microparticles were 
about 10x bigger than PLGA microspheres.
Interestingly, inclusion of high amounts (30%) GDL did lead to less bone 
formation (12.5 %) than 10 % GDL after 2 weeks of implantation. This observation 
can be related to the reduced fluid flow throughout the CPC-30%GDL composites 
due to the low liquid-to-powder ratio and the compact microstructure for CPC-
30%GDL (see Figure 3). Using histology it was observed that dissolution of GDL 
microparticles was incomplete (see Figure 7D), confirming that a poor access of 
water to the interior of compact CPC-30%GDL composites might have caused 
the residual presence of undissolved GDL microparticles.
After twelve weeks of implantation, of the amount of CPC degradation and new 
bone formation were comparable for CPC-10% GDL and the CPC-PLGA. This 
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confirms that although initial degradation rates (and thus acid production rates) 
of PLGA were slower than GDL, this initial lag time in degradation was compen-
sated for at later time-points. Both CPC-10%GDL and CPC-PLGA composites 
exhibited a very good biocompatibility and replacement by new bone tissue whe-
reas only CPC-30%GDL hardly degraded after 12 weeks of implantation. Even 
though these formulations of high GDL content did not degrade in vivo, no toxic 
or inflammatory events were observed, confirming the biocompatibility of GDL as 
porogen.
CPCs containing gelatin microspheres did not degrade after 2 or 12 weeks of 
implantation. In a previous study from our group adverse inflammatory responses 
were reported for upon injection of CPCs containing gelatin microspheres into 
bone defects [9]. In the current study, inflammation of gelatin-containing CPCs 
was not observed. Several reasons can be held responsible for these differen-
ces such as the absence of proper sterilization methods or preparation steps to 
block residual uncrosslinked glutaraldehyde groups in this previous study. The 
procedure to sterilize gelatin microspheres using ethylene oxide gas as well as 
the glycine washes performed to block unreacted GA prior to implantation as 
employed in the current study resulted into a considerably improved response 
of the bone tissue in the vicinity of the injected material. Nevertheless, gelatin-
containing CPCs did not degrade which can be attributed to the poor accessibility 
of proteolytic enzymes such as collagenases to CPC-gelatin constructs. Without 
these enzymes, degradation of crosslinked gelatin microspheres will not occur. 
These results confirm that acid production by porogens is a prerequisite to obtain 
significant degradation of apatitic CPCs in vivo. 
Quantification of the histological slides revealed abundant bone formation of 
up to 66 vol % of the ROI when 10 % GDL or PLGA were used as porogens. 
However, it was observed that the majority of the ROI was filled with trabecu-
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lar bone and no implant remnants were found. Due to the porous structure of 
trabecular bone, the amount of new bone formation was underestimated since 
histomorphometrical control experiments on rabbit femoral condyles without any 
defect revealed that trabecular bone consists for about 70 vol% of mineralized 
bone tissue whereas the remaining 30% consists of interstices containing bone 
marrow or fat. As a consequence, the above-mentioned values for new bone for-
mation of about 66 % correspond to almost complete bone regeneration after 12 
weeks of implantation of CPC-10%GDL and CPC-PLGA implants.
Summarizing, GDL was successfully introduced in the current study as acid-
producing porogen for CPC materials without compromising its osteocompatibility. 
After the here reported promising in vivo bone response results, GDL emerges as 
a good CPC porogen candidate because of its fast degradability and subsequent 
rapid bone formation. Moreover, CPC-GDL composites can be used as off-the-
shelf injectable materials without the need for additional and often expensive 
preparation steps to produce porogen particles of appropriate size and shape 
which are necessary for inclusion of gelatin and PLGA (microspheres) as porogen. 
In addition, CPC-GDL is cheap and can be stored at room temperature, which 
warrant further studies on the mechanism by which GDL microparticles create in 
situ porosity into CPCs as well as the biological response in animal models that 
are more relevant for clinical application.
5.Conclusion
The current study has shown that glucono-delta-lactone can be used as po-
rogen in injectable apatitic calcium phosphate cements (CPCs) to render these 
bone fillers resorbable within weeks rather than months. Self-setting, GDL-con-
taining CPCs were developed by simple mixing of GDL with calcium phosphate 
powder precursors and lowering the liquid-to-powder ratios, thereby producing 
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cements with setting times comparable to conventional CPCs. Histomorphome-
trical evaluation after 2 weeks of implantation in femoral condyles of rabbits re-
vealed that CPCs containing 10% of GDL degraded faster and were replaced by 
more bone tissue than CPCs containing PLGA, gelatin or high amounts (30 wt% 
of GDL). After 12 weeks, CPC degradation and concomitant new bone formation 
was equal for CPC-10%GDL and CPC-PLGA. Summarizing, the current showed 
that CPCs containing appropriate amounts of GDL display accelerated degrada-
tion and new bone formation compared to CPCs containing porogens made of 
conventional polymers such as PLGA or gelatin.
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1.Introduction
Injectable calcium phosphate cements (CPCs) are bone substitute materials 
originally developed by Brown and Chow in the early 1980’s [1]. The main 
advantages of CPCs include injectability and hence optimal filling of irregular 
bone defects through minimally invasive surgical techniques. Upon injection, 
CPCs transform into a solid with a composition close to the mineral phase of 
bone. CPCs are synthetic, off-the-shelf available and do not have the drawbacks 
related to the application of autologous bone (i.e. donor site morbidity and 
increased time of surgery). CPCs can be classified into apatitic and brushite 
cements depending on the end product of the setting reaction [2]. Brushite based 
cements are resorbed faster compared to apatitic based cements, but exhibit 
inferior mechanical properties, which compromises their use as bone substitute 
materials in a number of applications [3-7].
Due to the poor degradability of apatitic CPCs, different strategies to accelerate 
CPC degradation have been explored. Foaming agents, such as carbon dioxide, 
hydrogen peroxide and albumin, have been studied as inducers of macroporosity 
[8-10]. Although an interconnected pore network could be generated by these 
approaches, both pore size and pore distribution appeared to be uncontrollable 
[11]. Alternatively, the incorporation of rapidly degrading porogens into CPC has 
been explored, using salt and sugar crystals [12,13], and polymeric microspheres 
from natural (e.g. gelatin) or synthetic polymers (e.g. poly-trimethylene carbonate 
(PTMC), or poly(d,l-lactic-co-glycolic acid) (PLGA)) [14-16]. Especially PLGA mi-
crospheres have shown potential as CPC porogens, because (i) PLGA degrades 
into lactic and glycolic acid which further accelerate pH-dependent CPC degrada-
tion [17], (ii) PLGA properties (e.g. molecular weight and functional end-groups) 
can be tailored to control degradation speed [18-20], and (iii) the morphology of 
PLGA microspheres (i.e. hollow vs. dense, large vs. small) can be used as a tool 
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to further control porosity and degradation [21].
In their role as porogens, PLGA microspheres have shown beneficial effects 
enhancing passive CPC degradation and subsequent bone formation [22,23]. 
Nevertheless, in parallel to passive degradation, cell-mediated CPC-PLGA 
degradation can be further stimulated. In view of this, exploiting the drug-delivery 
functionality of PLGA microspheres for releasing stimulatory factors for cell-
based CPC degradation seems attractive. Since osteoclasts are known to be 
the predominant cell type in bone resorption [24] and have similar effects on 
calcium phosphate ceramics [25-27], it is straightforward to hypothesize that 
release of Receptor Activator of Nuclear factor Kappa-B Ligand (RANKL) will 
induce osteoclastogenesis and hence accelerate CPC degradation. Additionally, 
osteoclast-like cells in remodeling lacuna area have been observed after 
implantation of CPC in trabecular [28] and cortical [29] bone in goats. RANKL 
addition to the cell line RAW264.7 was shown to stimulate osteoclast-like 
cell formation when adsorbed onto pre-set brushite CPC materials [30]. For 
application in injectable CPC formulations, however, it is mandatory to explore 
suitable loading methods that effectively release RANKL while its biological 
activity is retained.
In an attempt to accelerate active CPC degradation, the aim of this study was 
to explore several loading methods for RANKL within CPC-PLGA formulations. 
RANKL was adsorbed to or incorporated in PLGA microspheres with either a 
hollow or dense morphology. Additionally, RANKL was loaded via the liquid 
phase of CPC. As controls, plain CPC scaffolds with RANKL adsorbed onto the 
surface were used. RANKL release and activity were studied by Reverse Phase 
High Performance Liquid Chromatography (RP-HPLC) and osteoclast-like cells 
formation in cell culture experiments, respectively.
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2.Materials and Methods
2.1.Materials
CPC powder consisted of a mixture of 85% alpha-tricalcium phosphate (a-TCP; 
CAM Bioceramics BV, Leiden, the Netherlands), 10% dicalcium phosphate an-
hydrous (DCPA; Sigma Aldrich, St. Louis, MO, USA) and 5% precipitated hydrox-
yapatite (pHA; Merck, Darmstadt, Germany). Na2HPO4 was purchased from 
Merck (Darmstadt, Germany).
Poly(lactic-co-glycolic acid) (PLGA) Purasorb® materials were obtained from 
Purac Biomaterials (Gorinchem, the Netherlands). Purasorb® PDLG 5002A (Mw 
= 17 kDa, acid terminated, L:G = 50:50) was used to prepare microspheres. 
Poly(vinyl alcohol) (PVA; 88% hydrolyzed, MW 22000) was obtained from Acros 
(Geel, Belgium) and isopropanol (IPN; analytical grade) and dichloromethane 
(DCM; analytical grade) were obtained from Merck (Darmstadt, Germany). Tri-
fluoroacetic acid (TFA) and acetonitrile both HPLC grade were purchased from 
Sigma Aldrich (St. Louis, MO, USA).
RANKL (mouse recombinant) was purchased from Prospec (East Brunswick, 
NJ, USA). RAW 264.7 murine cell line was purchased from LGD standards 
GibcoTM. Minimum Essential Medium (MEM) 22571 and Phosphate Buffer Saline 
(PBS) were obtained from Invitrogen (Carlsbad, CA, USA) and Tartrate-Resistant 
Acid Phosphatase (TRAP) staining kit 378 from Sigma Aldrich (St. Louis, MO, 
USA).
2.3.Material processing and characterization
2.3.1.Preparation and characterization of PLGA 
microspheres
Hollow PLGA microspheres (PLGAh) were prepared by a double water-in-oil-
in-water emulsion technique as described previously [31]. In parallel, dense PLGA 
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microspheres (PLGAd) were prepared by a single emulsion water-in-oil-in-water 
technique as described previously [21]. After preparation, both hollow and dense 
PLGA microspheres were frozen, freeze-dried for 24 hours and stored at -20ºC.
The morphology and size distribution of both PLGAh and PLGAd was determi-
ned by light microscopy. Microspheres were suspended in H2O and pictures were 
taken with an optical microscope equipped with a digital camera (Leica/Leitz DM 
RBE Microscope system, Leica Microsystems AG, Wetzlar, Germany). The size 
distribution of the microspheres was determined by digital image software (Leica 
Qwin®, Leica Microsystems AG, Wetzlar, Germany) using a sample size of at 
least 300 microspheres. In addition, to ensure hollow and dense morphology of 
the microspheres, Scanning Electron Microscopy (SEM, JEOL 6310) was used 
at an accelerating voltage of 10 kV.
PLGA microspheres were sterilized using gamma irradiation (25-50 kGy; Iso-
tron BV, Ede, the Netherlands) and afterwards stored at -20°C.
2.3.2.Preparation and characterization of CPC and CPC-
PLGA scaffolds
Syringes (2 mL; BD PlastipakTM, Franklin Lakes, NJ USA) containing 0.8 g 
CPC were sterilized using gamma irradiation (Isotron BV). Pre-set scaffolds were 
prepared by adding 0.35 mL 2% Na2HPO4 solution to syringes containing 0.8 g 
CPC and 0.2 g PLGAh or 0.36 g PLGAd. In addition, pre-set scaffolds without 
PLGA were fabricated by mixing 0.8 g CPC with 0.35 mL of 2% Na2HPO4 solu-
tion. Subsequently, the syringes were mixed vigorously for 30 seconds and the 
cement was injected into Teflon molds (Ø 6 mm, 2 mm height). Pre-set scaffolds 
were allowed to dry during 24 hours at room temperature.
Pre-set scaffolds containing either PLGAh or PLGAd were scanned using 
micro-computed tomography (µCT) (Skyscan -1072 X-ray microtomograph, 
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TomoNT version 3N.5, Skyscan®, Belgium; X-ray source was set to100 kV, current 
to 98 µA and the resolution was 7 µm pixel). Cone beam reconstruction was 
performed and the data were analyzed by CT analyzer (version 1.4, Skyscan®). 
A standardized region of interest (ROI) was specified (1 mm x 1 mm x 1 mm) to 
determine the volume percentage of PLGA within the pre-set scaffolds.
2.3.3.Preparation of RANKL loaded CPC and CPC-PLGA
RANKL was loaded into the scaffolds via four different approaches; (i) adsorbed 
or (ii) incorporated into the PLGA microspheres, (iii) adsorbed onto the CPC disc 
surface or (iv) incorporated into the liquid phase of CPC prior to setting.
RANKL adsorption to PLGA microspheres was performed after PLGA micros-
phere fabrication. RANKL was absorbed into PLGA microspheres by incubation 
of 0.2 g PLGAh or 0.36 g PLGAd with 5 mL RANKL solution (1 µg/mL in Milli-Q) 
for 30 minutes with subsequent lyophilization for 24 hours.
RANKL was incorporated into PLGAh microspheres by adding 5 mL of a 1 
µg/mL RANKL/Milli-Q solution in the water used for the first emulsification step 
during the preparation protocol. In parallel, 5 mL of a 1 µg/mL RANKL solution 
was added to the DCM/PLGA solution during PLGAd microsphere fabrication. 
CPC-PLGA composites preparation was carried out under sterile conditions by 
adding 0.2 g PLGAh or 0.36 g PLGAd (both with RANKL either adsorbed or in-
corporated) to each of these syringes.
To perform RANKL adsorption onto CPC (CPCa), 0.1 mL of 50 µg/mL RANKL 
solution was added to the surface of gamma-sterilized plain CPC pre-set discs 
(without PLGA microspheres).
For the preparation of scaffolds with RANKL incorporated into the liquid phase 
(CPCi), 0.1mL of 50 µg/mL RANKL solution was added to 0.25 mL 2% Na2HPO4 
solution prior to the formation of the CPC (without PLGA microspheres). The CPC 
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powder was sterilized by gamma radiation prior to CPC formation.
2.4.RANKL release and detection
RANKL release was monitored for 10 experimental groups (Table 1), for which 
either 1 scaffold or an amount of PLGA microspheres (i.e. 0.2 g PLGAh or 0.36 g 
PLGAd) was immersed in 1.5 mL PBS in glass vials (n=3) and incubated at 37ºC. 
Samples were taken by collecting 50 µL of the PBS after 1 hour and 7, 14, 21, 
28, 35 and 42 days of incubation. All samples were immediately stored at -20ºC.
The amount of RANKL in the samples was analyzed by Reverse Phase High 
Performance Liquid Chromatography (RP-HPLC). The system consisted of a Hi-
tachi L2130 HPLC pump, Hitachi L-2400UV detector and Hitachi L-2200 auto 
sampler, and a Vydac C4 column (250 mm x 4.6 mm; 5 µm). Two mobile pha-
ses were used: 0.1% TFA in water (mobile phase A) and 0.1% TFA in 90%/10% 
acetonitrile/water (mobile phase B). The flow was 1 mL per minute, the injection 
volume 20 µL and the UV detection wavelength 280 nm.
Experimental group Composition Activity*
PLGAha Hollow-adsorption +
PLGAda Dense-adsorption +
PLGAhi Hollow-incorporation -
PLGAdi Dense- incorporation -
CPCa CPC-adsorption +
CPCi CPC-incorporation -
CPC-PLGAha CPC-Hollow-adsorption +
CPC-PLGAda CPC-Dense-adsorption +
CPC-PLGAhi CPC-Hollw-incorporation -
CPC-PLGAdi CPC-Dense-incorporation -
Table 1: Experimental groups, abbreviations and activity results.
*Capacity to transform RAW264.7 into osteoclast-like cells
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2.5.RANKL activity
Samples taken during the release experiment were concentrated after RP-
HPLC analyses by using a Centrisart® I centrifugal ultra-filtration unit (Sigma 
Aldrich, St. Louis MO, USA) with a molecular weight cutting of 10 kDa and 
reconstituted with sterile MilliQ water to a concentration of 1 µg/µL and with 
a-MEM + 10% fetal calf serum (FCS) to a final concentration of 0.1 µg/µL, after 
which the samples were stored at -20ºC. Fractions of these RANKL releasates 
were reconstituted in 10 mL a-MEM supplemented with 10% FCS to a final 
concentration of 50 ng/mL (Carlsbad, CA, USA). RAW 264.7 cells were seeded 
at 4000 cells/cm2 in 8 wells glass chamber slides (Thermo Scientific, 177402, 
Rochester, NY, USA). Complete change of medium (0.4 ml per chamber) was 
performed for all experimental groups every 2 days during an 8-day cell culture 
period.
TRAP staining was performed according to the protocol described by the 
manufacturer (TRAP-staining kit 387; Sigma Aldrich, St. Louis MO, USA). After 
TRAP staining, 4',6-diamidino-2-phenylindole (DAPI) staining was performed to 
the cell culture media by adding 2 µL of DAPI stock solution dissolved in 5 mL 
PBS, rinsing after 1 minute with Milli-Q water. Slides were protected with a glass 
cover prior to visualization using fluorescence microscopy (Leica Microsystems 
AG, Wetzlar, Germany).
RANKL activity was quantified by determination of the density of osteoclast-
like cells in a 1 mm2 field (n=6), for which osteoclast-like cells are defined as 
being TRAP-positive with ≥3 DAPI positive nuclei.
2.6.Statistical analysis
Data are presented as mean ± standard deviation. Statistical analysis were 
performed using analysis of variance (ANOVA) combined with a posthoc Tukey-
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Kramer Multiple Comparisons Test. Results were considered significant at p<0.05. 
Calculations were performed using GraphPad Instat® (GraphPad Software Inc., 
San Diego, CA, USA).
3 Results
3.1.Characterization of PLGA microspheres and pre-set 
CPC-PLGA composites
Both PLGAh and PLGAd microspheres displayed a round and smooth 
appearance (Figure 1). The average particle size was 45 ± 6 µm for PLGAh and 
50 ± 3 µm for PLGAd (p>0.05).
In the pre-set CPC-PLGA composites, PLGA microspheres were homoge-
neously distributed within the CPC-matrix (Figure 1). Macroporosity due to mi-
crosphere incorporation was determined at 50 ± 6 % and 53 ± 5 % for CPC-
PLGAh and CPC-PLGAd, respectively (p>0.05) using µCT.
Figure 1: SEM images of dense (A) and hollow (B) PLGA microspheres, 
and CPC containing dense (C) and hollow (D) PLGA microspheres.
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3.2.RANKL release from CPC-PLGA composites
The RANKL release kinetics from PLGA microspheres, CPC-PLGA scaffolds, 
and plain CPC scaffolds (without PLGA-microspheres) are depicted in Figure 2.
For RANKL adsorbed onto PLGA microspheres, a burst release of 82.6 % and 
81.3 % was observed within 1 hour for PLGAh and PLGAd, respectively (p>0.05). 
Thereafter, RANKL release continued towards reaching 100 % release after 28 
days of incubation. In contrast, a burst release of only 24.3 % and 24.6 % (p<0.05 
compared to adsorbed equivalents) was observed when RANKL was incorpo-
rated in PLGAh and PLGAd, respectively (p>0.05). Thereafter, an accelerated 
release of RANKL was observed from day 14-21 to reach 100% release after 28 
days. No differences were observed between dense and hollow microspheres, 
whereas the loading method (i.e. adsorption or incorporation) significantly affec-
ted RANKL release during the first 21 days of incubation (p<0.05).
Regarding pre-set CPC-PLGA scaffolds, all RANKL release profiles showed 
a similar trend, irrespective of PLGA-microsphere type (i.e. PLGAh or PLGAd) 
and RANKL loading method (i.e. adsorbed to vs. incorporated in PLGA-micros-
pheres). This release profile consisted of a burst release (CPC-PLGAha 33.6 %, 
CPC-PLGAhi 25.0 %, CPC-PLGAda 33.3 %, CPC-PLGAdi 21.3 %) followed by 
a boost release from day 7 to 21, after which RANKL release progressed linearly 
to reach ~100 % after 42 days. Although to a lower extent, again adsorption of 
RANKL to either hollow or dense microspheres showed to result in a significantly 
higher initial burst release compared to incorporation of RANKL within hollow or 
dense microspheres (p<0.05).
For plain CPC scaffolds (without PLGA-microspheres), a burst release of 
27.0% and 20.7 % was observed for surface-adsorbed and incorporated RANKL, 
respectively (p<0.05). Thereafter, both groups showed a linear release reaching 
~100% release after 42 days.
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Figure 2: RANKL release from PLGA microspheres (A), CPC-PLGA composites (B) and 
CPC (C) detected by RP-HPLC.
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3.3.RANKL activity after release from CPC-PLGA 
composites
The activity of RANKL was detected by its capacity to transform RAW264.7 
cell into osteoclasts-like cells. The effects of RANKL on cytological characteristics 
of RAW264.7 cells are shown in Figure 3, which shows that in positive controls, 
RANKL induces the formation of multinucleated osteoclast-like cells that stain 
positive for tartrate-resistant acid phosphatase (TRAP).
For RAW264.7 cells, the addition of releasates containing RANKL revealed 
that releasates from PLGAha, PLGAda, CPCa, CPC-PLGAha and CPC-PLGAda 
induced transformation of RAW264.7 cells into osteoclast-like cells. In contrast, 
releasates from PLGAhi, PLGAdi, CPCi, CPC-PLGAhi and CPC-PLGAdi formu-
lations demonstrated to be unable to induce this transformation (Table 1).
The quantification of RANKL capacity to transform RAW264.7 cells into 
osteoclast-like cells is presented in Figure 4. After 8 days of cell culture, RANKL 
activity demonstrated to be similar for control (37.0 ± 2.6), PLGAha (37.3 ± 1.5) 
Figure 3: Cytological view of 
RAW264.7 cells in the cell culture 
model. (A) TRAP negative cells. (B) 
TRAP-positive cells. DAPI staining of 
TRAP negative (C) and positive (D) 
cells. Overlay images of TRAP-DAPI 
staining for TRAP negative (E) and 
positive (F) cells.
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and PLGAda (33.0 ± 2.6) (p>0.05), significantly lower for CPCa (25.7 ± 0.5 ) 
(p<0.05) and lowest for CPC-PLGAha (17.3 ± 2.1) and CPC-PLGAda (17.0 ± 4) 
(p<0.05).
Figure	4:	Number	of	osteoclast-like	cells	per	field	(1	mm2)	after	TRAP	and	DAPI	
staining of cell line treated with the different RANKL release batches.
(a)	significantly	different	compared	to	RANKL,	PLGAha,	PLGAda
(b)	significantly	different	compared	to	CPCa
4.Discussion
The aim of this study was to evaluate the in vitro release and activity of RANKL 
upon differential loading in injectable CPC-PLGA composites with the ultimate 
goal to enhance apatitic CPC degradation by stimulating cell-mediated degrada-
tion. The clinical application of CPC in an injectable form requires an integrated 
loading method of RANKL that will not interfere with the injectable nature of the 
CPC while delivering active RANKL in a sustainable manner. Therefore, RANKL 
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loading was performed via adsorption to or incorporation into hollow or dense 
PLGA microspheres. Beside the loading via PLGA microspheres, RANKL was 
incorporated into the liquid component of the CPC. For reasons of comparison, 
surface-adsorption of RANKL to pre-set CPC was included as a control. The 
hypothesis was that RANKL could be gradually delivered after loading via PLGA 
microspheres or the CPC liquid component. The results of the present study 
indicated that different RANKL release profiles can be obtained depending on 
the loading method. However, RANKL activity demonstrated only to be retained 
when RANKL was adsorbed to PLGA microspheres.
This study demonstrated unambiguously that different RANKL release profiles 
can be obtained using different RANKL loading methods. Adsorption of RANKL 
into PLGA microspheres lead to a burst release of the majority of loaded RANKL 
immediately upon contact with the release medium. In contrast, incorporation of 
RANKL into PLGA microspheres resulted in a more sustained release pattern. 
PLGA microsphere morphology (i.e. dense or hollow) appeared to have no effect 
on RANKL release. In contrast, when these PLGA microspheres were embedded 
within the CPC matrix a sustained release was found for both loading methods. 
Since proteins are known to adhere strongly to  calcium phosphate surfaces [32-
34], this sustained release pattern is most probably due to RANKL adsorption 
to the CPC-matrix after release from the PLGA microspheres. In parallel to the 
use of PLGA microspheres, RANKL was also applied directly within the liquid 
phase of the CPC, which resulted in a continuous RANKL release pattern similar 
to the one observed from RANKL adsorbed onto the CPC surface. This RANKL 
linear release was different from the sigmoidal release obtained with CPC-PLGA 
constructs with RANKL loading via PLGA microspheres, for which after an initial 
burst release a delay in RANKL release is observed until 7 days of incubation. 
This delayed release for CPC-PLGA constructs compared to the linear release 
 175 
CHAPTER 7
for pure CPC is most probably related to the necessity for PLGA degradation to 
achieve RANKL release. Several earlier reports have indeed demonstrated that 
PLGA microsphere degradation starts after ~1-2 weeks, depending on the type 
of PLGA [21].
RANKL activity upon release was demonstrated to be highly dependent on 
the loading method. While RANKL adsorption to PLGA microspheres resulted in 
release of active RANKL, loss of activity was found after RANKL incorporation 
into the PLGA microspheres or loading via the liquid phase of CPC. Although 
water-in-oil-in-water is the most commonly used method for incorporation of 
proteins into polymeric microspheres, protein inactivation has been reported [35]. 
During the fabrication process of PLGA microspheres with incorporated RANKL, 
inactivation can occur due to its interaction with the oil-water interface, which 
is formed when the aqueous RANKL solution is emulsified under high shear 
through the emulsification process with the organic solvent DCM. The formation 
of amorphous protein aggregates during this production step has shown to lead 
to protein inactivation [36]. Inactivation of RANKL when incorporated into the 
liquid phase of brushite CPC has been reported previously [37] and corroborates 
our findings regarding loss of RANKL activity upon loading via the liquid phase 
of apatite CPC. Physical disturbances in the mixing step during the CPC 
preparation, initial basic pH, the slightly exothermic nature of the CPC reaction 
or the CPC setting reaction can be the causes for the loss of RANKL activity 
when applied within the liquid component of the CPC [38,39]. On the other hand, 
preservation of RANKL activity was found for RANKL loading via adsorption to 
PLGA microspheres as well as for RANKL adsorption onto the surface of pre-
set CPC scaffolds. In view of injectable formulations, effective RANKL loading 
is only possible via adsorption to PLGA microspheres, which subsequently are 
incorporated within CPC.  An additional finding was that a reduced number of 
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osteoclast-like cells were present for the CPC-PLGA groups compared to the 
groups with only PLGA microspheres, indicating that RANKL activity decreases on 
CPC embedding PLGA microspheres. In previous experiments at our department 
it was shown that calcium and phosphate ions are released during incubation of 
CPC in aqueous media [11], which can be harmful during cell culturing leading 
to detachment and death of the seeded cells [40, 41]. The here used releasates 
from CPC-PLGA scaffolds are likely to contain high concentrations of these 
potentially harmful ions and hence also affect the outcome of the cell culture 
model with osteoclast-like cells.
Within the past decades, CPC passive degradation has been enhanced by 
the creation of pores via incorporation of PLGA microspheres. However, it needs 
to be emphasized that in vivo studies with CPC-PLGA formulations always 
demonstrated that CPC degradation remained the limiting factor in achieving fast 
and complete bone regeneration within the bone defect [42,43]. In view of this, the 
present study is a first exploration to exploit the drug-delivery capability of PLGA-
microspheres for a compound that can stimulate bone resorption (i.e. RANKL). 
However, safety issues regarding the use of RANKL may bring major concerns 
due to possible adverse effects, including uncontrolled degradation/resoption 
of healthy bone tissue adjacent to CPC-PLGA. Nevertheless, subcutaneous 
administration of RANKL (up to 40 µg twice per day) was shown to stimulate 
the bone remodelling process in mice without any negative side-effects [43]. 
Besides, a later study in rats revealed that, despite the fact that bone quality 
was diminished during subcutaneous RANKL administration (87 µg 5 times per 
week during 6 weeks), bone quality could be recovered after discontinuation of 
the RANKL treatment [44]. In contrast to these studies with parenteral RANKL 
administration, the current study used lower doses for the local administration 
of RANKL (5 µg per scaffold), which were still sufficient to stimulate osteoclast-
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like cell formation in vitro. Future studies should focus on the in vivo efficacy of 
RANKL release from injectable CPC-PLGA formulations to stimulate active cell-
based CPC degradation in addition to passive degradation.
5.Conclusion
Exploration of different RANKL loading methods within CPC demonstrated 
that only adsorption to PLGA microspheres and the subsequent incorporation 
of these loaded microspheres within CPC leads to the release of biologically 
active RANKL. The current findings may contribute to enhance cell-mediated 
remodelling of injectable CPC-PLGA bone substitutes.
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1.Introduction
Periodontitis is one of the most common inflammatory diseases characterized 
by formation of periodontal pockets, loss of attachment and alveolar bone, which 
if left untreated can lead to early tooth loss. The objective of the conventional 
treatment of periodontitis (i.e. scaling and root planning) is to arrest the disease 
progression, however this does not result in restoration of the damaged periodontal 
tissues (i.e. gingiva, cementum, periodontal ligament and alveolar bone). In order 
to achieve restoration of the whole periodontal complex or to restore the height 
of the alveolar bone around the affected teeth, clinical procedures for periodontal 
reconstruction have been successfully used since decades [1]. Most reconstructive 
procedures involve application of bone substitutes, barrier membranes or a 
combination of the above mentioned into the bony defects. Currently, the addition 
of growth factors to these biomaterials has been extensively explored [2].
In view of regenerative treatment for bone defects, calcium phosphate 
(CaP) materials are the predominant type of used bone substitute material [3]. 
Although several formulations are available for CaP-based materials (e.g. blocks, 
granules, putties, etc.), clinical application requires easy handling properties and 
control over degradation. To that end, CaP cements (CPC) were introduced in 
1986 by Brown and Chow [4] for reasons of injectability and hence perfect filling 
potential for bone defects with irregular dimensions. Despite presenting several 
advantages, including biocompatibility and excellent osteoconductivity [5,6], 
apatitic CPCs are hardly degradable, which impedes full regeneration of a bone 
defect when tested in bony defects in rats [7], rabbits [8] or goats [9]. Recently, 
injectable CPCs demonstrated to be more rapidly degradable when combined 
with poly(lactic-co-glycolic) acid (PLGA) microspheres  [10]. In more detail, it has 
been demonstrated that fine-tuning of the physical and chemical PLGA properties 
can affect polymer degradation. These properties include, from marginal to 
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substantial effect on CPC/PLGA degradation, molecular weight, end-terminal 
group functionalization, monomer ratio and morphology [11,12,13,14]. Regarding 
the latter property, it has been demonstrated that an environment with higher 
acidity evoked by acidic degradation products from dense PLGA microspheres 
enhances CPC degradation compared to a lower acidic environment from hollow 
PLGA microspheres both in vitro [15] and in vivo [16].
In addition to acting as a porogen, PLGA microspheres can be used as a 
delivery vehicle for biologically active compounds. Bone regeneration has been 
attempted mostly with BMP-2, [17, 18], but this growth factor has received negative 
attention lately due to complications associated with its use in spinal fusion 
surgeries [19], in which unnecessary early morbidity and long-term clinical failure 
were observed when BMP-2 was used. Moreover, ankylosis has been detected 
when BMP-2 was applied for periodontal tissue regeneration [20, 21, 22] (Kuboki 
et al., 1998; King et al., 1999; Selvig et al., 2002).  Beside BMP-2, other bioactive 
molecules such as transforming growth factor-β (TGF- β), platelet derived growth 
factor (PDGF), basic fibroblast growth factor (bFGF) and insulin-like growth 
factor (IGF) have shown beneficial effects upon release for periodontal tissue 
regeneration [23, 24]. In addition, synergistic effects have shown improvements 
in the tissue reaction when combination of growth factors were used in a canine 
model using open flap debridement [25]. Alternatively, the combination of IGF 
and PDGF resulted in an improved periodontal regeneration compared to their 
separate application [26,27]. PDGF is a naturally occurring protein that is known 
to promote periodontal regeneration  [28] and has been released from different 
osteoconductive matrices, including beta-tricalcium phosphate (β-TCP), CaSO4 
and chitosan or albumin-coated CPC in diverse periodontal sites for the stimulation 
of tissue regeneration  [29, 30, 31]. IGF is a protein with a high structural similarity 
to insulin. Despite being associated with activation of osteocytes, it appears not 
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to affect significantly cellular activities by itself, but rather acts as an adjuvant 
for other growth factors. Consequently, it has been applied in combination with 
other bioactive molecules, such as fibroblast growth factor (FGF) or transforming 
growth factor (TGF) [32]. The combination of IGF and PDGF is known to have a 
synergistic effect enhancing bone regeneration in a canine model with naturally 
occurring periodontal disease, in which the growth factor combination was applied 
in all premolar teeth via open flap debridement [33, 34].
In this study, the performance of injectable CPCs as a bone substitute material 
for alveolar bone defects was evaluated. Different CPC-formulations were gene-
rated by incorporating hollow or dense PLGA microspheres, either or not loaded 
with the growth factors PDGF and IGF. These CPC-formulations were injected 
into one-wall intrabony defects created in the mandible of Beagle dogs. Bone 
formation was assessed by histology and histomorphometry after 8 weeks.
2.Materials and Methods
2.1.Materials
CPC powder consisted of a mixture of 85% alpha-tricalcium phosphate (a-TCP; 
CAM Bioceramics BV, Leiden, the Netherlands), 10% dicalcium phosphate 
anhydrous (DCPA; Sigma Aldrich, St. Louis, MO, USA) and 5% precipitated 
hydroxyapatite (pHA; Merck, Darmstadt, Germany). Na2HPO4 was purchased 
from Merck (Darmstadt, Germany).
Poly(lactic-co-glycolic acid) (PLGA) Purasorb® materials were obtained from 
Purac Biomaterials (Gorinchem, the Netherlands). Purasorb® PDLG 5002A (Mw 
= 17 kDa, acid terminated, L:G = 50:50) was used to prepare microspheres. Poly 
vinyl alcohol (PVA; 88% hydrolyzed, MW 22000) was obtained from Acros (Geel, 
Belgium) and isopropanol (IPN; analytical grade) and dichloromethane (DCM; 
analytical grade) were obtained from Merck (Darmstadt, Germany).
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Recombinant human IGF-1 (expressed in E. coli; 70 amino acids, ~7.5 kDa) 
and recombinant human PDGF-BB (expressed in E. coli; 109 amino acids, ~12.3 
kDa) were obtained from R&D Systems (Minneapolis, MN, USA) and BioLegend 
(San Diego, CA, USA), respectively.
2.2.Material processing and characterization
2.2.1.Preparation and characterization of PLGA 
microspheres
Hollow PLGA microspheres (hPLGA) were prepared by a double emulsion 
technique following previously described procedures [8]. Briefly, 1.0 g of 
PLGA was dissolved in 4 mL of DCM in a 20 mL glass tube. Then, 500 µL of 
demineralized water (dH2O) was added while emulsifying at 8000 rpm for 90 
seconds. Subsequently, 6 mL of a 0.3% PVA solution were added and emulsified 
again at 8000 rpm for 90 seconds. The content of the glass tube was transferred 
into a stirred 1000 mL beaker containing 394 mL of 0.3% PVA solution. Directly, 
400 mL of a 2% IPN solution was added. The solution was stirred for 1 hour. The 
microspheres were allowed to settle for 15 minutes and the clear solution was 
decanted. The remaining suspension was centrifuged and the supernatant on top 
was aspirated. Finally, the microspheres were frozen, freeze-dried for 24 hours 
and stored at -20ºC.
Dense PLGA microspheres (dPLGA) were prepared by a single emulsion tech-
nique following previously described procedures [15]. Briefly, 0.2 g of PLGA was 
dissolved in 2 mL of DCM in a 20 mL glass tube. Then, this solution was transfe-
rred into a stirred beaker containing 100 mL of 0.3% PVA solution. Subsequently, 
50 mL of 2% IPN solution was added. The solution was stirred for 1 hour. The 
microspheres were allowed to settle for one hour and the clear solution was de-
canted. The remaining suspension was centrifuged and the clear solution on top 
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was aspirated. Finally, the microspheres were frozen, freeze-dried for 24 hours, 
sterilized by gamma irradiation (25-50 kGy; Isotron BV, Ede, the Netherlands) 
and stored at -20ºC.
The morphology and size distribution of the PLGA microspheres was determined 
by light microscopy. Microspheres were suspended in H2O and pictures were 
taken with an optical microscope equipped with a digital camera (Leica/Leitz 
DM RBE Microscope system, Leica Microsystems AG, Wetzlar, Germany). The 
size distribution of the microspheres was determined by digital image software 
(Leica Qwin®, Leica Microsystems AG, Wetzlar, Germany) using a sample size 
of at least 300 microspheres. In addition, to ensure hollow and dense nature of 
the microspheres, morphology was observed by Scanning Electron Microscopy 
(SEM, JEOL 6310) at an accelerating voltage of 10 kV.
2.2.2.Growth factor loading to PLGA microspheres
Growth factors IGF and PDGF were loaded simultaneously onto both hPLGA 
and dPLGA under sterile conditions. Initial concentrations of IGF and PDGF 
solutions were 500 µg/mL and 480 µg/mL respectively. For loading, 60 µg of 
PDGF and 60 µg of IGF in a total volume of 400 µL were mixed with 500 mg 
hPLGA or 900 mg dPLGA microspheres. The difference in mass for hPLGA 
compared to dPLGA was based on volume/weight calculations (data not shown) 
to obtain similar volumetric PLGA-microsphere loading amounts. The final loading 
amounts were 120 ng/mg hPLGA (hPLGAGF) and 67ng/mg dPLGA (dPLGAGF) for 
both PDGF and IGF.
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2.2.3.Preparation and characterization of CPC-PLGA 
composites
Plastic 2 mL syringes containing 0.8 g CPC powder were sterilized using 
gamma irradiation 25-50 kGy; Isotron BV, Ede, the Netherlands). CPC-PLGA 
composites preparation was carried out under sterile conditions by adding 0.2 
g hPLGA (w/o- growth factors) or 0.36 g dPLGA (w/0- growth factors) to each of 
these syringes. As such, four different CPC-PLGA formulations were generated 
(Table 1), in which the growth factor loading was approximately 500 µg/mL of 
CPC/PLGA composite for both PDGF and IGF. All syringes were sealed with a 
closed tip.
Pre-set composites were prepared by adding 0.35 mL 2% Na2HPO4 solution 
to the syringes containing CPC/PLGA. Subsequently, the syringes were mixed 
vigorously for 30 sec and the cement was injected into Teflon molds (3 mm x 6 
mm). Pre-set composites containing either dPLGA or hPLGA were scanned using 
a µCT (Skyscan -1072 X-ray microtomograph, TomoNT version 3N.5, Skyscan®, 
Belgium; X-ray source was set to100 kV, current to 98 µA and the resolution was 
7 µm pixel). Cone beam reconstruction was performed and the data were analy-
zed by CT analyzer (version 1.4, Skyscan®). A standardized region of interest 
(ROI) was specified (4 mm x 4 mm x 4 mm) to determine the volume percentage 
of PLGA within the pre-set composites.
Sample name PLGA Growth factors
CPC-hPLGA Hollow No
CPC-hPLGAGF Hollow Yes
CPC-dPLGA Dense No
CPC-dPLGAGF Dense Yes
Empty defect No No
Table 1: Experimental groups.
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2.2.4.In vitro growth factor release experiments 
In order to evaluate the in vitro release of PDGF and IGF, both growth factors 
were radiolabeled with the isotope iodide-125 (125I). Four composite groups were 
prepared, with each containing one growth factor with and one without radiolabel. 
In the groups with radiolabeled IGF (IGF*), 360 mg dPLGA or 200 mg hPLGA 
was mixed with a hot/cold mixture of IGF (total 10 µg) and 10 µg PDGF in PBS/
BSA with a final volume of 200 µL. Similarly, in groups with radiolabeled PDGF 
(PDGF*), 600 mg dPLGA or 200 mg hPLGA was mixed with 10 µg IGF and a hot/
cold mixture of PDGF (total 10 µg) in PBS/BSA with a final volume of 200 µL. 
After lyophilization, loaded hPLGA (0.2 g) or dPLGA (0.36 g) was added to 0.8 
g CPC in a 2 mL syringe and processed as described above to generate pre-set 
composites.
The four different pre-set composites were immersed in 4 mL PBS in glass 
vials (n=3) and incubated at 37 ºC during the release experiment. Growth factor 
retention was measured using a 1480 WizardTM automatic gamma counter from 
Wallac (Waltham, MA, USA) after PBS refreshments at days 1, 7, 14, 21, 28, 35, 
42 and 56. Small amounts of loaded growth factor inside glass vials were inclu-
ded to correct for radioactive decay.
2.3.Surgical procedure
A power-analysis was performed to calculate sample number using the fo-
llowing formula: n = 1 + 2C(s/d)2, in which population standard deviation (s) was 
estimated at 8 and the effect size (d) was set at 15. C-value was fixed at 7.85 (re-
sulting from 1-β=0.8 and a=0.05). The required number of samples per condition 
was as such calculated at 6 (n=6).
A total of 15 skeletally mature 2 year old female Beagle dogs with an average 
weight of ~12 kg were used as experimental animals. The protocol was approved 
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by the Animal Ethical Committee of the Radboud University Nijmegen Medical 
Center (Approval no: RU-DEC 2009-100) and national guidelines for the care and 
use of laboratory animals were applied. Two months prior to defect creation, the 
third mandibular premolars were extracted bilaterally after which the extraction 
sockets were allowed to heal.,
Surgery was performed under general inhalation anesthesia. The anesthesia 
was induced by an intravenous injection of Hypnorm (0.315 mg/mL fentanyl ci-
trate and 10 mg/ml fluanisone) and atropine, and maintained by a 1,5% of a 
FiO2 35% mixture and oxygen through a constant volume ventilator. To reduce 
the peri-operative infection risk, animals received antibiotic prophylaxis (Baytril®, 
2.5% (Enrofloxacin), 10 mg/kg). The surgical procedure is presented in Figure 1. 
The animals were immobilized in a ventral position with an open mouth and the 
soft tissues of the mandible were opened bilaterally in the mesial area of the four-
th premolar until the bone tissue was visible. After exposure of the bone, a 1-wall 
alveolar bone defect was created (4 mm depth, 5 mm height) using an ultrasonic 
Figure 1: Surgical procedure. Creation of bone defect using the ultra-
sonic device (A), bone defect (B), composite material moulded into the 
defect	(C),	closing	of	mucoperiosteal	flaps	(D).
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device (Piezosurgery, Mectron, Carasco, Italy) under constant physiologic saline 
irrigation. Then, the defect was thoroughly irrigated and packed with sterile cotton 
gaze. 
Injectable CPC/PLGA formulations were prepared by adding 0.35 mL of 
sterile 2% Na2HPO4 solution to the syringes containing CPC powder and PLGA 
microspheres, mixed vigorously for 30 sec and the cement was injected into 
the defects. Each defect was filled with one of the four different CPC/PLGA 
formulations or left empty, following a randomization scheme. The CPC/PLGA 
composite material was molded to desired shape using a spatula. Superfluous 
cement was removed with a spatula and soft tissues were closed by suturing the 
buccal and lingual mucoperiosteal flaps using resorbable polyglycolic acid Vicryl 
sutures 3-0 after initial setting (~10 minutes). X-ray imaging was performed to 
confirm defect filling and dimensions after surgery (Figure 2).
Pain control medication consisted of Fentanyl 5 ug/kg that was injected intra-
muscularly 15 minutes pre-operation, Carprofen (Rimadyl®) 4 mg/kg and Bupre-
norphine (Temgesic®) 10 ug/kg that were injected intramuscularly during surgery, 
and Carprofen (Rimadyl®) 4 mg/kg was administered subcutaneously every 8 
Figure 2: Representative X-ray ima-
ge of the CPC material location in the 
bone defect after the surgical proce-
dure.
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hours for 2 days after surgery. Softened food was given to the animals after the 
surgical procedure in order to minimize possible adverse tissue reactions and 
damage to the implant materials. After 8 weeks of implantation, the dogs were 
euthanized using an overdose of the short acting barbiturate Nembutal® which 
undergoes first-pass metabolism in the liver and it is a central nervous system 
depressant. Subsequently mandibles were harvested for evaluation. The num-
ber of implants placed, retrieved and used for histomorphometrical analyses are 
summarized in Table 3.
Sample name Implants placed Implants retrieved Implants used for 
analysis
CPC-hPLGA 6 6 5(*)
CPC-hPLGAGF 6 6 6
CPC-dPLGA 6 6 6
CPC-dPLGAGF 6 6 5(*)
Empty defect 6 6 5(*)
Table 3: Number of implants placed, retrieved and used for histomorphometrical 
analyses.
(*) The number of implants used for histomorphometrical analysis is less 
than the number of implants placed or retrieved due to tooth loss during the 
implantation
2.4.Histological procedures 
After harvesting of the mandibles and removal of surrounding soft tissues, fixa-
tion of excised specimens was carried out in 4% formaldehyde for 2 days, with 
subsequent decalcification in 10% ethylenedinitrilo-tetraacetic acid (EDTA) and 
dehydration in a graded series of ethanol. Finally, the specimens were embedded 
in paraffin and histological sections were prepared using a microtome. Hema-
toxylin–eosin staining of the sections was performed for all the samples and con-
secutive sections were stained with elastica-van Gieson to verify bone tissue.
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2.5.Histological and histomorphometrical analysis
Histological evaluation was performed using a light microscope (Leica 
Microsystems AG, Wetzlar, Germany). Additionally, histomorphometrical 
analysis was performed by evaluating the ROI, which consisted of a box with 
fixed dimensions of 4 mm in length (distal-mesial direction) and 5 mm in height 
(apical-coronal direction) placed 
into the defect area by locating 
the lower left corner into the 
damaged area of the tooth 
root (Figure 3). Digitalized 
images (magnification 5x) were 
recorded and bone content was 
determined by color recognition 
using image analysis techniques 
(Leica Qwin Pro-image analysis 
system, Wetzlar, Germany) by a 
blinded evaluator (RFL).
Consecutive elastica-van Gieson (EVG) stained sections were used to verify 
assignment of tissue as bone tissue in the ROI.
Figure 3: Region of interest. The arrow indicates 
a mark made during the surgical procedure in the 
tooth to facilitate the implant location during his-
tology.
2.6.Statistical analysis
Data are presented as mean ± standard deviation. Significant differences were 
determined using analysis of variance (ANOVA) combined with a posthoc Tukey-
Kramer Multiple Comparisons Test. Results were considered significant if p<0.05. 
Calculations were performed using GraphPad Instat® (GraphPad Software Inc., 
San Diego, CA, USA).
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3.Results
3.1.Characterization of PLGA microspheres and pre-set 
CPC-PLGA composites
Both hPLGA and dPLGA microspheres displayed a round and smooth appea-
rance (Figure 4). The average particle size was 45 ± 20 µm for hPLGA micros-
pheres and 44 ± 6 µm for dPLGA.
In the pre-set CPC-PLGA composites, PLGA microspheres were homoge-
neously distributed within the CPC-matrix (Figure 4). Macroporosity due to mi-
crosphere incorporation was determined by micro-computed tomography  analy-
sis in 56 ± 0.5 % and 55 ± 0.8 % for CPC-hPLGA and CPC-dPLGA, respectively.
Figure 4: SEM micrographs of hollow PLGA microspheres (A), dense 
PLGA microspheres (B), CPC-hollow PLGA microspheres composites 
(C) and CPC-dense PLGA microspheres composites (D).
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3.2.In vitro growth factor release
The kinetics of the release of IGF and PDGF from CPC-hPLGA and CPC-
dPLGA are depicted in Table 2 and Figure 5. An initial burst release was obser-
ved during the first day for both IGF and PDGF, with 24.6 % and 10.7 % of IGF 
released from CPC-hPLGA and CPC-dPLGA (p=0.01), respectively, and 29.7 % 
and 20.9 % of PDGF released from CPC-hPLGA and CPC-dPLGA (p=0.03), res-
pectively.
Subsequent measurements of the retained labelled growth factors in the di-
fferent composites revealed a biphasic pattern with limited release in the period 
from day 2 until day 14 and a sustained release in the period from day 15 until 
day 56. This sustained release of both growth factors showed dependency on 
both CPC-formulation and growth factor type. Growth factor release was signi-
ficantly faster from CPC-hPLGA compared to CPC-dPLGA (p=0.009) and the 
release of PDGF (1.65 %/day for CPC-hPLGA; 1.63 %/day for CPC-dPLGA) was 
faster compared to that of IGF (1.18 %/day for CPC-hPLGA; 0.89 %/day for CPC-
dPLGA; p=0.0043).
After 8 weeks, total IGF release was 66.6 % and 51.7 % for CPC-hPLGA and 
CPC-dPLGA, respectively. Total PDGF release reached 92.7 % and 91.1 % for 
CPC-hPLGA and CPC-dPLGA, respectively.
           Release period
0-1 days 2-14 days 15-56 days Total release
CPC-hPLGA IGF 24.6 ± 3.6 4.3 ± 0.1 37.7 ± 3.1 66.6 ± 6.8
PDGF 29.7 ± 5.1 14.3± 0.2 48.7 ± 1.2 92.7 ± 4.1
CPC-dPLGA IGF 10.7 ± 0.2 1.4 ± 0.1 39.6 ± 1.1 51.7± 1.9
PDGF 20.9 ± 2.1 8.1 ± 0.7 62.1 ± 2.2 91.1 ± 0.7
Table 2: Growth factor release (in %/period related to initial amount loaded)
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Figure 5: Radio-labelled growth factor retention in the CPC-PLGA composites.
3.3.Clinical observations
Though all 15 dogs exhibited good health during the post-implantation period, 
3 animals lost one of the fourth premolars adjacent to the defect. Tooth loss was 
random, showing no apparent relation to the experimental groups. The number of 
implants placed, retrieved and used for histomorphometrical analyses are sum-
marized in Table 3.
3.4.Descriptive light microscopy
Light microscopic examination of HE-stained sections of alveolar bone defects 
(Figure 6) generally revealed that defects in all experimental groups showed a 
decrease of the coronal tissue volume. Variable amounts of newly formed bone 
were observed in the ROI and verification of bone tissue in HE-stained sections 
was carried out using EVG-staining of consecutive sections (Figure 7). The 
newly-formed bone exhibited alveolar bone characteristics (i.e. cancellous bone 
morphology) and a structure similar to the preexistent bone in the vicinity of the 
 200 
DEGRADATION OF CALCIUM PHOSPHATE CEMENTS
defect site. Discrimination between old 
and new bone was possible on basis of 
morphological/staining differences.
Empty defects generally showed ab-
sence of new bone formation and limited 
soft tissue ingrowth within the ROI. De-
fects filled with CPC-hPLGA presented 
limited amounts of bone formation and soft tissue ingrowth, which were mainly 
located at the borders of the ROI. In the CPC-hPLGAGF filled defects, an appa-
rent increase in bone formation was observed in comparison to CPC-hPLGA. 
Additionally, the inner areas of the ROI frequently displayed  soft tissue ingrowth. 
Figure	6:	Representative	histological	figures	
of alveolar bone defects: empty (A), CPC-
hPLGA (B), CPC-hPLGAGF (C), CPC-dPLGA 
(D), CPC-dPLGAGF (E).
Figure 7: Comparison of haematoxylin-eosin stain (A) and elastica-van 
Gieson stain (B) for consecutive sections to verify assignment of bone 
tissue in the ROI.
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Figure	8:	Histomorphometrical	quantification	of	bone	formation	in	the	region	
of interest.
(a)	significantly	different	compared	to	empty	defects
(b)	significantly	different	compared	to	CPC-hPLGA
(c)	significantly	different	compared	to	CPC-hPLGAGF
Defects filled with CPC-dPLGA or CPC-dPLGAGF showed a similar histological 
aspect with an apparent increased amount of new bone formation with trabecular 
structure and limited amounts of soft tissue ingrowth.
3.5.Histomorphometry: bone formation
Quantitative evaluation of new bone formation within the ROI revealed that 
bone formation varied extensively among the experimental groups (Figure 8). 
Empty defects showed significantly lower new bone formation (3.9%) compared 
to all other groups (p<0.001). For CPC-hPLGA and CPC-dPLGA, bone formation 
showed significant inter-group differences (p=0.0003) with values of 16.4% and 
50.7%, respectively. Additional loading of the PLGA microspheres with IGF and 
PDGF demonstrated to increase bone formation for CPC-hPLGAGF compared to 
CPC-hPLGA (35.5% vs. 16.4%; p=0.02), but not for CPC-dPLGAGF compared to 
CPC-dPLGA (49.7% vs. 50.7%; p=0.7).
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4.Discussion
The aim of this study was to evaluate the performance of injectable CPC-
PLGA composites as a bone substitute material for alveolar bone defects in 
the mandible of Beagle dogs. The hypothesis was that bone formation could 
be improved by incorporation of dense PLGA (dPLGA) microspheres compared 
to the incorporation of hollow equivalents (hPLGA) due to the effects of more 
acidic PLGA degradation products on CPC degradation. Additionally, it was 
hypothesized that the loading of a growth factor combination (i.e. IGF and PDGF) 
to these PLGA microspheres could further stimulate bone formation. The results of 
the present study demonstrate that bone formation can be substantially improved 
using dPLGA compared to hPLGA microspheres. However, further stimulation 
of bone formation by loading PLGA microspheres with IGF and PDGF was 
observed only for hPLGA microspheres, albeit to a lesser extent than for plain 
dPLGA microspheres. Together, these results demonstrate that filling alveolar 
bone defects with CPC-dPLGA results in superior bone formation compared to 
CPC-hPLGA either or not loaded with IGF and PDGF.
IGF and PDGF release from PLGA microspheres embedded in a CPC-matrix 
(CPC-hPLGAGF and CPC-dPLGAGF) was monitored in vitro by radio-labeling 
techniques. Sustained release profiles of both IGF and PDGF have been previously 
observed from PLGA microspheres  [35, 36]. However, in comparison to simple 
release of growth factors from PLGA microspheres, growth factors released 
from microspheres embedded in a CPC matrix are likely to rapidly adsorb to the 
CPC-matrix. Such rapid adsorption of proteins has been previously described by 
Hou et al. [37] for HA surfaces, for which it is necessary to emphasize that HA 
is a major component of the presently used CPC either initially (in the form of 
precipitated hydroxyapatite) or after transformation of alpha-TCP. In view of the 
in vitro release in this study, a faster release of PDGF was observed compared 
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to IGF, irrespective of the composite formulation. It is likely that differences in 
the chemical nature and in the three dimensional structure of both proteins are 
the reason for this observation. On the other hand, growth factor release from 
CPC-hPLGA was significantly faster compared to that from CPC-dPLGA. This 
is probably related to an earlier loss of integrity that occurs due to the fragility of 
the CPC-hPLGA once PLGA degradation starts [15]. In contrast, although PLGA 
degradation is enhanced due to an autocatalytic process, due to the lower pH 
generated during/after PLGA degradation in dense PLGA microspheres, the three 
dimensional structure of the microspheres is maintained for a longer time period 
and therefore the bioactive molecules may be released in a somewhat slower 
ratio. An interesting observation was the allocation of different stages of IGF and 
PDGF release, showing consecutively an initial burst release, a stage of limited 
release, and a stage of sustained release. This allocation can be attributed to the 
degradation characteristics of PLGA-microspheres embedded in CPC-matrix, for 
which onset of degradation was previously shown between 2 and 6 weeks after 
incubation [15].
PLGA microsphere properties are major factors regarding CPC-matrix de-
gradation of CPC-PLGA composites, as demonstrated in vitro [38] as well as 
in vivo [7]. In view of the available tools to modulate PLGA microsphere proper-
ties (i.e. molecular weight, end-terminal group functionalization, and hollow vs. 
dense morphology), PLGA microsphere morphology has been demonstrated as 
the most powerful tool in a recent study using CPC-PLGA composites for filling 
rabbit femoral condyle defects [16]. The hydrolytic degradation of PLGA libera-
tes acidic monomers (i.e. lactic and glycolic acid) into the surrounding media, 
which affects CPC degradation. From a volumetric perspective, the dPLGA mi-
crospheres used in this study present a 1.8 times higher PLGA mass compared 
to hPLGA, which generates a more acidic environment upon PLGA degradaton. 
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In the present study that included administration of pain killers post-operatively, it 
was demonstrated that these more acidic environments and their effects on CPC-
matrix degradation do not evoke adverse tissue responses and even allow for 
improved bone formation. Additionally, previous reports have demonstrated that 
microsphere morphology only marginally affect the mechanical strength of the 
composites with compression strengths of 22 ± 5 MPa and 24 ± 3 MPa measured 
for CPC with hollow and dense microspheres, respectively  [15].
The biological effects of the growth factor combination IGF and PDGF appea-
red to be different for CPC-hPLGA compared to CPC-dPLGA. Previous reports 
have demonstrated that bone formation can be stimulated using growth factors, 
such as FGF-2 in combination with granulated β-TCP  [39] or when using amor-
phous calcium phosphate glass cement in 1-wall periodontal defects in beagle 
dogs  [40]. In parallel, the combination of IGF and PDGF has been loaded onto 
calcium phosphate scaffolds as delivery system [31, 41]. The reason for the ab-
sence of a stimulatory effect of IGF and PDGF released from CPC-dPLGA is 
unclear. Possible explanations for this observation are likely to be related to the 
maximum amount of bone that can be formed in relation to material degradation. 
Observation of the histological slides revealed that the majority of the defect is 
completely (or nearly completely) filled with new bone tissue when both CPC-
dPLGA are applied, therefore the addition of growth factors cannot further stimu-
late bone formation in the ROI. Furthermore, a potential growth factor inactivation 
can occur as a result from an increased acidic environment when dense PLGA 
microspheres are hydrolyzed to lactic and glycolic acid monomers in comparison 
to the less acidic pH generated when hollow PLGA microspheres are degraded.
Operations were performed according to the previously described one-wall 
periodontal defects [42,43]. Although no adverse reaction signs were observed 
during thefirst ten days of immediate post-operative care, complete premolar loss 
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was observed in 3 of the 30 implantation sites. The lost one of the fourth premolars 
adjacent to the defect can be related to several causes such as, chewing of the 
toys present in the animal cages (as required by the animal ethical committee) or 
chewing of the bar cages (used for transportation of the dogs). Animals are more 
likely to chew different objects when they are experiencing pain what can occur 
despite of the administration of postoperative pain relief medication. In addition, 
teeth loosening can be a consequence of the complete removal of the bone at 
the mesial side.
The results of this study revealed CPC-dPLGA as the material of choice for 
bone substitution applications in alveolar bone. However, it needs to be emphasi-
zed that no direct comparison was made with autologous bone grafts, which are 
generally regarded as the gold standard. Nevertheless, the application of CPC-
dPLGA encompasses several advantages from a cost, (off-the-shelf) availability, 
and surgery time perspective.
5.Conclusion
Injectable CPC-PLGA with PLGA microspheres of different morphologies 
(hollow (h) or dense (d)) applied as bone substitute materials in 1-wall alveolar bone 
defects in Beagle dogs demonstrated absence of adverse tissue reactions and 
significantly increased bone formation compared to empty defects. CPC-dPLGA 
resulted in significant more bone formation than CPC-hPLGA. Furthermore, 
loading the growth factor combination IGF and PDGF to PLGA microspheres 
demonstrated to beneficially affect bone formation only for CPC-hPLGA. 
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English summary 
Polylactic-co-glycolic acid (PLGA) is the most often used synthetic polymer 
within the field of bone regeneration owing to its biocompatibility and biodegra-
dability. As a consequence, a large number of medical devices comprising PLGA 
have been approved for clinical use in humans by the American Food and Drug 
Administration. As compared to the homopolymers of lactic acid (polylactic acid) 
and glycolic acid (polyglycolic acid), the co-polymer PLGA is much more versatile 
with respect to the control over degradation rate. As a material for bone rege-
neration, the use of PLGA has been extensively studied for several applications 
while include as either scaffolds, coatings, fibers or micro- and nanospheres to 
meet various clinical requirements. In addition, PLGA has been commonly used 
as delivery vehicle for bioactive factors in order to stimulate bone regeneration 
due to its tailorable degradability which allows for control over release kinetics. 
Chapter 2 summarizes recent developments with regard to the use of PLGA in 
bone regeneration by categorizing PLGA by its application forms, while strate-
gies to functionalize PLGA as for controlled delivery of biomolecules are being 
reviewed as well.
The aim of chapter 3 was to evaluate the effect of PLGA microsphere dimension 
on bone formation after injection of CPC/PLGA in a guinea pig tibial intramedullarly 
model. To this end, injectable CPC/PLGA formulations were prepared using PLGA 
microspheres with either a small (~25 μm) or large (~100 μm) diameter, which 
were incorporated at a 20/80 ratio (wt.%) within apatite CPC. Both CPC/PLGA 
formulations were injected into a marrow-ablated tibial intramedullary cavity 
and after an implantation period of 12 weeks, histology and histomorphometry 
were used to address bone formation. The results demonstrated bone ingrowth 
throughout the entire scaffold material for both CPC/PLGA formulations upon 
PLGA microsphere degradation. More importantly, bone formation within the 
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CPC-matrix was >2-fold higher for CPC-PLGA with 25 μm PLGA microspheres. 
Additionally, the pattern of bone and marrow formation showed distinct differences 
related to PLGA microsphere dimension. In general, this study demonstrates that 
PLGA microsphere dimensions of ~25 μm, leading to pores of ~25 μm within 
CPC, are sufficient for bone ingrowth and allow substantial bone formation. 
Further, the results demonstrate that PLGA microsphere dimensions provide a 
tool to control bone formation for injectable CPC/PLGA bone substitutes.
Calcium phosphate cements (CPC) are frequently used as bone substitute 
material. Despite their superior clinical handling and excellent biocompatibility, 
they exhibit a poor degradability which limits bone ingrowth into the implant. Mi-
crospheres have been prepared from poly (D, L-lactic-co-glycolic) acid (PLGA) 
and included in injectable CPC as porogen in order to enhance its macroporosity 
after degradation of the polymeric microspheres. Upon degradation of PLGA mi-
crospheres, acid is produced that enhances the dissolution rate of CPC. Never-
theless, the effect of the characteristics of PLGA microspheres on the degradation 
rate of CPCs has never been studied before. Therefore, the purpose of chapter 4 
was to investigate the dependence of CPC degradation on chemical and morpho-
logical characteristics of incorporated PLGA microspheres. With respect to che-
mical characteristics of the PLGA microspheres, the effect of both PLGA molecu-
lar weight (5, 17 and 44 kDa) and end-group functionalization (acid-terminated or 
end-capped) was studied. In addition, two types of PLGA microspheres differing 
in morphology (hollow vs. dense) were tested. The results revealed that although 
both chemical parameters clearly affected the polymer degradation rate when 
embedded as hollow microspheres in CPC, PLGA and CPC degradation rates 
were mainly dependent on the end-group functionalization. Moreover, it was con-
cluded that dense microspheres were more efficient porogens than hollow ones 
by increasing the CPC macroporosity during in vitro incubation. By combining 
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all test parameters, it was concluded that dense PLGA microspheres consisting 
of acid terminated PLGa of 17 kDa exhibited the highest and fastest acid produ-
cing capacity and correspondingly the highest and fastest amount of porosity. 
In conclusion, the presented data indicated that the combination of dense, acid-
terminated PLGA microspheres with CPC emerges as a successful combination 
to achieve enhanced apatitic CPC degradation.
Apatitic calcium phosphate cements (CPC) are frequently used to fill bone 
defects due to their favourable clinical handling and excellent bone response, but 
their lack of degradability inhibits complete bone regeneration. In order to ren-
der these injectable CaP cements biodegradable, hollow microspheres made of 
poly (D,L-lactic-co-glycolic) acid (PLGA) have been previously used as porogen 
since these microspheres were shown to be able to induce macroporosity upon 
degradation as well as to accelerate CPC degradation by release of acid degra-
dation products. Recently, the capacity of PLGA microspheres to form porosity 
in situ in injectable CPCs was optimized by investigating the influence of PLGA 
characteristics such as microsphere morphology (dense vs. hollow) and end-
group functionalization (acid terminated vs. end-capped) on acid production and 
corresponding porosity formation in vitro. Chapter 5 has investigated the in vivo 
bone response to CPCs containing two types of microspheres (hollow and den-
se) made of PLGA with two different end-group functionalizations (end capped 
and acid terminated). Microspheres were embedded in CPC and injected in the 
distal femoral condyle of New Zealand White Rabbits for 6 and 12 weeks. Histo-
logical results confirmed the excellent biocompatibility and osteoconductivity of 
all tested materials. Composites containing acid terminated PLGA microspheres 
displayed considerable porosity and concomitant bone ingrowth after 6 weeks, 
whereas end capped microspheres only revealed open porosity after 12 weeks 
of implantation. In addition, it was found that dense PLGA microspheres indu-
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ced significantly more CPC degradation and bone tissue formation compared 
to hollow PLGA microspheres. In conclusion, it was shown that PLGA micros-
pheres have a strong capacity to induce fast degradation of injectable CPC and 
concomitant replacement by bone tissue by controlled release of acid polymeric 
degradation products without compromising the excellent biocompatibility and 
osteoconductivity of the CPC matrix.
Injectable calcium phosphate cements are frequently used for filling of bone 
defects due to their excellent osteocompatibility. Their poor degradability, howe-
ver, limits complete regeneration of bone defects. Porogens that produce acid by-
products are particularly attractive to create macroporosity in situ since calcium 
phosphate cements (CPC) degrade by acid dissolution. The aim of chapter 6 
was to investigate if glucono delta-lactone (GDL) can be used as acid-producing 
porogen for incorporation into CPC without compromising its osteocompatibility. 
In vitro studies confirmed that CPCs containing either low or high amounts of 
GDL were injectable and self-setting, while a considerable amount of porosity 
was formed already within 1 day of incubation in phosphate buffered saline due to 
dissolution of GDL . Histomorphometrical evaluation after 2 weeks of implantation 
revealed that CPC containing 10% of GDL degraded faster and was replaced by 
more bone tissue than CPCs containing either PLGA or gelatin microspheres. 
Summarizing, the chapter 6 showed that CPCs containing appropriate amounts 
of GDL display accelerated degradation and new bone formation compared to 
CPCs containing porogens made of conventional polymers such as PLGA or 
gelatin.
Ideally, bone substitute materials would undergo cell-mediated degradation 
during the remodelling process of the host bone tissue while being replaced by 
newly-formed bone. In an attempt to exploit the capacity of Receptor Activator of 
Nuclear factor Kappa-B Ligand (RANKL) to stimulate osteoclast-like cells forma-
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tion, chapter 7 explored different loading methods for RANKL in injectable cal-
cium phosphate cement (CPC) and the effect on release and biological activity. 
RANKL was loaded via the liquid phase of CPC by adsorption onto or incorpora-
tion into poly(lactic-co-glycolic acid) (PLGA) microspheres with two different mor-
phologies (i.e. hollow and dense), which were subsequently embedded in CPC. 
As controls non-embedded PLGA-microspheres were used as well as plain CPC 
scaffolds with RANKL adsorbed onto the surface. RANKL release and activity 
were evaluated by Reverse Phase High Performance Liquid Chromatography 
(RP-HPLC) and osteoclast-like cells formation in cell culture experiments, respec-
tively. Results indicated that sustained release of active RANKL can be achieved 
upon RANKL adsorption to PLGA microspheres, whereas inactive RANKL was 
released from CPC-PLGA formulations with RANKL incorporated within the mi-
crospheres or within the liquid phase of the CPC. These results demonstrate that 
effective loading of RANKL in injectable CPC is only possible via adsorption to 
PLGA microspheres, which are subsequently embedded within the CPC-matrix.
Chapter 8 aimed to provide information on material degradation and subse-
quent alveolar bone formation using composites consisting of calcium phosphate 
cement (CPC) and poly(lactic-co-glycolic) acid (PLGA) with different microsphere 
morphology (hollow versus dense). In addition to the plain CPC-PLGA composi-
tes, loading the microspheres with the growth factors platelet derived growth factor 
(PDGF) and insulin-like growth factor (IGF) was investigated. A total of 4 different 
CPC composites were applied into 1-wall mandible bone defects in Beagle dogs 
in order to evaluate them as candidates for alveolar bone regeneration. These 
composites consisted of CPC and hollow or dense PLGA microspheres with or 
without the addition of PDGF-IGF growth factor combination (CPC-hPLGA, CPC-
dPLGA, CPC-hPLGAGF, CPC-dPLGAGF). Histological evaluation revealed sig-
nificantly more bone formation in CPC-dPLGA than in CPC-hPLGA composites. 
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The combination PDGF-IGF enhanced bone formation in CPC-hPLGA materials, 
but significant more bone formation occurred when CPC-dPLGA was used with 
or without the addition of growth factors. The findings demonstrated that CPC-
dPLGA composites as the biologically superior material for use as an off-the-shelf 
material due to its good biocompatibility, enhanced degradability and superior 
bone formation.
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Dutch summary / Samenvatting
Polylactic-co-glycolic acid (polymelk-co-glycolzuur, PLGA) is het meest ge-
bruikte synthetische polymeer in het biomedische veld vanwege vanwege de 
biocompatibiliteit en biologische afbreekbaarheid van dit polymeer. Dankzij deze 
eigenschappen zijn veel PLGA-bevattende medische devices door de Amerika-
anse Food and Drug Administration goedgekeurd voor klinisch gebruik in men-
sen. Vergeleken met polymeren die bestaan uit slechts één van de twee com-
ponenten van PLGA (dus polymeren van lactic acid (melkzuur) of glycolic acid 
(glycolzuur)) is de controle over de degradatiesnelheid van PLGA groter. Het ge-
bruik van PLGA is daarom uitgebreid bestudeerd voor diverse toepassingen op 
het gebied van botregeneratie, zoals onder andere in scaffolds,  deklagen, vezels 
of micro- of nanodeeltjes. Omwille van de controleerbare afbreekbaarheid wordt 
PLGA bovendien gebruikt als afbreekbaar dragermateriaal voor bioactieve fac-
toren die botherstel stimuleren. Hoofdstuk 2 vat de recente ontwikkelingen met 
betrekking tot het gebruik van PLGA in het veld van de botregeneratie samen. 
Per toepassing worden de verschillende mogelijkheden van PLGA beschreven. 
Daarnaast zijn de diverse strategieën besproken die ingezet kunnen worden om 
PLGA te functionaliseren voor gebruik als afgiftemateriaal van biomoleculen.
In hoofdstuk drie is het effect van de afmeting van PLGA microdeeltjes op 
botregeneratie onderzocht na injectie van calciumfosfaat cement (CPC)/PLGA in 
het beenmerg van scheenbenen van cavia’s. Hiertoe werden injecteerbare CPC/
PLGA formuleringen gemaakt van PLGA microdeeltjes met een kleine (~25 µm) 
of grote (~100 µm) diameter. Deze bollen werden vervolgens in een 20/80 gewi-
chtsratio vermengd met het CPC. Na verwijdering van het beenmerg zijn beide 
CPC/PLGA formuleringen geïnjecteerd in een beenmergholte in het scheenbeen. 
Na een implantatieperiode van 12 weken zijn histologie en histomorfometrie ge-
bruikt om botvorming te bestuderen. De resultaten lieten voor beide CPC/PLGA 
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formuleringen zien dat botvorming was opgetreden door het hele scaffold heen 
tijdens de afbraak van de PLGA microdeeltjes. Er werd twee keer zoveel bot 
gevormd met CPC/PLGA met kleine (~25 µm) diameter microdeeltjes. Ook was 
het patroon van bot- en mergvorming duidelijk verschillend, afhankelijk van de 
afmetingen van de PLGA microdeeltjes. In het algemeen bewees deze studie dat 
PLGA diameters van ~25 µm, die leidden tot poriën van ~25 µm in CPC, genoeg 
waren voor botingroei en substantiële botvorming tot gevolg hadden. Bovendien 
lieten de resultaten zien, dat PLGA microbol afmetingen een middel zijn om de 
mate van botvorming te sturen in injecteerbare CPC/PLGA botvervangers.
Calciumfosfaat cementen (CPC) worden veelvuldig gebruikt als botvervan-
gend materiaal. Ondanks hun superieure klinische hanteerbaarheid en exce-
llente biocompatibiliteit, kan er alleen een beperkte botingroei in het implantaat 
plaatsvinden, omdat ze slecht afbreekbaar zijn. Microdeeltjes van poly (D,L-lac-
tic-co-glycolic) acid (PLGA) zijn daarom gemaakt en toegevoegd aan injecteer-
baar CPC om als porievormer te dienen en zo de macroporositeit en degradatie 
van de polymere microdeeltjes te versnellen. Als gevolg van de degradatie van 
PLGA microdeeltjes wordt zuur geproduceerd dat op zijn beurt het uiteenvallen 
van CPC versnelt. Desalniettemin is het effect van de eigenschappen van de 
PLGA microdeeltjes op de CPC degradatiesnelheid nog nooit eerder in detail 
onderzocht. Het doel van hoofdstuk 4 was daarom dan ook om te bestuderen hoe 
afhankelijk de CPC afbraak was van de chemische en morfologische eigenscha-
ppen van geïncorporeerde PLGA microdeeltjes. De chemische eigenschappen 
van de microdeeltjes die onderzocht zijn, waren het effect van het moleculair 
gewicht van PLGA (5, 17 en 44 kDa) en het type eindgroep (zuur vs. ester). 
Twee typen PLGA microdeeltjes werden gebruikt, die een verschillende morfolo-
gie hadden (holle vs gevulde). De resultaten toonden aan dat de PLGA en CPC 
afbraaksnelheid voornamelijk afhankelijk waren van het type eindgroep, ondanks 
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dat beide chemische parameters de polymeer degradatiesnelheid beïnvloedden. 
Bovendien bleken gevulde microdeeltjes efficiëntere porievormers te zijn dan de 
holle microdeeltjes. Door het combineren van alle geteste parameters kon ge-
concludeerd worden dat gevulde PLGA microdeeltjes, bestaande uit PLGA met 
een grootte van 17 kDa en zure eindgroepen, de hoogste en snelste zuurproduc-
tie hadden en daardoor ook de hoogste en snelste porositeitsvorming. Het kan 
geconcludeerd worden dat de in hoofdstuk 4 gepresenteerde data aantonen dat 
de combinatie van CPC met gevulde PLGA microdeeltjes met zure eindgroepen 
de meest succesvolle formulering was om versnelde degradatie van apatitisch 
CPC te bewerkstelligen.
Apatitische calciumfosfaat cementen (CPC) worden veelvuldig toegepast om 
botdefecten op te vullen dankzij hun gunstige klinische hanteerbaarheid en ex-
cellente botrespons, maar een complete botregeneratie is niet mogelijk doordat 
het apatitisch CPC nauwelijks degradeert. Om deze CaP cementen toch biode-
gradeerbaar te maken, kunnen PLGA microdeeltjes als porievormer worden ge-
bruikt, aangezien het aangetoond is dat deze microdeeltjes tijdens hun degrada-
tie in staat zijn om zowel microporositeit in het CPC te vormen als de degradatie 
van CPC te versnellen als gevolg van het vrijkomen van zure degradatieproduc-
ten. Recentelijk is de capaciteit van PLGA microdeeltjes om in situ porositeit te 
genereren in injecteerbare CPCs geoptimaliseerd door de invloed van relevante 
eigenschappen van de PLGA microdeeltjes (zoals de morfologie (gevuld vs. hol) 
en type eindgroep (zuur vs. ester)) te onderzoeken op de zuurproductie en ove-
reenkomstige porositeitsvorming in vitro. In hoofdstuk 5 is de in vivo botrespons 
op CPCs onderzocht die twee typen PLGA microdeeltjes (hol vs. gevuld) met 
twee verschillende eindgroepen (zuur vs. ester) veroorzaakten. De microdeelt-
jes werden ingesloten in CPC en geïnjecteerd in het dijbeen van konijnen ge-
durende 6 en 12 weken. De histologische resultaten bevestigden de excellente 
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biocompatibiliteit en botingroei van alle geteste materialen. PLGA composieten 
met een zuur als eindgroep waren al na 6 weken poreus en deels vervangen 
door nieuw botweefsel, terwijl microdeeltjes met een hydrofobe ester eindgroep 
dit slechts lieten zien na 12 weken. Daarnaast bleken gevulde PLGA microdeel-
tjes significant meer CPC degradatie en vorming van botweefsel te veroorzaken 
vergeleken met holle PLGA microdeeltjes. Geconcludeerd kan worden dat PLGA 
microdeeltjes in staat zijn om zowel snelle degradatie van injecteerbare CPC 
als bijgaande vervanging door botweefsel te induceren door gecontroleerde pro-
ductie van zure degradatieproducten afkomstig van het PLGA polymeer, zonder 
daarbij negatieve effecten te veroorzaken op de excellente biocompatibiliteit en 
botrespons van de CPC matrix. 
Zoals boven vermeld, worden injecteerbare calciumfosfaat cementen vaak 
gebruikt om botdefecten op te vullen vanwege hun uitmuntende compatibiliteit 
met bot. Hun slechte afbreekbaarheid beperkt echter het volledige herstel van 
botdefecten. Porievormers die zure afbraakproducten vormen, zijn bijzonder 
aantrekkelijk om porositeit te vormen in CPC, omdat de calciumfosfaat oplost 
onder zure omstandigheden. Het doel van hoofdstuk 6 was om na te gaan of 
glucono delta-lacton (GDL) ook gebruikt kan worden als een zuur-producerende 
porievormer die toegevoegd kan worden aan CPC, zonder de compatibiliteit van 
CPC met botweefsel te verminderen. In vitro studies bevestigden dat CPCs met 
zowel lage als hoge hoeveelheden GDL geïnjecteerd konden worden zonder dat 
de uitharding in gevaar kwam. Al na één dag waren deze formuleringen tamelijk 
poreus door het uiteenvallen van GDL. Histomorfometrische evaluatie na een 
twee weken durende implantatiestudie liet zien dat CPC dat 10% GDL bevatte, 
sneller degradeerde en door meer bot was vervangen dan CPCs met PLGA of 
gelatine microdeeltjes. Hoofdstuk 6 heeft dus laten zien dat CPCs met de juiste 
hoeveelheid GDL versnelde afbraak en nieuwe botvorming kunnen veroorzaken, 
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vergeleken met CPCs die porievormers bevatten van meer conventionele poly-
meren als PLGA of gelatine.
Idealiter zouden botvervangende materialen, terwijl ze vervangen worden 
door het nieuw gevormde bot, door cellen worden afgebroken tijdens het proces 
van botregeneratie. Daarom is geprobeerd om het vermogen van de Receptor 
Activator of Nuclear factor Kappa-B (activator van de receptor van de kernfac-
tor Kappa-B) ligand (RANKL) te benutten om osteoclast-achtige celvorming te 
stimuleren. Hoofdstuk 7 onderzoekt verschillende manieren om RANKL in te 
brengen in injecteerbaar CPC en bestudeert het effect van de methode op de 
vrijgifte en de biologische activiteit. RANKL werd ingebracht via de vloeibare 
fase van CPC door adsorptie op of incorporatie in PLGA microdeeltjes met twee 
verschillende morfologiën (nl. hol en gevuld) die vervolgens in het CPC ingeslo-
ten werden. Niet-ingesloten PLGA microdeeltjes en CPC matrijzen met daarop 
RANKL geadsorbeerd, werden gebruikt als controles. De vrijgifte en activiteit van 
RANKL werden bepaald door respectievelijk Reverse Phase High Performance 
Liquid Chromatography (RP-HPLC, een vorm van vloeistof chromatografie) en 
osteoclast-achtige celvorming in celkweek experimenten. De resultaten lieten 
zien dat vertraagde afgifte van actief RANKL bewerkstelligd kan worden als dit 
geadsorbeerd is aan de PLGA microdeeltjes, terwijl inactief RANKL vrij kwam 
van CPC-PLGA formuleringen waarin het RANKL ingesloten was in de PLGA 
microdeeltjes of toegevoegd was tijdens de vloeibare CPC fase. Deze resultaten 
tonen aan dat een effectieve belading van RANKL in injecteerbaar CPC alleen 
mogelijk is via adsorptie aan PLGA microdeeltjes die vervolgens ingesloten wor-
den binnen de CPC-matrix.
Hoofdstuk 8 had als doel om informatie te verzamelen over composietdegra-
datie en de daarop volgende alveolaire botvorming, gebruikmakend van CPC 
en PLGA composieten met een verschillende morfologie (hol vs. gevuld). Naast 
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het standaard CPC-PLGA composiet met PLGA microdeeltjes, werden ook mi-
crodeeltjes in deze studie meegenomen waarop groeifactoren (PDGF en IGF) 
geadsorbeerd waren. Vier verschillende CPC composieten werden aangebra-
cht in gaten in het onderkaakbot van honden om te bestuderen of ze alveolaire 
botregeneratie kunnen stimuleren. Deze composieten bestonden uit CPC, ge-
combineerd met holle en gevulde PLGA microdeeltjes met of zonder toevoeging 
van de twee groeifactoren (CPC-hPLGA, CPC-dPLGA, CPC-hPLGAGF, CPC-
dPLGAGF). Histologische evaluatie liet significant meer botvorming zien voor 
CPC-dPLGA dan in CPC-hPLGA composieten. De groeifactoren versnelden de 
botvorming in CPC-hPLGA materialen, maar significant meer botvorming vond 
plaats wanneer CPC-dPLGA gebruikt was, met of zonder de toevoeging van de 
groeifactoren. De gevonden resultaten tonen aan dat CPC-dPLGA composieten 
het meest geschikt zijn voor toepassing als botvuller vanwege de goede biocom-
patibiliteit, versnelde afbraak en superieure botvorming. 
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Closing remarks and future perspectives
In the present thesis several apatitic CPC-PLGA formulations have been stu-
died to obtain insight in the degradation behavior of this composite material. By 
studying the physicochemical properties of PLGA in relationship to the degrada-
tion of CPC-PLGA composites, it was shown that apatitic CPCs can be resorbed 
in vivo owing to acid production by dense PLGA microspheres and concomitant 
dissolution of the CPC matrix. Besides, glucono delta-lactone has been proposed 
as a candidate porogen to render CPC bone fillers resorbable within weeks rather 
than months. In parallel to these physicochemical approaches to stimulate de-
gradation of CPC, cell-mediated CPC degradation and new bone formation were 
also studied in this thesis by investigating the effect of delivery of therapeutic 
proteins (growth factors and RANKL) from CPC-PLGA composites. The results 
of this thesis provided evidence that critically sized bone defects can be healed 
upon injection of CPC-PLGA composites, while the addition of growth factors did 
not result into a further improvement of the bone regeneration process.
The future perspective of CPC-PLGA composites is bright since the strong 
potential of the combination of CPC with PLGA was unambiguously proven in the 
current thesis. Nevertheless, several hurdles need to be taken before commer-
cialization and clinical translation of these findings will occur, such as the develo-
pment of a cost-effective procedure for PLGA production or the validation of the 
sterilization process. In addition, the promising pre-clinical results should now be 
confirmed in clinical trials to evaluate the added value of resorbable CPC-PLGA 
composites in direct comparison with the conventional bone substitutes.
Regarding the combination of GDL and CPC, the current thesis highlights CPC-
GDL composites as off-the-shelf injectable materials without the need for additio-
nal expensive processing steps. In addition, the low cost of GDL and possibility of 
room temperature storage are additional advantages for final commercialization. 
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The promising properties of the combination CPC-GDL warrant further studies on 
the mechanism by which GDL microparticles create in situ porosity inside CPCs 
as well as on its biological performance in relevant in vivo models for clinical 
applications. Several aspects such as the importance of initial GDL particle size, 
injectability properties of CPC-GDL composites or the ideal ratio between CPC 
and GDL to generate adequate CPC porosity still need to be addressed. In addi-
tion, the combination of GDL with porogens of slower degradation characteristics 
(i.e. PLGA microspheres) may be a step forward in the fabrication of customized 
CPC composites where gradual creation of porosity is achieved.
Additional research should be performed on the in vivo behavior of CPC and 
bone tissue towards the acidic by-products generated after both PLGA and GDL 
degradation. The adequate balance between acidity, CPC degradation and new 
bone tissue formation has to be elucidated for the different clinical requirements.
Despite the promising results presented in this thesis from both CPC-PLGA 
and CPC-GDL, it has to be taken into account that these materials still lack suffi-
cient mechanical properties to be applied for load bearing applications. 
Moreover, further in vivo studies are needed to draw unambiguous conclusions 
on the possibility to enhance CPC-PLGA degradation by delivering RANKL wi-
thout affecting the surrounding bone tissue negatively. To this end, investigations 
are needed to assess the effect of RANKL concentration in both CPC degrada-
tion and bone tissue remodelling. 
Whereas no added value was found for the delivery of growth factors in the 
current thesis, the addition of growth factors may still be necessary in order to 
stimulate bone tissue formation when CPC composites are aimed to regenerate 
bone in a compromise situation such as in osteoporotic bone. Still, if bioactive 
factors are found to be needed, release and activity studies should be performed 
to achieve controlled delivery of the molecules of interest in their active con-
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formation. Furthermore, research has to focus on the reduction of the included 
amount of growth factors. From a biological safety point of view as well as cost 
effectiveness, they have to be limited according to physiological concentrations. 
This can only be achieved by using more efficient loading/release methods such 
as covalent bonding of molecules to the free carboxyl end-groups of PLGA.
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